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Chronic liver diseases contribute to approximately 4% of deaths worldwide. The high mortality associated 
with liver disease is partially due to 1) difficulty diagnosing liver disease until a later stage and 2) difficulty 
treating liver disease once diagnosed. Therefore, there is an urgent need to better understand the 
biological mechanisms underlying liver disease. This dissertation is focused on understanding the role of 
the scaffolding protein IQ motif-containing GTPase-Activating Protein 1 (IQGAP1), an evolutionarily 
conserved scaffolding protein that is frequently up-regulated in liver disease, in the liver’s response to 
nutritional and cholestatic stress as well as in liver tumorigenesis. In chapter 2, I review how IQGAP1’s 
complex structure relates to its dynamic function in cells. In chapter 3, I show that hepatic IQGAP1 
expression is increased after a 24-hour fast and that deletion of IQGAP1 blunts the ketogenic response to 
fasting and ketogenic diet feeding, which is associated with impaired PPARα activation and hyperactive 
mTORC1 signaling. Furthermore, in chapter 4 I show that IQGAP1 is upregulated at a transcriptional level 
by bile acid signaling and its deletion results in increased toxin-induced liver injury and bile acid 
accumulation. E-cadherin, which is important for maintaining adherens junctions, has reduced expression 
in the absence of IQGAP1, suggesting that IQGAP1 may protect against liver injury by stabilizing E-
cadherin and maintaining bile canaliculi integrity. Lastly, in chapter 5 I show that both overexpression and 
deletion of IQGAP1 can result in increased tumor burden. In these tumors, overexpression of IQGAP1 
was associated with increased β-catenin activation while deletion of IQGAP1 increased cell proliferation 
and MET activation. Together, these results show that while IQGAP1 normally has low expression in the 
liver of adult mice, its expression increases in response to physiological stresses to maintain nutrient 
availability and protect against excess damage. However, in the long-term, both too much and too little 
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CHAPTER 1: INTRODUCTION 
 
 
“…the king of Babylon stood at the parting of the ways, at the head of the two 
ways, to use divination: he made his arrows bright, he consulted with images, he 




“…it cannot be 
But I am pigeon-liver’d and lack gall 
To make oppression bitter, or ere this 
I should have fatted all the region kits 
With this slave’s offal: bloody, bawdy villain!” 
-William Shakespeare, Hamlet 
 
 
“…because the liver is a source of many diseases, and is a noble organ that 
serves many organs, almost all of them: so it suffers, it is not a small suffering; 
but a great and manifold one.” 
-Paracelsus, De origine morborum ex tartaro  
 
 
Many ancient civilizations including those in Mesopotamia and Egypt believed the liver was the 
“seat of life” (Jastrow, 1907; Siddiqui, 1976). Over 4,000 years ago, Babylonians began the practice of 
using the liver of sacrificed animals, most frequently sheep, for divination because they thought it held the 
essence of the soul and would provide access to the “divine mind” (Osler, 1921), and soon this practice 
spread across much of the ancient world. Recognizing that no two livers were exactly the same, priests 
used external anatomical markers such as the size of the gall bladder or the absence of a pyramidal 
process (a pressure-induced process often found on the left lobe of the liver) to foretell the future. The 
liver became associated with emotion and to this day references to liver and bile are still found in 
literature of many languages – including Shakespeare’s Hamlet – to indicate bravery, anger, arrogance, 
and other emotions (Mellinkoff, 1979). 
 The liver was held in this place of honor largely due to its rich blood supply, which was 
considered the essential element for life. The Greek philosopher Galen (129-210 A.D.) posited that the 
liver was the source of all veins and made blood, which remained a prevailing theory for nearly 1,500 
years (Kuntz, 2008). However, this was overturned by Vesalius (1514-1564 A.D.) whose intricate 
anatomical studies revealed that the liver was not the source of the inferior vena cava but drained into it, 




 Despite early anatomical misconceptions, the liver has long been recognized as an essential 
organ for life, and its disease has been recognized for nearly as long. Babylonian terracotta models of 
sheep livers (ca. 2000 B.C.) contain symbols that say things like “may your liver be smooth”, as if they 
recognized that a cirrhotic liver has a rough texture (Kuntz, 2008). At the time of Hippocrates (460-377 
B.C.), recognized symptoms of liver disease already included jaundice, ascites, decolorized and foul-
smelling stools, fever, itching, indigestion, and upper abdominal pain, though the mechanisms may not 
have been appropriately defined (e.g., ascites resulting from the liver melting) (Kuntz, 2008). 
 As the understanding of liver physiology and disease advanced, so too did the treatments. Early 
treatments included bleeding of the basilic vein, which was thought to drain into the liver, and, for 
Hippocratic physicians, “restoring the life-balance” of the four humors – whatever that meant (Kuntz, 
2008). Later, consumption of liver from various animals such as ox, wolf, or donkey or a special diet that 
was both costly and difficult to maintain were prescribed, nonetheless highlighting the potential role of 
nutritional interventions in treating liver disease. In the 5th century A.D., Caelius Aurelianus used poultices 
and laxatives to treat liver disease. In the 1800s, laxatives such as Carter’s Little Liver Pills and Bile 
Beans were thought to treat “biliousness” or “liverishness” (Ivy, 1942a; Ivy, 1942b). Today, a whole 
industry centers around similar treatments including laxatives, cleanses, fasts, and detoxes (all one in the 
same?) that are claimed to remove toxins from the liver, but ultimately have little, if any, therapeutic effect 
and may even be harmful (Vanderperren, 2005; Piscaglia, 2005; Kesavarapu, 2017). 
 The study of the liver over millennia has elucidated many fundamental aspects of liver physiology 
first based on its anatomy, then, following the invention of the microscope, based on its microscopic 
characteristics. From these, the liver became recognized as a “chemical laboratory” or the “kitchen of the 
body” due to its central role in performing metabolic reactions such as glycogenesis, detoxification, and 
urea synthesis (Eckstein, 1969). One of its primary roles was determined to be synthesis of bile acids, 
which were thought to simply function in promoting intestinal fat absorption but, as discussed later, have 
many more roles. With the advancement of biomolecular and histological techniques in the last 150 
years, our understanding of the liver has exponentially grown. Yet, there remains a disconnect between 




Liver disease in the modern world 
 Chronic liver diseases are rampant in the modern world. Liver disease is progressive and is 
typically defined by the etiological factor. It is thought to start with a single hit to the liver, which could be a 
chronic viral infection, accumulation of fat or another substance such as copper, or exposure to a toxin. 
This can lead to inflammation and fibrosis, scar tissue formation, and eventually cancer. The American 
Liver Foundation estimates that at least 30 million people in the United States (10%) have some form of 
liver disease, and many of these diseases, including non-alcoholic fatty liver disease (NAFLD), hepatitis C 
infection, and liver cancer, are on the rise (American Liver Foundation). 
 Worldwide, the prevalence of liver disease is even more profound. NAFLD is estimated to affect 
nearly a quarter of the world population, with the highest prevalence in South America and the Middle 
East (Younossi, 2016). A subset of these patients will progress to a more advanced form of liver disease 
called non-alcoholic steatohepatitis (NASH), which is estimated to affect 1.5-6.45% of people (Younossi, 
2018). Active hepatitis C infection can be found in about 71 million people (1% of the world population) 
and is most prominent in Central Asia, Eastern Europe, and Subsaharan Africa (Polaris Observatory HCV 
Collaborators, 2017). Approximately 3.6% of the world’s population is infected with Hepatitis B virus, with 
the highest prevalence in Africa and the west Pacific regions (Kim, 2018). Other common causes of liver 
disease include alcohol consumption and aflatoxin exposure. Strikingly, cirrhosis and liver cancer can 
arise from any of these diseases and, together, these cause an estimated 4% of deaths worldwide 
(Byass, 2014). 
 The high global burden and mortality of liver disease is a consequence of many factors – lack of 
effective treatments, late diagnosis, and difficulty implementing preventative strategies, to name a few. Of 
these, prevention has been shown to effectively reduce the burden of disease since many of the 
etiological factors are known. Vaccines and other infection control strategies can limit the spread of 
hepatitis B virus and hepatitis C virus (Ward, 2019). Safe food processing can limit exposure to aflatoxin 
(Rushing, 2019). Lifestyle interventions and weight loss can reduce the incidence of NAFLD and alcoholic 
liver disease (ALD) (Utz-Melere, 2018), though they have limited effectiveness in the context of obesity 
(Blüher, 2019). On the other hand, improved diagnosis is difficult because liver disease is frequently 
asymptomatic until later stages (Martini, 2017). Furthermore, treatment has limited efficacy due to the 
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irreversible damage of many of these insults. Curative treatment does exist for hepatitis C virus (Curry, 
2015; Feld, 2015; Foster, 2015), though cost is a barrier (Ward, 2015). Notably, only a subset of cirrhotic 
patients showed improved liver function with this treatment despite the reduction in viral load (Curry, 
2015). Liver resection and transplant are also effective for a small subset of patients, though limited by 
extent of disease and availability of donor organs (Bernal, 2017; Fernandes, 2019). For advanced 
hepatocellular carcinoma, two systemic kinase inhibitors Sorafenib and Lenvatinib have been shown to 
increase survival by a mere 3 months (Llovet, 2008; Kudo, 2018). Thus, there is an urgent need to 
improve our understanding of the biological mechanisms of liver disease to guide rational design of novel 
diagnostics and therapies. 
 
Overview 
 Liver disease is a broad and publicly relevant issue. This dissertation addresses the question of 
what molecular pathways promote liver disease progression from an integrated molecular approach 
focused on understanding the role of the scaffolding protein IQ motif-containing GTPase Activating 
Protein 1 (IQGAP1) in physiological and pathological liver processes. The Anakk laboratory first came 
upon IQGAP1 in the context of hepatocellular carcinoma (Anakk, 2013). IQGAP1 is a large multi-
functional protein that is overexpressed in many types of cancer (Walch, 2008; Hasyashi, 2010; White, 
2010; Liu, 2010; Fowler, 2011; White, 2011; Dong, 2016) and regulates pro-tumorigenic processes 
including cell proliferation (Jadeski, 2008), migration (Mataraza, 2003), and adhesion (Kuroda, 1998). 
While expressed in low levels in the adult liver, IQGAP1 levels increase in response to many different 
types of liver stress (Kunimoto, 2009; Anakk, 2013; Erickson, 2018), suggesting that it could have a role 
in regulating the liver’s adaptive injury response. In chapter 2, I review how this protein can coordinate 
many distinct cellular processes and respond dynamically to physiological cues. In chapter 3, I show that 
IQGAP1 regulates long-term ketosis in the liver. In chapter 4, I show that IQGAP1 protects the liver from 
toxin-induced injury. In chapter 5, I show that IQGAP1 has a complex role in promoting liver cancer. 
Lastly, in chapter 6, I discuss these results as a whole and how they help us better understand liver 
biology and liver disease. These studies will: (1) provide insight into the role of IQGAP1 in multiple 
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physiological contexts, (2) identify novel pathways regulated by IQGAP1, and (3) elucidate long-term 
consequences of IQGAP1 dysregulation. 
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CHAPTER 2: IQGAP1 IS A DYNAMIC AND PLEIOTROPIC SCAFFOLDING PROTEIN 
 
In its most simple form, a cell is a collection of billions of protein molecules enclosed within a lipid 
bilayer shell (Milo, 2013). For the cell to survive, these molecules must work together to maintain the 
integrity of and duplicate three billion bases of genetic code, break down nutrients for energy, and 
synthesize new molecules, as appropriate within the environment. In the case of multicellular organisms, 
this requires not only responding to nutrients and toxins in the environment but also to signals released 
from other cells within the body that provide feedback on how the cell must function to benefit the entire 
organism. Appropriate and timely responses to this feedback are essential for survival. For example, 
excess nutrients or growth factors in the environment may signal to a cell that it is an appropriate time to 
use available resources to grow and divide. On the other hand, cells may inappropriately proliferate and 
grow in the absence of these signals in the context of cancer. 
 Considering the abundance and diversity of molecules that must interact within a cell to respond 
appropriately to stimuli, it is remarkable how quickly and accurately cells can adapt to their environment. It 
is estimated that ~6% of mammalian proteins are involved in intracellular signal transduction (Legewie, 
2008). Should these proteins be freely floating in the cell, cellular signaling would be at a severe entropic 
disadvantage, as the likelihood of finding a correct binding partner would be extremely low. Over the past 
three decades, there has been growing appreciation that structures exist within cells to spatially and 
temporally organize cellular processes, which can accelerate signal transduction (Bhattacharyya, 2006; 
Kholodenko, 2006; Scott, 2009). As a result, this can increase the effective concentration of proteins in a 
certain space at an appropriate time, which increases the likelihood of interaction. For example, 
nucleoplasmin is a molecular chaperone that participates in genome stability, DNA duplication, and 
transcriptional regulation (Laskey, 1993). Its sequence contains a nuclear localization signal (NLS), which 
directs it to localize to the nucleus. Therefore, its concentration is higher in the nucleus, where it is more 
likely to regulate DNA. 
 Within these compartments, additional structures are required to coordinate intracellular 
communication. This is in part achieved by “professional recruitment proteins” (PRPs) that can facilitate 
complex formation and network interactions (Buday, 2010). Common characteristics of PRPs include that 
they have no enzymatic activity and can bind and bring together two or more enzymes involved in signal 
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transduction. Categories of PRPs include adaptor proteins, docking proteins, and scaffolding proteins, 
which are rather fluid definitions as they have much overlap and proteins can often be assigned to 
multiple categories (Buday, 2010). In general, adaptor proteins are small and can only bind two partners 
at a time, docking proteins are specialized to initiate signaling cascades by organizing proteins at the cell 
membrane, and scaffolding proteins are typically larger multi-domain proteins that allow for more complex 
regulation of cellular signaling. Of these categories of PRPs, scaffolding proteins are the most adept to 
respond to various signaling inputs, suggesting that they have a larger impact on diverse cellular 
processes. 
 While scaffolding proteins are classically considered as passive tethering proteins, there is 
growing evidence that they can take an active role in signal transduction (Alexa, 2010). Scaffolding 
proteins often have structured binding domains for protein-protein interactions but also have high levels of 
structural disorder, which provides flexibility for dynamic regulatory rearrangements (Buday, 2010). Thus, 
while they have been considered globular structural proteins, it is more likely that they exist as 
interconverting structures (Cortese, 2008). This is an important feature because it expands the scaffold’s 
ability to bind diverse signaling proteins, highlights the interdependence of different regions of the 
scaffold, and suggests that modifications or mutations that alter the flexibility of the scaffold may affect its 
function. Therefore, while scaffolds can interact with large numbers of proteins, their structure and post-
translational modifications can vary depending on the context, resulting in a preference for binding certain 
proteins over others. 
 The IQ motif-containing GTPase Activating Protein (IQGAP) family contains some of the largest 
and most complex scaffolding proteins known and exemplifies the flexibility and dynamic regulation of 
scaffolding proteins. They are highly conserved proteins, as homologs have been identified in a variety of 
organisms from Saccharomyces cerevisiae and Caenorhabitis elegans to higher-order Mus musculus and 
Homo sapiens (Schmidt, 2008; Hedman, 2015). Their size ranges from 1575-1657 amino acids, and each 
contains five defined domains, the calponin homology domain (CHD), WW domain (WW), four tandem IQ 
motifs together referred to as the IQ domain (IQ), a Ras-GTPase Activating Protein (GAP)-related domain 
(GRD), and a rasGAP C-terminus (RGCT) domain, along with a IQGAP repeat (IR) region containing 
8 
 
coiled-coiled motifs (Figure 2.1). They exhibit an appreciable amount of disorder, with 30.66%, 28.25%, 
and 33.7% disordered amino acids in IQGAP1, IQGAP2, and IQGAP3, respectively (www.PONDR.com). 
 IQGAP1 was the first protein in this family to be discovered and was initially identified in 1994 for 
its GRD that resembles the structure of Ras activating proteins but lacks GAP activity (Weissbach, 1994). 
In the next two decades, over 140 IQGAP1 binding partners for IQGAP1 have been identified, highlighting 
its central role as a regulator of cell signaling (Brown, 2006; White, 2012; Hedman, 2015). IQGAP1 has a 
wider tissue distribution than the other IQGAP isoforms and is dysregulated in a number of disease states 
(Hedman, 2015), making it a broadly interesting molecule to study from both a biological and translational 
perspective. Here, I begin with a reductionist approach toward understanding IQGAP1’s role in these 
complex states by examining IQGAP1 structure and interaction partners, then IQGAP1’s role in cellular 
processes, and ultimately how IQGAP1 affects cellular functioning in physiological contexts, with a focus 
on cancer progression. 
 
IQGAP1 binds proteins via distinct interaction domains 
Calponin Homology Domain (CHD) 
 CHDs are found in both signaling and cytoskeletal proteins and are commonly found in actin-
binding proteins (Bonet-Kerrache, 1994; Winder 1995; Garbe, 2007). Canonically, the actin-binding 
domain contains two consecutive CHDs (type 1 and type 2), which are both necessary to bind to F-actin 
with low micromolar affinity (Gimona, 2002). In contrast, IQGAP1 contains a single CHD (type 3). 
Interestingly, this CHD is sufficient to bind to actin (Fukata, 1997) with an affinity of 47 µM (Mateer, 2004). 
Functionally, IQGAP1 can cross-link F-actin in vitro (Bashour, 1997). This suggests that despite 
containing a single CHD, IQGAP1 is able to interact with actin under a physiological context. 
 Recently, it was demonstrated that the CHD (AA 1-191) of IQGAP1 can dimerize, which is 
required for binding to both actin and Ca2+/calmodulin at this site in a mutually exclusive manner (Liu, 
2016). The authors postulated that this dimerization aligns the CHDs from two distinct IQGAP1 molecules 
in a manner similar to those of type 1/2 CHDs. In another study, however, deletion of AA 35-265 of 
IQGAP1 remained capable of self-association (Ren, 2005), suggesting that other domains of IQGAP1 can 
contribute towards dimerization. Instead, these authors identified that the N-terminus of IQGAP1 (AA 2-
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863) could bind endogenous IQGAP1 in vitro, and specifically AA 763-863 (IQ domain) were required for 
dimerization. Furthermore, treating cells with peptides containing AA 763-863 could inhibit self-
association of IQGAP1, suggesting that this is a biologically relevant interaction (Ren, 2005).  
Interestingly, AA 2-522 (containing the CHD and IR region) of IQGAP1 can efficiently cross-link 
actin regardless of calcium presence (Mateer, 2002). On the other hand, Ca2+/calmodulin prevented actin 
cross-linking in the presence of full-length IQGAP1. Since Ca2+/calmodulin strongly binds to the IQ 
domain, it is possible that this binding could prevent dimerization at this site, which could affect 
dimerization at the CHD, though this was not specifically measured. However, the N-terminus on its own 
would not rely on IQ domain dimerization for its interaction, so it is able to effectively dimerize and 
promote actin polymerization. Thus, it is likely that there are multiple regions of IQGAP1 that can mediate 
dimerization with different strengths of interaction and these interactions are required for certain IQGAP1 
functions. 
 Further evidence for the importance of dimerization at the IQ domain and Ca2+/calmodulin binding 
for CHD activity is observed in IQGAP1 co-localization with actin. IQGAP1 co-localizes with actin at actin-
rich ruffling membranes and lamellipodia (Hart, 1996). Increasing intracellular Ca2+ content promotes 
calmodulin binding to the IQ domain of IQGAP1 and releases IQGAP1 from actin fibers, which causes 
IQGAP1 to dissociate from the cell cortex in a reversible manner (Mateer, 2002). This is in line with the 
proposed mechanism that calmodulin binding to the IQ domain blocks IQGAP1 dimerization that is 
required for actin binding. Importantly, this does not cause F-actin to disassemble, suggesting that 
IQGAP1 is not required F-actin stability in short time periods (20 min). On the other hand, AA 2-522 
(containing the CHD and IR region) of IQGAP1 can efficiently polymerize actin regardless of Ca2+ 
presence indicating that it is Ca2+/calmodulin binding to the IQ domain and not the CHD that regulates the 
interaction with actin. 
 It is possible that IQGAP1 has a unique role not to cross-link actin filaments but to associate actin 
filaments with other proteins. For example, the IQGAP-like S. cerevisiae protein Cyk1p/Iqg1p is required 
to recruit actin to the myosin II-containing cytokinetic ring (Lippincott, 1998). Deletion of Iqg1p results in a 
failure of myosin II to contract at the end of mitosis, which requires actin recruitment. Expression of an 
Iqg1p construct lacking the IQ domain was unable to rescue this phenotype in the absence of 
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endogenous WT Iqg1p, suggesting that dimerization at this site is required for its activity. However, it is 
notable that myosin can also bind to the WW/IQ domain of human IQGAP1 (Weissbach, 1998), so the IQ-
deletion mutant could also simply not be able to associate with the myosin at the cytokinetic ring. Deletion 
of the CHD of IQGAP1 did not affect its localization but was not able to recruit actin (Shannon, 1999). 
These results highlight the interdependence of the CHD and IQ domains in coordinating actin binding and 
IQGAP1 dimerization. 
 
IQGAP Repeat (IR) Region 
 Just after the CHD lies a unique region of IQGAP proteins known as the IR region. This is a 
protein sequence that contains six copies of a 50-60 amino acid motif in IQGAP1. Approximately 20% 
(12/59) of the residues of each repeat are identical and another 20% (12/59) contain a consistent type of 
amino acid (i.e. polar uncharged, positive, negative, hydrophobic) in >5 of the repeats (Figure 2.2, A). 
However, the structure and function of these repeats is unknown. PFAM analysis revealed that six coiled-
coil (CC) domains also exist within IQGAP1, four of which can be found in the IR region 
(http://pfam.xfam.org/protein/P46940.1). Interestingly, these do not appear to line up with the IR repeats 
(Figure 2.2, B). For example, IR1 encompasses AA 216-275 while CC2 lies within AA 263-297, indicating 
partial overlap of the motifs. Additionally, IR4 includes AA 455-514 and CC4 contains AA 487-514, a 
complete overlap. CC motifs may immediately follow IR regions, such as CC3, which spans the gap 
between IR2 and IR3. CC motifs consist of a supercoiled α-helix, which forms a repeating structure in 
which adjacent helices could form a compact “knobs-into-holes” arrangement (Truebestein, 2016). One 
proposed function of CC motifs is to serve as a “molecular spacer”. In other words, the motif simply 
functions to separate different domains within a protein. As there is high disorder within CC2 and CC3, 
which mostly lie between two IR repeats, it is possible that this is their function. CC motifs may also be 
able to allosterically transfer structural information across the protein or they could act as molecular 
scaffolds and directly interact with other proteins, though evidence of this is scarce. 
 Few proteins have been found that bind to the IR region of IQGAP1. Chiefly, this includes ShcA, 
which is an adaptor protein that mediates signaling downstream of activate membrane receptors and a 
proto-oncogene (Saucier, 2004; Im, 2015). ShcA binds to AA 401-522 of IQGAP1 (Smith, 2010). This 
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region includes part of IR3, IR4, and CC4. However, it does not bind like a typical ShcA binding partner – 
it lacks the canonical NXXF motif common for ShcA binding partners, it does not compete for binding with 
other ShcA binding partners suggesting an atypical binding site, and it has uncharacteristic kinetic 
properties of interaction with ShcA. Another study found Ezrin to be a binding partner to this region (Liu, 
2014). In this study, they pulled down proteins from mouse kidney whole-cell lysate using the IR region 
and performed mass spectrometry. While they identified Ezrin as well as a number of other proteins from 
this pull down, they failed to identify ShcA. Interestingly, a different group identified the Ezrin binding site 
of IQGAP1 to be the IQ domain, not the IR region (Nammalwar, 2015). Further, the highly disordered CC 
regions of the IR may alter the dynamics of protein interactions associated with the IR region under 
different contexts, which in turn poses an additional challenge in elucidating the function of the IR region. 
 
WW Domain 
 The WW domain is one of the smallest protein modules, containing two conserved tryptophan 
residues that are spaced 20-22 amino acids apart (Bork, 1994). Typically, this domain folds into a triple-
stranded β-sheet (Macias, 1996) that binds to proline-rich or proline-containing motifs (Chen, 1995). 
However, the WW domain of IQGAP1 binds ERK1 (Roy, 2005) and ERK2 (Roy, 2004), which both lack a 
proline-rich region. Many WW domain-containing proteins contain multiple copies of the domain such as 
mouse YAP, which has two repeats, and human Nedd-4, which has four. IQGAP1 has a single copy. 
While these differences are notable, it is unknown how they contribute to IQGAP1 function. 
 Not only can IQGAP1 bind ERK1/2, but it also binds upstream proteins and appears to act as a 
classical tethering scaffold for this pathway (Roy, 2005). ERK1/2 functions within the mitogen activated 
protein (MAP) kinase pathway that transmits extracellular signals to the nucleus, is a potent regulator of 
proliferation, and is often hyperactive in cancer (Dunn, 2005). Upon membrane receptor activation such 
as by epidermal growth factor (EGF) binding to the EGF receptor (EGFR), Ras, a small GTPase, 
becomes activated. IQGAP1 constitutively binds the EGFR and becomes phosphorylated upon EGF 
binding to EGFR (McNulty, 2011). This enhances EGFR autophosphorylation and activation. While the 
effect of this regulation on Ras activity was not directly shown, it is likely that the presence of IQGAP1 
enhances Ras activation as AA 713-863 (IQ Domain) can bind to both active and inactive K-Ras, bringing 
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it closer to EGFR (Matsunaga, 2014). Once active, Ras can activate Raf kinase (Avruch, 2001). EGF 
treatment enhances B-Raf binding to IQGAP1 (Ren, 2008), which is required for EGF-induced activation 
of B-Raf (Ren, 2007). This is likely due to the enhanced recruitment of B-Raf to already-bound Ras on 
IQGAP1 (Matsunaga, 2014). Both B-Raf (Ren, 2007; Ren, 2008; Heil, 2011) and C-Raf (Sbroggiò, 2011) 
bind to IQGAP1 via AA 746-863 (IQ) and 717-997 (IQ), respectively. Interestingly, deletion of AA 1515-
1657 (RGCT) also prevents C-Raf binding, highlighting the interactive roles of distant regions of IQGAP1. 
Activated Raf then activates MAPK/ERK Kinase 1/2, which binds to AA 699-863 of IQGAP1 (Roy, 2005). 
MEK1/2 then activates Extracellular Signal-Related Kinase 1/2 (ERK1/2), which activates numerous 
transcription factors such as ELK1 and kinases to diversify the signaling output (Roskoski, 2012). Thus, 
IQGAP1 functions to tether this linear pathway and facilitate signaling. 
One issue with the linear tethering mechanism proposed for IQGAP1 is that while it can align the 
proteins into an effective order, it can restrict the output of the pathway by preventing amplification of the 
signal. A potential benefit of kinase cascades is that they can amplify input signals (such as EGF binding 
to EGFR) at each step of signal transfer. However, if a scaffold were to bind the members of the pathway 
with high affinity, it would restrict each kinase’s ability to phosphorylate multiple downstream targets and 
increase the signal strength, assuming that it also binds the substrates with high affinity. One way to 
overcome this is cooperative assembly of pathway components. For example, ERK2 binds constitutively 
to IQGAP1 and recruits MEK (Roy, 2005). This suggests that MEK has a lower affinity for IQGAP1 than 
ERK2 an can readily dissociate to activate other ERK proteins. Additionally, there is increased B-Raf 
binding following EGF stimulation (Ren, 2008), suggesting a more dynamic interaction. Importantly, 
IQGAP1 is required for B-Raf activation in cells exposed to EGF (Ren, 2007). By restricting B-Raf 
activation to when it is bound to a scaffolding protein, there is reduced likelihood of off-target effects of the 
signaling pathway. 
Regulation of MAPK pathway requires an optimal level of IQGAP1, since both overexpression 
and knockdown of IQGAP1 expression diminishes MAPK activity (Roy, 2005). This is a common effect for 
scaffolding proteins (Good, 2011). Importantly, modifying IQGAP1 levels does not change expression of 
MAPK pathway components. Instead, it is likely that this bifunctional effect is due to an inadequate ratio 
of IQGAP1 to MAPK proteins. If IQGAP1 expression is too low, functional MAPK complexes are unable to 
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form due to lack of available scaffold. On the other hand, if IQGAP1 expression is too high, it is less likely 
that MAPK components will all bind to the same IQGAP1 molecule. This results in a dose-dependent 
effect of IQGAP1 on the pathway output. It is important to note that a majority of the proteins upstream of 
ERK bind to the IQ domain, which is also the prominent site of IQGAP1 dimerization and calmodulin 
binding. B-Raf binding can also be blocked by calmodulin in vitro, suggesting that it competes with 
calmodulin for binding (Ren, 2008). Taken together, it is possible that certain components of the MAPK 
pathway are constitutively bound to IQGAP1. Upon activation of the pathway, these bound components 
can recruit other members of the pathway to facilitate complex formation in the context of competition with 




 IQ motifs are a common calmodulin-binding sequence of amino acids found in over 100 proteins 
such as neuromodulin (Andreasen, 1983; Alexander, 1987) and unconventional myosins (Cheney, 1992). 
This motif contains 20-25 amino acids with the core sequence IQXXXRGXXXR (where X is any amino 
acid) and generally occurs in tandem repeats. IQGAP1 contains four tandem IQ motifs, together referred 
to as the IQ domain (IQ). These four motifs vary slightly in sequence, but all contain the highly conserved 
portion of the IQ motif (IQXXXR) and the second “fine-tuning” part (GXXXR). These are thought to bind 
the C-terminal and N-terminal lobes of calmodulin, respectively. This is important because only 
“complete” IQ motifs such as these are able to bind calmodulin in the absence of Ca2+ (Houdusse, 1995). 
While IQ motifs generally bind calmodulin in the absence of Ca2+ (Andreasen, 1983; Alexander, 1987; 
Baudier, 1991; Brockerhoff, 1994; Wolenski, 1995), IQGAP1 was identified early on as the only protein in 
MCF-7 cells that could bind calmodulin with high affinity both in the presence and absence of Ca2+, 
though Ca2+ doubled the interaction (Joyal, 1997). Later it was found that Ca2+/calmodulin binds to all four 
IQ motifs while apocalmodulin binds to only IQ3 and IQ4 (Li, 2003), which could explain this observation. 
The differential binding of apocalmodulin to IQ3/4 relative to IQ1/2 was determined to be dependent on 
arginine residues, since mutation of these to glutamine in those motifs abrogated binding to 
apocalmodulin. However, these arginine residues are also present in IQ1 and one of them is present in 
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IQ2, and deletion of these residues do not affect calmodulin binding to these motifs. Thus, it is likely that 
additional residues that are present in IQ3/4 but not IQ1/2 may be important for this interaction. 
 The IQ domain of IQGAP1 not only binds to typical IQ motif binding partners such as calmodulin 
(Hart, 1996; Li, 2003) and S100 proteins (Heil, 2011; Mbele, 2002), it also forms unexpected interactions. 
Its interacting proteins include EGFR (McNulty, 2011), MEK1/2 (Roy, 2005), Rap1 (Jeong, 2007), B-
Raf/C-Raf (Ren, 2008; Sbroggio, 2011), Myosin essential light chains (Weissbach, 1998), and PIPKγ 
(Choi, 2013). It can also bind other IQGAP1 molecules to form dimers and oligomers (Ren, 2005). The 
large number of binding partners suggests that these proteins must compete for binding to this region of 
IQGAP1. This is exemplified by studies of calmodulin binding, which can be enhanced by Ca2+. These 
have shown that Ca2+/calmodulin binding blocks binding of EGFR (McNulty, 2011), Rap1 (Jeong, 2007), 
and B-Raf (Ren, 2008) to the IQ motifs. Interestingly, Ca2+/calmodulin binding not only affects proteins 
binding to the IQ motifs, but it also modulates binding to other domains. As previously described, 
presence of Ca2+/calmodulin reduces binding of actin to the CHD. Additionally, Cdc42 (Joyal, 1997; Ho, 
1999) binding to the GRD and E-Cadherin (Li, 1999) and β-Catenin (Briggs, 2002) binding to the RGCT 
are disrupted by Ca2+/calmodulin. 
 
Ras-GAP Related Domain (GRD) 
 The IQGAP1 GRD has a strikingly similar structure to previously identified Ras-GAP domains 
proteins such as p120GAP and neurofibromin (Trahey, 1987; Wallace, 1990; Viskochil, 1990). Usually, 
Ras-GAP domains bind to GTPases, enhancing their weak intrinsic GTP-hydrolyzing activity and shutting 
off their signaling (Gideon, 1992). However, IQGAP1 was found to lack GAP activity (Kuroda, 1996). This 
is likely due to substitutions in two conserved residues in the GRD, L11893Y and R1146T. 
 The most remarkable of these two substitutions is R1146T, which replaces an arginine in the 
canonical catalytic site with a threonine. In a similar GAP domain of GAP-334, Arg789 appears to stabilize 
the negative charge on the γ phosphate of GTP as hydrolysis progresses (Scheffzek, 1997), and mutation 
of this residue dramatically decreases the rate of GAP-stimulated hydrolysis without affecting binding 
(Scheffzek, 2005). As a neutral amino acid, threonine in this position of IQGAP1 cannot provide the same 
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charge stabilization and is the most likely reason that IQGAP1 lacks GAP activity. Though this threonine 
is highly conserved within the IQGAP family, its function is unknown. 
 The L1193Y mutation is also of interest because it is adjacent to a conserved Arginine (Arg1194) 
that mediates binding to GTPases. Mutation of a similarly placed leucine to an isoleucine in the p190GAP 
Ras-GAP domain has been shown to result in a protein that can bind Ras (Brownbridge, 1993) but cannot 
promote its GTPase activity (Skinner, 1991). Similarly, the IQGAP1 GRD can bind GTPases such as 
Cdc42 and Rac1, but it stabilizes them in their active GTP-bound form, reducing their GTPase activity 
rather than enhancing it (Hart, 1996; Ho, 1999). In GAP-334, the corresponding conserved arginine 
(Arg903) stabilizes the “finger loop” structure in the catalytic site by hydrogen bonding three upstream 
residues. The equivalent Arg1194 of IQGAP1 forms a hydrogen bond with a single residue upstream 
(Kurella, 2009). Therefore, it is possible that the tyrosine substitution destabilizes the arginine that 
normally functions to place the residue in position 1194. However, the residues in IQGAP1 homologous to 
the “arginine finger” motif, located in helix α2ac, are more stabilized by other residues, which may 
counteract this substitution. 
 Since IQGAP1 binds Cdc42 and Rac1 without GAP activity, it is possible that IQGAP1 functions 
downstream of these GTPases. Supporting evidence for this includes that dominant-active Cdc42Val12 and 
Rac1Val12 bind IQGAP1 and localize it to membrane ruffling areas (Kuroda, 1996). This can be blocked by 
expression of the dominant-negative Rac1Asn17 or Cdc42Asn17. However, IQGAP1 binding to Cdc42 and 
Rac1 is not affected by the classic mutations to the Switch I or “effector loop” region of these Rho 
GTPases that decrease their binding to known effectors such as PAK, ACK, and WASP (Kurella, 2009). 
This indicates that the IQGAP1 interaction is more similar to a GAP interaction than an effector protein 
interaction, which suggests that it may function upstream of Cdc42 and Rac1. In fact, overexpressing 
IQGAP1 increases active Cdc42 in cells and localizes Cdc42 to the plasma membrane, indicating that it 
can act upstream of Cdc42 (Swart-Mataraza, 2002). Thus, IQGAP1 appears to be a more potent 
regulator of Cdc42 and Rac1 rather than an effector, but it is possible that there is bidirectional regulation 
between IQGAP1 and its RhoGAP interaction partners. 
 The binding of Cdc42 and Rac1 may, in part, be regulated by competition. Their binding regions 
are partially distinct, as AA 950-1407 of IQGAP1 binds Cdc42 similar to WT but shows no interaction with 
16 
 
Rac1 (Owen, 2008). Rac1 can bind AA 864-1657 of IQGAP1, but it is unknown whether this is the 
smallest region necessary for Rac1 to bind (Kurella, 2009). This suggests that there are determinants for 
Rac1 binding outside of the region that binds Cdc42. Importantly, both of these proteins require more 
than just the GRD to bind to IQGAP1. Furthermore, displacement assays reveal only partial competition 
between Cdc42 and Rac1 for binding IQGAP1, consistent with having partially overlapping interactions 
(Owen, 2008). Data indicate that a weak ternary Rac1-IQGAP1-Cdc42 complex can be formed as well. 
As previously mentioned, distally bound Ca2+/Calmodulin can block Cdc42 binding to the GRD (Joyal, 
1997; Ho, 1999). Since Ca2+/Calmodulin cannot directly bind the GRD, it is possible that its binding to the 
IQ domain causes a conformation change that could affect the GRD structure. Additionally, IQGAP1 can 
be phosphorylated within the C-terminus at Ser1441 in mice and both Ser1441 and Ser1443 in humans 
(Grohmanova, 2004). Phosphorylation of IQGAP1 decreases its affinity for active Cdc42, instead 
preferring to bind nucleotide-free Cdc42. This phosphorylation is regulated by PKCα and PKCε 
(Grohmanova, 2004; McNulty, 2011) and can occur in response to extracellular signals such as EGF 
stimulation (McNulty, 2011). Thus, the GRD is dynamically regulated by binding competition and post-
translational modifications. 
 
RasGAP C-Terminus (RGCT) 
 Located near the C-terminus of IQGAP1, the RGCT is a region with unknown structure that is 
entirely unique to IQGAP proteins. Within the RGCT, there are two serine residues (Ser1441 and Ser1443) 
that can be phosphorylated. Phosphorylation of these sites shifts preference from binding active GTP-
bound Cdc42 to binding nucleotide-free Cdc42 (Grohmanova, 2004). Furthermore, secondary structure 
prediction using GenTHREADER revealed α-helices formed by AA 1244-1460, which resembles the 
structure of Rho-GEFs (Cherfils, 1998). Unexpectedly, WT IQGAP1 was able to promote GDP release 
from Cdc42-GDP, but a phosphomimetic mutant of IQGAP1 (SS1441/1443DE) did not have this activity. 
Unlike typical GEFs, however, IQGAP1 cannot promote subsequent GTP incorporation into Cdc42 
(Grohmanova, 2004). Thus, unphosphorylated IQGAP1 can prepare Cdc42 for receiving GTP by 
removing bound GDP but inhibits incorporation of GTP into Cdc42 in vitro. On the other hand, 
phosphorylated IQGAP1 stabilizes Cdc42 in its active GTP-bound form. Taken together, IQGAP1 
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promotes Cdc42 activity by both maintaining active Cdc42 levels through binding via the GRD and 
creates a population of Cdc42 molecules that are primed for activation through binding to the GEF-like 
RGCT. 
 An additional function of the phosphorylation sites of the RGCT is to respond to extracellular 
signals and modify the effect of IQGAP1 on EGFR activity. Binding of EGF to EGFR results in IQGAP1 
phosphorylation, likely due to PKCα and PKCε activation (Grohmanova, 2004; McNulty, 2011). IQGAP1 
binds EGFR via the IQ domain (AA 717-916) regardless of phosphorylation state, indicating that 
phosphorylation may not affect binding at distal sites. Upon EGF stimulation, EGFR dimerizes and 
autophosphorylates several tyrosine residues, which is essential to activate downstream signaling. 
Unexpectedly, phosphorylation of IQGAP1 is required to increase EGFR phosphorylation in response to 
EGF treatment, as phosphomimetic IQGAP1 and phospho-resistant IQGAP1 promote and prevent EGFR 
phosphorylation, respectively (McNulty, 2011). This is contradictory because active EGFR likely regulates 
PKC activity, which is required for IQGAP1 phosphorylation, but IQGAP1 phosphorylation is also required 
for EGFR activation. However, it is possible that EGF could also active PKC by another mechanism. 
 The C-terminus of IQGAP1 also contains multiple phosphoinositide regions. Just downstream of 
the RGCT is an atypical phosphoinositide (aPI) binding domain within AA 1559-1667. This region can 
bind both surface-tethered and soluble PIP3 and PI(3,4)P2, lipid products of class I PI 3-kinase activity 
(Dixon, 2012). Additionally, within the RGCT, a poly basic motif (PBM2) comprising of AA 1491-1560 can 
bind to PIP2 and PIP3. Mutational analysis revealed that a cluster of lysine pairs in this region mediates 
the interaction. Importantly, binding to PIP2 reduces autoinhibitory interactions of the GRD and RGCT 
domains (Dixon, 2012; Choi, 2013) between one or multiple molecules. This allows IQGAP1 to occupy a 
more open conformation that can bind to partners such as N-WASP and the Arp2/3 complex (Benseñor, 
2007; Le Clainche, 2007). It is thought that PIPKγ recruits IQGAP1 to the membrane where it then 
generates PIP2 to activate the IQGAP1 C-terminus to selectively stimulate actin polymerization at the 
leading edge (Choi, 2013). This could explain why IQGAP1 co-localizes with actin at ruffling edges and 





IQGAP1 controls dynamic responses to environmental cues 
 Since IQGAP1 is such a promiscuous scaffolding protein, with a large number of binding partners 
that can competitively bind to each domain, a major question is how do we study its function in vivo? As 
discussed above, the distinct domains of IQGAP1 regulate many different signaling pathways but, 
importantly, function interdependently. While groups have tried to study IQGAP1 function by 
overexpressing shortened constructs such as only the IR and WW domains or the C-terminal half, these 
constructs typically result in abnormal outcomes that are not recapitulated by overexpression of the full 
length IQGAP1 (Wang, 2009; Tekletsadik, 2012). It is difficult to interpret these experiments because a 
shortened construct could be sufficient to promote the activity of its binding partners or it could sequester 
a protein away from the rest of the signaling pathway and thus have an inhibitory effect (Jameson, 2013). 
An additional caveat to studying IQGAP1’s biological function is that IQGAP1 can be expressed in many 
subcellular compartments including the nucleus (Johnson, 2011), cytoplasm (Mateer, 2002), and cell 
membrane (Kuroda, 1998). It can also be associated with the cytoskeleton or in a labile pool in the 
cytoplasm (Yuan, 2013). Presumably, IQGAP1 would have different functions depending on its 
subcellular localization, but there are no current methods for modifying its function in one compartment 
while retaining it in another. Thus, experimentally manipulating IQGAP1 expression is likely to alter many 
different cellular processes simultaneously. However, modifying full-length IQGAP1 expression by either 
overexpression or knockdown is most likely to mimic the cellular response to extracellular cues, as 
shorter IQGAP1 isoforms have not been identified. 
 Looking to studies that only modify full length IQGAP1 expression in cell culture, a consensus has 
formed around the role of IQGAP1 in many cell functions. A large number of studies have shown that 
overexpression of IQGAP1 increases cellular proliferation while knocking down IQGAP1 has the opposite 
effect (Emadali, 2006; Jadeski, 2008; Meyer, 2008; Wang, 2009; Chen, 2010; White, 2011; Huang, 2014; 
Lu, 2014; Jin, 2015; Meng, 2015; Sun, 2015; Dong, 2016; Su, 2016; Liang, 2017). Similarly, many have 
shown that IQGAP1 expression directly corresponds to the extent of migration and/or invasion (Mataraza, 
2003; Yamaoka-Tojo, 2004; Ikeda, 2005; Benseñor, 2007; Mataraza, 2007; Bogatkevich, 2008; Dong, 
2008; Sakurai-Yageta, 2008; Chen, 2010; Hayashi, 2010; Lee, 2010; Liu, 2010; Wu, 2011; Huang, 2014; 
Lu, 2014; Jin, 2015; Meng, 2015; Sun, 2015; Dong, 2016; Liang, 2017; Li, 2019), though a single study 
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showed the opposite – knockdown of IQGAP1 can increase invasion (Bessède, 2016). Overexpression of 
IQGAP1 can also promote AKT activation (Chen, 2010; Huang, 2014; Liang, 2017) and β-catenin activity 
(Briggs, 2002; Sharma, 2007; Wang, 2008; Jin, 2015), while knocking down IQGAP1 can have the 
opposite effects on both AKT (Yamaoka-Tojo, 2004; Yamaoka-Tojo, 2006; Naidu, 2017) and β-catenin 
(Sharma, 2007; Lu, 2014; Jin, 2015; Su, 2016). It is important to note, however, in some cases IQGAP1 
knockdown had no effect on β-catenin activation suggesting there could be a certain threshold or 
condition in which decreasing IQGAP1 expression can regulate β-catenin activation (Hage, 2009; 
Hayashi, 2010). 
 The role for IQGAP1 in other cell functions in cell culture is more up to debate. For example, 
overexpression and knockdown of IQGAP1 have been shown to both increase cell adhesion (Yan, 2009; 
Yuan, 2013; Tanos, 2015; Sun, 2015) and decrease cell adhesion (Kuroda, 1998; David, 2011; Tian, 
2014; Tian, 2015; Sun, 2015). In terms of kinase signaling, overexpression of IQGAP1 has been shown to 
increase ERK activation (Huang, 2014; Meng, 2015; Sun, 2015; Liang, 2017) and decrease ERK 
activation (Roy, 2004; Roy 2005). Epithelial-to-mesenchymal transition (EMT) involves the transition from 
cells from a polarized epithelial cell phenotype to a migratory and apoptosis-resistance mesenchymal 
phenotype, and knockdown of IQGAP1 has been shown to both increase expression (Bessède, 2016) 
and decrease expression (Dong, 2016; Su, 2016) of EMT markers. Since these experiments were 
performed by different groups in different cell lines and with potentially different culturing conditions, this 
suggests that the function of IQGAP1 in these processes is more sensitive to extracellular cues than its 
role in proliferation and motility.  
 
IQGAP1 in health and disease 
 Since cell culture studies involve a homogeneous population of cells in a dish, it is possible that 
these results may not translate to a physiological context. As a large, ubiquitously expressed scaffolding 
protein with diverse binding partners that can not only integrate signaling pathways within the cell but can 
also respond to extracellular signals, it is expected that IQGAP1 has a central role in regulating 
physiological processes. However, IQGAP1-null (Iqgap1-/-) mice are born at normal frequency and show 
few obvious defects (Li, 2000). These mice were generated by replacing exon 29/36 (GRD) with a PGK-
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neo cassette to disrupt expression. Despite having an intact ORF other than at exon 29, these mice are 
believed to act as complete knockouts as protein expression is depleted in lung, kidney, spleen, and 
stomach, which all express high levels of IQGAP1 (Li, 2000). The liver has lower expression of IQGAP1 in 
adult WT mice, but Iqgap1-/- livers still show a functional loss of protein (Schmidt, 2008). On the other 
hand, mRNA detection using primers for different regions of IQGAP1 show dramatic reduction at exon 29 
in the GRD Iqgap1-/- livers, but little to no difference in expression compared to Iqgap1+/+ livers in other 
regions (Figure 2.3). Thus, it is likely that the substitution of a neomycin cassette for exon 29 affects 
translation/protein stability resulting in the functional IQGAP1 protein knockout. 
 Upon closer inspection, Iqgap1-/- animals do show phenotypic changes. For example, IQGAP1 is 
important for neuronal dendritic spine formation, and Iqgap1-/- mice exhibit memory defects (Gao, 2011). 
Furthermore, in the adult mouse brain, IQGAP1 is predominantly expressed in proliferating neural 
progenitors and neuronal cells located in the subventricular zone (SVZ) and the rostral migratory stream 
(RMS) (Balenci, 2006). These are a site of self-renewing neurons and a route by which these neurons 
migrate toward the olfactory bulb, respectively. Importantly, Iqgap1-/- animals, while containing similar 
numbers of neural progenitors in the SVZ, show delayed neuronal differentiation and impaired neuronal 
progenitor migration when stimulated with VEGF, which is consistent with the reduced migration observed 
when IQGAP1 was knocked down in cell culture. IQGAP1 expression in progenitor cells has important 
implications in malignant transformation, as neural stem-like cells can be precursors for brain tumors such 
as gliomas (Holland, 2000). In fact, IQGAP1 is expressed in a subpopulation of proliferating cells within 
glioblastomas in rats (Balenci, 2006) and is a marker of aggressive grade III gliomas with poor prognosis 
in humans (McDonald, 2007). Decreasing IQGAP1 expression by re-expressing miR-124a, which is 
downregulated in human glioma tissues, or IQGAP1 knockdown leads to reduced proliferation of glioma 
cells in culture (Lu, 2014). This indicates that IQGAP1 could promote proliferation of neural stem cells, 
which may contribute to tumorigenesis. 
 Another example of the role for IQGAP1 in vivo is regulation of the micro-environment. 
Differentiated CD8+ T cells isolated from Iqgap1-/- mice produce more cytokines in response to phorbol-
12-myristate-13-acetate (PMA) and ionomycin stimulation, which activates the pro-inflammatory 
transcription factor NFAT (Sharma, 2011). IQGAP1 was shown to form a complex with the long non-
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coding RNA NRON, NFAT, and three kinases that inactivate NFAT. Deletion of IQGAP1 relieves NFAT 
inhibition to increase the production of pro-inflammatory cytokines. Additionally, IQGAP1 inhibits TGFβ-
induced differentiation of mesenchymal-type cells such as hepatic stellate cells (HSCs) into activated, 
extracellular matrix-producing myofibroblasts in the liver (Liu, 2013). Thus, Iqgap1-/- mice were shown to 
have more activated myofibroblasts in their liver and subsequently more liver fibrosis at 1 year of age. As 
myofibroblasts produce growth factors and cytokines that could promote tumor implantation, 
angiogenesis, and progression (Kang, 2011), Iqgap1-/- livers exhibited increased tumor burden when 
xenografted with a cancer cell line both 3 days and 10 days post-implantation. 
 Taken together, these data reveal conflicting conclusions for the role of IQGAP1 in regulating 
tumor development and function. On one hand, IQGAP1 is overexpressed in a number of human cancers 
and is associated with a more aggressive phenotype (McDonald, 2007; Dong, 2006; Nabeshima, 2002; 
Jin, 2012; Hayashi, 2010; Xia, 2014; Anakk, 2013; Zhang, 2015; Zhao, 2014). Many animal studies 
(Schmidt, 2008; Anakk, 2013; Jameson, 2013; Bessède, 2016) and in vitro studies (Jin, 2015; Nussinov, 
2018) support the concept that IQGAP1 functions as a tumor promotor, and attempts are being made to 
target IQGAP1 as an anti-cancer approach (Jameson, 2013). However, there is evidence that in certain 
circumstances IQGAP1 may actually function as a tumor suppressor. For example, IQGAP1 expression is 
lower in human bladder cancers compared to surrounding urothelium and xenografted cells expressing 
shRNA for IQGAP1 show more robust tumor growth in mice (Hensel, 2015). 
 It appears that IQGAP1 can have both beneficial and detrimental roles in tumorigenesis 
depending on the context, highlighting the need to understand the role of IQGAP1 in both physiological 
and pathological contexts. Our lab previously found that hepatic IQGAP1 expression is induced by bile 
acids, which precedes the formation of aggressive liver tumors in mice (Anakk, 2013). As bile acids are 
physiological signaling molecules that can reach pathological levels in liver disease, we decided to 
assess IQGAP1 function in the liver along a spectrum of disease, from regulating the response to 
changes in nutrition status to mediating the response to liver injury and promoting tumor development. 






Figure 2.1. IQGAP family structure. 
(A) Domain structure of IQGAP family proteins with residue numbers indicated. (B) Sequence identity 








IR1 216 ALHAAVIAINEAIDRRIPADTFAALKNPNAMLVNLEEPLASTYQDILYQAKQDKMTNAK 
IR2 304 NTFSALANIDLALEQGDALALFRALQSPALGLRGLQQQNSDWYLKQLLSDKQQKRQSGQ 
IR3 387 RRLAAVALINAAIQKGVAEKTVLELMNPEAQLPQVYPFAADLYQKELATLQRQSPEHNL 
IR4 455 EMLSSVALINRALESGDVNTVWKQLSSSVTGLTNIEEENCQRYLDELMKLKAQAHAENN 
IR5 537 ERILAIGLINEALDEGDAQKTLQALQIPAAKLEGVLAEVAQHYQDTLIRAKREKAQEIQ 
IR6 622 KFALGIFAINEAVESGDVGKTLSALRSPDVGLYGVIPECGETYHSDLAEAKKKKLAVGD 
CONSENSUS xxhxAhhxINxAhnxGDhxxxhxxLxuPxhxLxxhxxxxxxxYxxxLhxhKxxxxxxxx 
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Figure 2.2. IR region sequence and structure. 
(A) Amino acid sequence of the six IR repeats of IQGAP1 (Weissbach, 1994). (B) Disorder of the IR 
region and corresponding IR repeats 1-6. Disorder was predicted by assigning scores to individual amino 
acids: bulky hydrophobic (Ile, Leu, and Val) and aromatic (Trp, Tyr, and Phe) amino acid residues are 
associated with low disorder and polar amino acids (Arg, Gln, Ser, Glu, and Lys), structure-breaking 
residues (Gly and Pro), and Ala are associated with high disorder (www.PONDR.com). The location of 






Figure 2.3. Iqgap1 deletion is specific to exon 29 in the GRD. 
Hepatic gene expression of Iqgap1 in Iqgap1+/+ and Iqgap1-/- livers using primers designed to recognize 
the CHD, WW, GRD, and RGCT domains of IQGAP1 normalized to Tbp. Two-way ANOVA with 
Bonferroni’s multiple comparisons test was used to determine significance between four groups under 








IQGAP1 is a ubiquitously expressed scaffolding protein that integrates multiple cellular processes, 
including motility, adhesion, and proliferation, but its role in metabolism is unknown. Here, we show that 
IQGAP1 is induced upon fasting and regulates β-oxidation of fatty acids and synthesis of ketone bodies in 
the liver. IQGAP1-null (Iqgap1-/-) mice exhibit reduced hepatic PPARα transcriptional activity, as 
evidenced during fasting, after ketogenic diet, and upon pharmacological activation. Conversely, we 
found that the activity of fed-state sensor mTORC1 is enhanced in Iqgap1-/- livers, but acute inhibition of 
mTOR in Iqgap1-/- mice was unable to rescue the defect of ketone body synthesis. However, re-
expressing IQGAP1 in the livers of Iqgap1-/- mice was sufficient to promote ketone body synthesis, 
increase PPARα signaling, and suppress mTORC1 activity. Taken together, we uncover what we believe 
to be a previously unidentified role for IQGAP1 in regulating PPARα activity and ketogenesis. 
 
Introduction 
To invariably meet cellular energy demands, the mammalian metabolic response has evolved 
specific programs to regulate energy usage. The liver coordinates these adaptations in part by promoting 
glycogen and fatty acid synthesis in the fed state and switching to fat breakdown and ketone body 
synthesis in the fasted state (Krebs, 1966; Cherrington, 871999; Kersten, 2000; Evans, 2004; Cahill, 
2006; Yecies, 2011; Laplante, 2012; Cornu, 2013). Ketone body synthesis can also be induced 
nutritionally with a low-carbohydrate, high-fat diet known as the ketogenic diet (KD). This creates a unique 
metabolic state in mice that has many similar characteristics to fasting (Kennedy, 2007). 
Coordination of these metabolic responses is tightly regulated in hepatocytes. In the fed state, the 
nutrient sensor mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) regulates protein 
translation through p70-S6 Kinase 1 (S6K1) and eukaryotic translation initiation factor 4E binding protein 
1 (4E-BP1) (Brunn, 1997; Burnett, 1998), lipid synthesis through sterol responsive element binding 
                                                 
1 Adapted from: Erickson HL, Anakk S. Identification of IQ motif-containing GTPase-activating protein 1 
as a regulator of long-term ketosis. JCI Insight. 2018 Nov 2; 3(21) pii: 99866. Doi: 
10.1172/jci.insight.99866 PMID: 30385723 
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protein (SREBP) (Porstman, 2008), and glycolysis through phospho-fructo kinase (Düvel, 2010). In 
addition, mTORC1 suppresses fasting-associated ketogenesis (Sengupta, 2010) and autophagy (Kim, 
2011a; Martina, 2012; Cornu, 2013; Saxton, 2017). Inversely, during the fasting state mTORC1 activity is 
suppressed by AMPK (Gwinn, 2008) and activation of the nuclear receptor PPARα is increased (Kersten, 
1999). PPARα, the master regulator of the fasting response (Kersten, 1999), controls hepatic fatty acid 
oxidation and ketogenesis by targeting several rate limiting genes in these pathways (Grabacka, 2016).  
The IQ motif-containing GTPase Activating Protein (IQGAP) family of multi-domain scaffolding 
proteins includes three members, of which IQGAP1 is ubiquitously expressed (Li, 2000). IQGAP1 
interacts with a multitude of binding partners and integrates signals that control diverse cellular processes 
such as cell-cell adhesion (Kuroda, 1998), cell motility (Mataraza, 2003), cell proliferation (Roy, 2004), 
and membrane receptor signaling (McNulty, 2011). More recently, its role in scaffolding PI3K/AKT 
signaling and subsequent glucose homeostasis has been identified (Choi, 2013; Chawla, 2017). Since all 
of the cellular processes regulated by IQGAP1 require energy, we hypothesized that IQGAP1 has an 
additional role in energy regulation by coordinating the response to changes in nutritional state. 
Here we show that compared to the fed state, hepatic IQGAP1 levels are induced upon fasting 
and its loss impairs the ketogenic response. Since PPARα regulates ketogenic responses, we examined 
its pharmacological activation in the presence and absence of IQGAP1. Compared to Iqgap1+/+ controls, 
IQGAP1-null (Iqgap1-/-) mice show blunted response to PPARα agonism. Mechanistically, Iqgap1-/- mice 
exhibit increased mTORC1 activation, which in turn can inhibit the fasting response. Conversely, 
reintroducing IQGAP1 to the liver of Iqgap1-/- mice decreases mTORC1 activity. These data together 
highlight the importance of IQGAP1 in maintaining an appropriate ketogenic response. Importantly, these 
findings can be recapitulated in primary liver cells and the well-established human hepatoma HePG2 cell 
line, indicative of a cell autonomous role for IQGAP1. Taken together, these results show that IQGAP1 is 






Iqgap1+/+ and Iqgap1-/- mice (generated in A. Bernards’s laboratory, Massachusetts General Hospital, 
Boston, Massachusetts, USA, and obtained from Valentina Schmidt, Stony Brook University, Stony 
Brook, New York, USA) maintained on a 129/SVJ background were housed in flow cages at 24 ℃ on a 
12/12-hour-light/dark cycle, with lights on starting at 5AM CST, corresponding to zeitgeber time (ZT) 0. 
Genotype was confirmed by PCR analysis of genomic DNA as previously described (Li, 2000). 
 
Male 16- to 20-week-old mice were used for all experiments, while 11-week-old female mice were used 
for adenoviral expression of IQGAP1. We used sample sizes typical for this type of work (n ≥ 5-6 mice per 
group). We randomly assigned mice of the same genotype to different treatments but was not blinded 
during experiments and analysis. Mice were allowed ad libitum access to food and water except during 
fasting when they were transferred to a clean cage with access only to water. Fasting experiments were 
initiated at ZT4, which was approximately 9 AM (n = 6-8 mice per genotype). Control mice were allowed 
ad libitum access to food and were sacrificed at ZT4 (n = 8-9 mice per genotype). RF mice were given 
standard chow at ZT4 following a 24-hour fast and were sacrificed 2 hours later at ZT6 (n = 6-9 mice per 
genotype). An additional cohort of RF mice was injected with 10 mg/kg rapamycin intraperitoneally 1 hour 
prior to RF (n = 6-13 mice per genotype). The standard chow diet was Teklad F6 Rodent Diet (8664, 
Envigo), consisting of 31%, 19%, and 50% kcal from protein, fat, and carbohydrates, respectively. In 
contrast, the KD (TD.96355, Envigo) consisted of 9.1%, 90.5%, and 0.4% kcal from protein, fat, and 
carbohydrates, respectively. The KD was divided into 6-cm dishes and frozen prior to feeding, and fresh 
diet was provided daily (n = 6 mice per genotype). For fibrate treatment, Wy-14,643 (WY, Cayman 
Chemical) was dissolved in 100% ethanol to a final concentration of 16.5 mg/mL. The WY solution or 
vehicle was further diluted with corn oil (CO) to a final concentration of 5 mg/mL and stirred under vacuum 
overnight to remove excess ethanol. Mice were oral gavaged with either CO or WY (50 mg/kg) for 4 
consecutive days and sacrificed on the fifth day (n = 5-6 mice per group). For hepatic expression of GFP 
and IQGAP1, female Iqgap1-/- mice were administered high-titer adenovirus expressing either cDNA via 
28 
 
tail vein injection. Three days after injection, mice were started on a 0.5 g/kg doxycycline (Dox) diet and 
sacrificed after 2 weeks (n = 3 mice per group). All mice were sacrificed at ZT4-6. 
 
Blood was collected from each mouse by retro-orbital bleeding just prior to sacrifice. Sera were separated 
by centrifugation and stored at -80 ℃ in opaque tubes. Liver and gonadal white adipose tissues were 




Sodium octanoate (500 mM) in sterile H2O was injected intraperitoneally at 6 µL/g of body weight into 
Iqgap1+/+ and Iqgap1-/- mice after a 24-hour fast. Serum ketones were measured in tail blood using a 
Keto-Mojo Ketone and Glucose Meter immediately before octanoate injection and 2 hours following 
octanoate injection (n = 6-8 mice per group).  
 
Primary hepatocyte isolation and culture 
Mouse hepatocytes were isolated using a 2-step collagenase perfusion technique (Li, 2010). Briefly, livers 
of male adult 129/SVJ Iqgap1+/+ and Iqgap1-/- mice were perfused with 50 mL Solution 1 (1 µM EDTA in 
1x Hanks Balanced Salt Solution without Ca2+ or Mg2+). Livers were then perfused with 50 mL Solution 2 
(3,000 U collagenase type I from Worthington, 0.54 µM CaCl2, 40 µg/mL trypsin inhibitor, and 15 mM 
HEPES, pH 7.4, in 1x Hanks Balanced Salt Solution with Ca2+ and Mg2+). The perfused liver was then 
transferred to a Petri dish containing wash buffer (Williams E media with 1x penicillin/streptomycin and 1x 
L-glutamine) and gently massaged to loosen liver cells. The cell suspension was filtered through a 70-µm 
filter. For isolation of hepatocytes and nonparenchymal cells (NPCs), the cell suspension was centrifuged 
twice at 50 g for 10 minutes. The supernatant was transferred to a new tube and centrifuged at 680 g to 
isolate NPCs. The pellet contained hepatocytes. The isolated hepatocytes and NPCs were incubated in 
red blood cell lysis buffer followed by 3 washes with 1x PBS with 10-minute spins at 320 g and 680 g, 
respectively, after each wash. For primary cell culture, the cell suspension was centrifuged at 600 g for 4 
minutes. The pellet was suspended in 25 mL wash buffer and layered onto a Percoll gradient and 
29 
 
immediately centrifuged at 600 g for 10 minutes. The pellet, enriched for live hepatocytes, was washed 3 
times and then cells were suspended in growing medium (wash media supplemented with 1x Insulin-
Transferrin-Selenium [ITS] solution from Gibco) and plated at 5 x 105 live cells/mL in 6-well collagen-
coated plates. Media were changed 4-6 hours after plating to remove dead cells. Cells were cultured for 
another 24 hours in growing medium. 
 
Adenovirus production and cell culture 
HepG2 cell line (catalog HB-8065) and HEK293T cell line (catalog CRL-3216) were obtained from ATCC 
and cultured according to ATCC specifications. This cell line tested negative for mycoplasma (Biotool, 
catalog B3903). For in vivo infection, adenoviruses expressing full-length Iqgap1 and Gfp were generated 
as previously described (Anakk, 2013). For IQGAP1 overexpression in cell culture, HepG2 cells were 
cultured in tetracycline-free DMEM and transfected with tetracycline-inducible FLAG-tagged Iqgap1 and 
rtTA plasmids using a Mirus TransIT-X2 kit. The next day, the media were replaced with fresh DMEM 
containing 2 ng/mL dox, and protein was collected 24 hours later. For glucose and serum starvation 
experiments, HepG2 cells were cultured with HBSS supplemented with 10% FBS, 2 mM glutamine, and 
10 U/mL penicillin and streptomycin for 12 hours. After this, the HepG2 cells were switched to HBSS 
media lacking either glucose or FBS or both for 6 hours prior to analysis.  
 
Serum chemistry 
Sera were thawed on ice prior to each metabolite assay. Assays were run in duplicate for triglycerides 
(Infinity Triglyceride Stable Reagent, Fisher Scientific), β-hydroxybutyrate (β-hydroxybutyrate (Ketone 
Body) Colorimetric Assay Kit, Cayman Chemical), and free fatty acids (Free Fatty Acid Fluorometric 
Assay Kit, Cayman Chemical). All assays were performed according to the kit instructions, unless stated 
otherwise. For the Free Fatty Acid Kit, absorbance was read at 570 nm and was adjusted for background 
reading at 600 nm. Additionally, Mouse/Rat FGF-21 Quantine ELISA kit (R&D Systems) was used to 





Glucose tolerance test 
Glucose tolerance test was performed as previously described (Norris, 2003). Briefly, mice were fasted 
for 13 hours overnight and administered 2 g/kg D-glucose intraperitoneally. Blood glucose concentrations 
were measured at 0, 15, 30, 60, and 120 minutes after injection using tail blood. 
 
Hepatic triglyceride assay 
Frozen liver tissue (< 50 mg) was weighed and homogenized in 1 mL isopropanol. Samples were 
centrifuged at 4 ℃ and 9,931 g for 15 minutes, and supernatant containing triglycerides was separated. 
Triglyceride content was measured using Infinity Triglyceride Liquid Stable Reagent (Fisher Scientific) 
and normalized to frozen liver weight. 
 
Histology 
Formalin-fixed liver samples were embedded in paraffin wax. Five-micron sections were cut and used for 
H&E staining according to standard methods (Cardiff, 2014). For Oil red O staining, additional liver 
samples were frozen in OCT media upon collection and cut into 8-micron sections. Once dried, the 
sections were fixed in 10% formalin, rinsed with running tap water then 60% isopropanol, and stained with 
fresh Oil red O working solution (0.15 g Oil red O dye in 50 mL of 60% isopropanol) for 15 minutes. The 
slides were then rinsed with 60% isopropanol, stained using Modified Harris Hematoxylin (Richard Allan, 
72711) for 3 minutes, rinsed with diH2O, and cover slipped. 
 
Quantitative RT-PCR 
Total RNA from frozen whole liver tissue was extracted using TRIzol solution (Invitrogen) according to the 
manufacturer’s protocol. RNA quality was determined by A260/280 and bleach RNA gel as previously 
described (Aranda, 2012). RNA (5 µg) was treated with DNase (Promega) and reverse transcribed using 
random hexamer primers (New England Biosciences) and the Maxima Reverse Transcriptase kit (Thermo 
Fisher Scientific). The cDNA was diluted to 12.5 ng/µL with molecular grade water (Corning) and used for 
qRT-PCR assays. qRT-PCR was performed on an Eco Real-Time PCR system (Illumina) in triplicate 
using 50 ng cDNA per reaction and PerfeCTa SYBR Green FastMix (Quanta). All assays were run with 
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an initial activation step for 10 minutes at 95 ℃, followed by 40 cycles of 95 ℃ for 10 seconds and 60 ℃ 
for 30 seconds. Primer sequences are described in Table 3.1. Gapdh, β-actin, and 36b4 were used as 
housekeeping genes. 
 
Western blot analysis 
Protein was extracted from approximately 50 mg frozen liver tissue. RIPA buffer (25 mM Tris, pH 7, 150 
mM NaCl, 0.5% sodium deoxycholate, protease inhibitor [Pierce Protease Inhibitor Mini Tablets, EDTA 
Free; Thermo Fisher Scientific], and 1% Triton X-100) was added to each liver sample, which was 
homogenized by adding eight to ten 1-mm beads and bullet blending for 3 times for 1 minute each time, 
with 1 minute on ice in between. Samples were sonicated until nonviscous. Protein concentration was 
measured by BCA assay (Pierce BCA Protein Assay Kit, Thermo Fisher Scientific). For Western blot, 
10-50 µg of total protein was loaded onto 8%-12% SDS-PAGE gels. After transfer, the membrane was 
incubated with antibodies described in Table 3.2. 
 
Coimmunoprecipitation 
HepG2 cells were transfected with dox-inducible FLAG-IQGAP1 and were treated with dox or vehicle for 
24 hours. After induction, approximately 107 cells were lysed in lysis buffer (50 mM Tris, pH 7.8, 150 mM 
NaCl, 30 mM EDTA, 0.5% Triton X-100). The lysate was then split, and equal amounts were 
immunoprecipitated with a FLAG antibody overnight, washed and resolved on an 8% SDS-PAGE gel. 
After transfer, blots were probed with antibodies for mTOR. 
 
Statistics 
Data are expressed as mean ± SD. All statistical analyses were performed using GraphPad Prism 
software version 6. Student’s unpaired 2-tailed t test was used to compare two groups. Two-way ANOVA 
with Bonferroni’s multiple comparisons test was performed to compare two groups with two treatments. 
Asterisks indicate a statistically significant difference between the treatment group and its respective 
genotype control unless the groups are otherwise indicated. Significance is defined as P < 0.05. Outliers 





All animal studies were approved by the University of Illinois at Urbana-Champaign Institutional Animal 
Care and Use Committee and were carried out as outlined in the Guide for the Care and Use of 
Laboratory Animals (National Academies Press, 2011). 
 
Results 
Iqgap1 is induced in the liver during fasting and alters the fasting response 
As a central coordinator of cellular signaling, IQGAP1 expression levels largely determine its 
function as a scaffold (Jameson, 2013). To investigate whether IQGAP1 could coordinate metabolic 
signaling, we first fasted Iqgap1+/+ (wild-type) 129/SVJ mice for 24 hours and found a 2-fold induction of 
IQGAP1 in the liver (Figure 3.1, A and B). The liver is primarily composed of hepatocytes, which perform 
the major metabolic functions. However, non-parenchymal cells (NPCs) such as endothelial cells, kupffer 
cells, stellate cells, and cholangiocytes are also present. To confirm that IQGAP1 is expressed in 
hepatocytes, we assessed Iqgap1 transcript levels and found that the overall liver gene expression 
pattern reflects that of hepatocytes despite NPCs having ~30-fold higher expression (Figure 3.1, C). The 
increase in Iqgap1 expression was specific to the liver and was not observed in gonadal white adipose 
tissue (WAT) (Figure 3.1, D). We asked if the decrease in glucose or growth factor during fasting is 
responsible for IQGAP1 induction and found that neither glucose nor serum starvation of HepG2 cells 
altered IQGAP1 expression (Figure 3.1, E). 
We next asked whether deletion of IQGAP1 could affect the fasting response by comparing 
fasted Iqgap1+/+ and Iqgap1-/- mice. Both sets of mice lost similar amounts of body weight and liver weight 
upon fasting, as expected (Table 3.3). Serum glucose levels also decreased with fasting, but this 
decrease was more dramatic in Iqgap1-/- mice since they were hyperglycemic in the fed state and 
hypoglycemic in the fasted state compared to Iq gap1+/+ mice (Table 3.3). The observed hyperglycemia in 
Iqgap1-/- mice was consistent with the observed modest insulin resistant under chow (Figure 3.2, A) and 
published data that show that loss of IQGAP1 results in poor glucose tolerance (Chawla, 2017). Further, 
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we found that the reduction of glucose is not due to a lack of gluconeogenic response in the Iqgap1-/- 
livers (Figure 3.2, B-D). 
Normally, serum glucose levels are maintained during prolonged fasting by switching to an 
alternate fuel source. For instance, lipolysis and fatty acid release from adipose tissue result in elevation 
of serum fatty acids that can be directly used by many tissues, including liver, as fuel. Iqgap1+/+ and 
Iqgap1-/- mice exhibited a similar percent increase in serum nonesterified fatty acids (NEFAs), even 
though the absolute fasting serum NEFA and triglyceride values were significantly lower in Iqgap1-/- mice 
(Table 3.3). This can be attributed to the lower average serum NEFA and triglyceride levels in Iqgap1-/- 
mice in the fed state. To test if these differences are due to poor fat mobilization, we examined the WAT 
weight and found that Iqgap1-/- mice lost an average 8% of their visceral WAT by weight upon fasting 
while the Iqgap1+/+ mice lost 5% (Table 3.3). Histological analysis of WAT depots did not reveal any 
differences in adipocyte size (Figure 3.3, A). Furthermore, we found comparable expression of lipogenic 
genes, including Srebp1c and its target Fasn (Figure 3.3, B-C), as well as lipases Hsl, Lpl, and Atgl in 
adipose tissue of both animals (Figure 3.3, D). Additionally, phosphorylation of HSL in WAT were induced 
to a higher extent upon fasting in Iqgap1-/- mice compared to Iqgap1+/+ controls (Figure 3.3, E). These 
data indicate that the adipose tissue expression profile of fat mobilization gees was unaltered in Iqgap1-/- 
mice. 
Despite lower serum fatty acids in the serum of Iqgap1-/- mice, fat accumulated to a similar level 
in Iqgap1+/+ and Iqgap1-/- mice upon fasting (Table 3.3), suggesting that IQGAP1 deletion does not affect 
fat uptake into hepatocytes. We next examined if the fatty acids taken up by the liver during fasting are 
oxidized and converted to ketone bodies, which are essential alternate fuels during fasting. Serum levels 
of β-hydroxybutyrate, the predominant form of ketone body, were dramatically increased in Iqgap1+/+ 
mice, but this was blunted in Iqgap1-/- mice (Figure 3.4, A). We also examined serum ketone 
concentrations after injection with octanoate, a medium-chain fatty acid substrate that can be rapidly 
converted to ketones (Figure 3.4, B). The increase in serum β-hydroxybutyrate was lower in Iqgap1-/- 
mice compared with Iqgap1+/+ mice (Figure 3.4, C). This result demonstrates that, despite substrate 
availability, Iqgap1-/- mice exhibit impaired ketogenesis. Furthermore, induced expression of fatty acid β-
oxidation genes medium-chain acyl-CoA dehydrogenase (Acadm) and enoyl-CoA hydratase/3-
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hydroxyacyl-CoA dehydrogenase (Ehhadh) as well as FGF21 (Fgf21), a known endocrine signal during 
ketosis (Badman, 2007; Inagaki, 2007), was significantly dampened in the absence of IQGAP1 (Figure 
3.4, D-F). These changes corresponded to lower circulating FGF21 levels in Iqgap1-/- mice (Figure 3.4, 
G). These data uncover a role for IQGAP1 in maintaining appropriate hepatic fatty acid metabolism and 
ketogenesis. 
 
IQGAP1 is crucial to long-term ketogenic adaptation of the liver 
 Since we localized the metabolic defect in Iqgap1-/- mice to decreased hepatic expression of 
multiple genes involved in the β-oxidation pathway, we examined long-term ketosis in these animals. To 
do this, Iqgap1+/+ and Iqgap1-/- mice were fed a high-fat, low-carbohydrate ketogenic diet (KD) for 4 
weeks. Both cohorts displayed similar changes in overall body weight (Figure 3.5, A), but liver:body 
weight ratio was reduced in KD-fed Iqgap1+/+ but not Iqgap1-/- mice (Figure 3.5, B). Iqgap1-/- livers 
appeared pale (Figure 3.5, C) and microsteatotic (Figure 3.5, D) compared with that of Iqgap1+/+ mice. On 
the other hand, the reduction in serum NEFA and triglycerides was seen in both groups of mice (Figure 
3.5, E and F). Further, the WAT size, though originally smaller in Iqgap1-/- mice compared to Iqgap1+/+ 
controls, increased by a similar proportion in both groups (Figure 3.6, A) and had similar expression of 
lipase genes (Figure 3.6, B-D), indicating a metabolic defect in the liver. 
 To understand the basis of increased fat accumulation in KD-fed Iqgap1-/- livers, we examined the 
expression of genes controlling fatty acid breakdown and ketogenesis. We found that induction of 
carnitine palmitoyltransferase 1A (Ctp1a), β-oxidation genes Ehhadh and Acadm (but not Hadha), 
ketogenic genes hydroxymethylglutaryl-CoA synthase 2 (Hmgcs2) and 3-hydroxybutyrate dehydrogenase 
(Bdh1), Fgf21, and cytochrome P450 4A10 (Cyp4a10), which are all peroxisome proliferator receptor α 
(Ppara) targets, was all significantly decreased in the absence of IQGAP1 (Figure 3.7, A-H). Subsequent 
to the reduced β-oxidation and ketogenesis, we found lower levels of circulating ketone bodies in KD-fed 
Iqgap1-/- animals compared with those in Iqgap1+/+ animals (Figure 3.7, I). These results indicate that 




Loss of IQGAP1 deregulates PPARα signaling and mTORC1 activation 
 The nuclear receptor PPARα is a critical transcriptional regulator of the fasting and ketogenic 
response (Kersten, 1999; Badman, 2007). In fact, Ppara-/- mice are unable to adapt to nutritional 
challenges and develop fatty liver (Kersten, 1999; Hashimoto, 2000). Therefore, we next examined 
PPARα activation in the presence and absence of IQGAP1 by treating mice with the PPARα agonist Wy-
14,643 (WY) (Green, 1995; Schoonjans, 1996). It is interesting to note that Ppara transcript levels were in 
a higher range upon corn oil (CO) control treatment in Iqgap1-/- and were not induced by WY compared 
with Iqgap1+/+ mice (Figure 3.8, A). Several downstream targets of PPARα, including Acadm, Hadha, 
Hmgcs2, and Bdh1, were not significantly induced in WY-treated Iqgap1-/- mice while Cpt1a and Ehhadh 
displayed similar induction to that of WY-treated Iqgap1+/+ mice (Figure 3.8, B-G). Surprisingly, WY 
treatment led to higher transcript expression of Fgf21 and Cyp4a10 in Iqgap1-/- livers than in Iqgap1+/+ 
livers. However, the fold induction compared with CO-treated mice was similar between the two groups, 
since the basal levels following CO treatment was higher for these two genes in Iqgap1-/- livers (Figure 
3.8, H and I). On the other hand, fed-state serum ketone concentrations did not reveal any increase in 
response to WY treatment in Iqgap1-/- mice (Figure 3.8, J). 
 Next, we investigated the activity of the fed-state sensor mTORC1 in Iqgap1+/+ and Iqgap1-/- 
livers. Activation of mTORC1 was measured by assessing phosphorylation of its two bona fide targets – 
S6 ribosomal protein and 4E-BP1. S6 phosphorylation at S240/244 and S235/236 sites, along with 
phosphorylation of 4E-BP1 (Brunn, 1997; Burnett, 1998) showed an approximate 2-fold increase in 
Iqgap1-/- livers compared with Iqgap1+/+ livers upon refeeding (RF) (Figure 3.9, A) Additionally, primary 
hepatocytes from Iqgap1-/- mice exhibited higher S6 phosphorylation (Figure 3.9, B), indicative of 
increased mTORC1 activity when IQGAP1 is absent. Conversely, increasing IQGAP1 levels in the HepG2 
cell line was able to decrease S6 phosphorylation (Figure 3.9, C). To determine if IQGAP1 could regulate 
mTORC1 through a direct interaction, we expressed FLAG-tagged IQGAP1 in HEK293T cells and pulled 
down IQGAP1-interacting proteins using an anti-FLAG antibody. We found higher levels of mTOR pulled 
down in cells expressing FLAG-IQGAP1 (Figure 3.9, D). Together, this suggests that IQGAP1 can directly 
mTOR activation.  
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To identify the mechanism responsible for higher activity of mTORC1, we examined upstream 
signals, such as AKT, which can promote mTORC1 activity, and AMPK, which can inhibit its activity. As 
expected, we found that P-mTOR (S2448) levels decreased in the fasted state and were restored upon 
RF in Iqgap1+/+ mice (Figure 3.9, E). The induction of P-mTOR relative to total mTOR levels was higher in 
Iqgap1-/- mice, validating increased mTORC1 activity in the absence of IQGAP1. Compared with Iqgap1+/+ 
livers, Iqgap1-/- livers in the RF state exhibited higher P-AKT (S473) levels, whereas the changes in P-
AMPK relative to total AMPK were similar between groups (Figure 3.9, E). The increase in AKT signaling 
is intriguing since it has been shown that Iqgap1-/- livers exhibit a blunted increase in P-AKT levels 10-15 
minutes after insulin treatment (Choi, 2016; Chawla, 2017). Since RF experiments were performed 120 
minutes after feeding and not immediately, Iqgap1+/+ mice did not show a robust increase in P-AKT. It is 
possible that this in turn may exaggerate the P-AKT levels observed in Iqgap1-/- livers. Nonetheless, the 
increase in P-AKT levels is consistent with higher mTORC1 activity. 
 
Short-term mTOR inhibition does not alleviate the ketogenic defect in Iqgap1-/- mice 
 We next tested whether inhibiting mTOR can reverse any of the β-oxidation defects observed in 
Iqgap1-/- mice by treating mice with rapamycin 1 hour prior to refeeding. We ensured that loss of IQGAP1 
did not affect mTORC1 inhibition by rapamycin in vivo (Figure 3.10, A). Hepatic triglyceride concentration 
was reduced when mTOR was inhibited in the RF state (Figure 3.10, B), while serum triglyceride 
concentration was reduced when mTOR was inhibited in the RF state (Figure 3.10, C). No alteration in 
hepatic triglyceride levels was observed in Iqgap1-/- livers. However, serum triglyceride concentrations 
were lower in the fasted state and were modestly elevated in the RF state but significantly lower in the 
rapamycin-treated RF condition (Figure 3.10, C). Serum NEFA levels, on the other hand, were high 
during fasting, which indicates fat mobilization from adipose tissue, and this was reduced upon RF 
independent of mTORC1 activation (Figure 3.10, D). Similarly, serum ketone concentration dropped 
dramatically after refeeding independent of mTORC1, suggesting that the feeding cue more robustly 
regulates serum ketone levels than mTORC1 inhibition (Figure 3.10, E). RF, as expected, reduced Ppara 
expression, which wasn’t affected by rapamycin treatment (Figure 3.10, F). Expression of PPARα target 
genes involved in β-oxidation, such as Cpt1a, Ehhadh, and Acadm (Figure 3.10, G-I), was reduced upon 
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RF in Iqgap1+/+ mice. Iqgap1-/- livers displayed lower levels of PPARα target genes under fasted and RF 
conditions, and rapamycin treatment did not alter their expression pattern. These results suggest that 
mTOR-independent mechanisms may contribute toward β-oxidation in the liver and ketogenesis in 
Iqgap1-/- livers. 
 Despite no changes in PPARα target gene expression, the differences in serum and hepatic fatty 
acids suggest there could be differences in lipogenic gene expression in Iqgap1-/- mice. The lipogenic 
genes Srebp1c and fatty acid synthase (Fasn) are regulated by mTORC1 but are suppressed in livers 
with chronic mTORC1 activation (Yecies, 2011). We examined expression of these genes and found 
them significantly downregulated in Iqgap1-/- mice (Figure 3.10, J-K). RF did not alter Sreb1c transcript 
levels but induced Fasn expression in Iqgap1+/+ mice. mTOR inhibition in RF mice dramatically reduced 
expression of Srebp1c in both Iqgap1+/+ and Iqgap1-/- mice, indicating that mTOR activation is important 
to maintain this regulator of lipogenesis (Figure 3.10, J). On the other hand, Fasn transcript levels were 
reduced with rapamycin treatment in Iqgap1+/+ mice but not in Iqgap1-/- mice (Figure 3.10, K). Notably, in 
Iqgap1-/- mice the levels of Fasn gene expression increased upon mTOR inhibition, which could be 
subsequent to the transient relieving of chronic mTOR activation in these animals. Taken together, these 
indicate that the increased mTORC1 activation in the absence of IQGAP1 affects lipogenesis in the RF 
state. 
 
Restoration of hepatic IQGAP1 expression reverses PPARα and mTORC1 effects. 
 Finally, we examined if re-expressing IQGAP1 specifically in the livers of Iqgap1-/- mice is 
sufficient to restore metabolic gene expression. Compared with adenoviral GFP control, adenoviral 
IQGAP1 results in reduced hepatic mTORC1 activity (Figure 3.11, A) and increased serum ketone 
concentrations in the fasted state (Figure 3.11, B) in Iqgap1-/- mice. Importantly, reintroducing IQGAP1 
was sufficient to induce PPARα target genes (Figure 3.11, C-F), indicating that IQGAP1 is necessary to 
maintain fatty acid oxidation and ketogenesis. Taken together, these data reveal that IQGAP1 levels are 





 The liver plays a central role in nutrient metabolism, and several transcriptional, post-
translational, and allosteric regulators that orchestrate this process have been identified (Krebs, 1966; 
McGarry, 1977; Cherrington, 1999; Reddy, 2001; Evans, 2004; Howell, 2011; Kersten, 2014). Scaffolding 
proteins can integrate different signals, but their metabolic roles are yet to be fully elucidated. In this 
study, we examined a role for IQGAP1, a multidomain-containing scaffolding protein that interacts with 
numerous signaling molecules, including calmodulin (Hart, 1996), MAPK (Roy, 2005), PI3K (Choi, 2013), 
AKT (Chen, 2010), and forkhead box protein O1 (Pan, 2017), in coordinating the hepatic response to 
long-term ketosis. While its role in cellular signaling has been well studied (Briggs, 2003; Smith, 2015), 
the role for IQGAP1 in hepatic metabolism is poorly understood. 
 We found increased IQGAP1 expression in the liver upon fasting that was not secondary to the 
decrease in serum glucose levels. Instead, we identified that the IQGAP1 increase was associated with 
fatty acid oxidation and ketogenesis, since Iqgap1-/- mice showed defects in these pathways and re-
expressing hepatic IQGAP1 could reverse the PPARα signaling defect. Despite being slightly more 
hypoglycemic than the Iqgap1+/+ mice during fasting, Iqgap1-/- mice did not show alterations in the 
gluconeogenic response, which could be attributed to intact expression of Pgc1α, a key regulator of 
gluconeogenesis (Yoon, 2001), in the livers of Iqgap1-/- mice. Rather, this hypoglycemia may be 
secondary to lower serum ketone body levels. In particular, we found that IQGAP1 was required to 
maintain long-term ketogenesis, since Iqgap1-/- mice displayed a poor ability to break down fat and 
synthesize ketone bodies when we challenged them with nutritional ketosis for 4 weeks (Kennedy, 2007; 
Bielohuby, 2011). This defect was not due to mobilization of fatty acids into the liver since hepatic 
triglycerides were increased in Iqgap1-/- mice. But the reason for lower circulating concentrations of NEFA 
and triglyceride levels in Iqgap1-/- mice is therefore unclear. Overall, these data indicate downstream 
defects in hepatic fatty acid metabolism and ketogenesis in Iqgap1-/- mice. 
 We mapped the metabolic defect in Iqgap1-/- livers to impaired ligand-activated nuclear receptor 
PPARα signaling. PPARα is a primary regulator of the fasting response such that Ppara-/- mice exhibit 
elevated hepatic triglycerides, reduced expression of β-oxidation genes, and lower serum FGF21 and 
ketone body levels during prolonged ketosis (Badman, 2007; Inagaki, 2007). Similarly, Fgf21-/- mice also 
39 
 
show lower ketone body levels when fed KD (Badman, 2009; Puchalska, 2017). Iqgap1-/- mice exhibit an 
overlapping phenotype with both Ppara-/- and Fgf21-/- mice, indicating that IQGAP1 is crucial for regulating 
ketogenesis (Table 3.4). Furthermore, it has been shown that fatty acids, particularly those synthesized 
de novo by fatty acid synthase, act as physiological ligands for PPARα (Chakravarthy, 2009). Hepatic 
Fasn-/- mice mimic Ppara-/- mice but are rescued by agonistic activation of PPARα (Chakravarthy, 2005). 
We treated Iqgap1-/- animals with the  PPARα synthetic agonist WY (Green, 1995) and found that PPARα 
activation did not restore all the PPARα gene targets examined in this chapter; a subset of genes, 
including Ppara, Acadm, Hmgcs2, and Bdh1, did not respond, whereas Cpt1a and Ehhadh were induced 
at levels compared to those of Iqgap1+/+ mice. PPARα agonistic induction of Fgf21 and Cyp4a10 was 
higher in Iqgap1-/- animals, and these data suggest that endogenous ligand may be a limiting factor for 
PPARα activation of these genes in Iqgap1-/- mice. 
 Since we found a defective response to fasting cues in the liver, we examined the levels of the 
fed-state sensor mTOR in Iqgap1-/- mice and was surprised to find increased mTORC1 activity. Further, 
examination during fasted and refed states revealed that deletion of IQGAP1 resulted in higher mTORC1 
downstream kinase signaling. We also observed that transiently increasing IQGAP1 expression could 
suppress mTORC1 signaling in cells. This result is opposite to a previous study (Tekletsadik, 2012), 
which showed that the IR-WW domain of IQGAP1 positively regulated mTORC1 in the absence of growth 
factors. We attribute this difference in data to the context and experimental approaches utilized. We used 
the livers from Iqgap1-/- animals after nutrient deprivation, whereas the previous study used either IR-WW 
or C-terminal domains of IQGAP1 for their analysis. These seemingly contradictory results could be 
resolved if the IR-WW construct, instead of increasing the amount of functional IQGAP1 in the cell, was 
shown to compete with full-length IQGAP1 as discussed in Chapter 2. Further studies will be necessarily 
to elucidate how IQGAP1 performs this inhibitory function in vivo. However, in line with multiple earlier 
reports, we did observe that IQGAP1 can directly bind to mTOR (Chen, 2010; Tekletsadik, 2012). 
It was shown that mTORC1 can inhibit PPARα activation by recruiting the corepressor NCoR1 to 
PPARα-response elements (Sengupta, 2010). Our data, along with this finding, suggest that the 
dampening in PPARα activation in Iqgap1-/- mice could be secondary to the higher mTORC1 activity. To 
test this, we inhibited mTORC1 activity with rapamycin and validated the reduction in S6 and 4E-BP1 
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phosphorylation. However, we were unable to reproduce the effect on ketone body levels and PPARα 
target gene expression expected in wild-type mice that was previously reported in Sengupta, 2010. There 
are a number of conditions that varied between studies that could contribute to this discrepancy. We tried 
to reproduce their results using wild-type C57BL/6 mice instead of 129/SVJ mice and starting the fast at 
ZT12 instead of ZT4, but this was not sufficient to see the effect on serum ketone levels (data not shown). 
It is possible that there are other contributing factors that have not yet been tested. Going forward, it will 
be important to test the length and timing of rapamycin treatment in relation to fasting and feeding states 
as these can contribute to its effects (Fang, 2013; Li, 2014). Should a causative relationship be 
established between the increased mTORC1 in the absence of IQGAP1 and impaired ketogenesis, this 
would indicate that intermittent, transient increases in mTORC1 activity can have a long-term effect on 
PPARα and ketone body metabolism. Typically, hepatic mTORC1 acts as the major regulator of cellular 
energetics (Cornu, 2013; Saxton, 2017), but it is possible that mTORC2 could also attribute to the 
phenotype. 
 Lastly, we demonstrate that re-introducing IQGAP1 in Iqgap1-/- mice was able to rescue 
expression of PPARα and several of its targets. Thus, we conclude that IQGAP1 functions to modulate 
PPARα activity and subsequent control of the nutritional response to long-term ketosis. 
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Figures and Tables 
 
 
Figure 3.1. Iqgap1 is induced in the liver with fasting.  
Iqgap1+/+ mice were fed ad libitum or fasted for 24 hours. (A) Immunoblots of whole liver extracts. Each 
lane is a mixture of liver extracts from 2 mice (n = 6 mice per group). (B) Quantification of average relative 
IQGAP1 protein per mouse, measured from 7 Western blots. IQGAP1 levels were normalized to GAPDH 
expression using densitometry. Each dot represents a single mouse. (C) Iqgap1 gene expression 
normalized to Gapdh expression in liver, hepatocytes (Heps), and NPCs of fed mice. (D) Gene 
expression of Iqgap1 in WAT of fed and fasted mice normalized to Gapdh expression. (E) Immunoblot of 
protein extracts from HepG2 cells subjected to serum or glucose deprivation for 24 hours. Each lane 
contains pooled protein from three separate wells. Values are displayed as mean ± SD. Two-tailed 
unpaired t-test was used to determine significance between two groups. Significance is indicated with * P 







Figure 3.2. Loss of Iqgap1 results in mild glucose intolerance but does not affect gluconeogenic gene 
expression. 
Iqgap1+/+ and Iqgap1-/- mice were fed ad libitum or fasted for 24 hours. (A) Intraperitoneal glucose 
tolerance test (n = 7 mice per group). Mean area under curve (AUC) is listed. (B-D) Hepatic gene 
expression of (B) Pepck, (C) Pgc1a, and (D) Hnf4a normalized to Gapdh expression. Values are 
displayed as mean ± SD. Two-way ANOVA with Bonferroni multiple comparisons test was used to 
determine significance between two groups under two conditions. Significance is indicated with * P < 






Figure 3.3. WAT response to fasting is comparable between Iqgap1+/+ and Iqgap1-/- mice. 
Both groups of mice were fed ad libitum or fasted for 24 hours. (A) Representative images of WAT 
sections stained with hematoxylin/eosin (H&E). (B-E) WAT gene expression of lipogenic genes (B) 
Srebp1c and (C) Fasn and (D) lipases Atgl, Hsl, and Lpl. Gene expression was normalized to 36b4 
expression. (F) Immunoblot of Iqgap1+/+ and Iqgap1-/- WAT protein extracts. Each lane contains WAT 
extracts from a single mouse. Values are displayed as mean ± SD. Two-way ANOVA with Bonferroni 
multiple comparisons test was used to determine significance between two groups under two conditions. 
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Treatment P < 0.0001
Genotype P = 0.0048
Interaction P = 0.0258
Treatment P < 0.0001
Genotype P = 0.0135
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Treatment P < 0.0001
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Genotype P = 0.0030










Iqgap1   Fast-/-Iqgap1    Fed+/+ Iqgap1    Fast+/+A
Fed Fast
 
Figure 3.4. Deletion of IQGAP1 blunts the ketogenic response 
Mice were fed ad libitum or fasted for 24 hours. (A) Representative images of H&E and Oil Red O staining 
of liver sections from Iqgap1+/+ and Iqgap1-/- mice (n = 5-6 mice per group). Scale bar: 50 µm; 10 µm 
(inset). (B) Serum β-hydroxybutyrate levels (n = 3 mice per group). (C) Schematic depicting the workflow 
for measuring ketogenic potential. (D) Serum ketone body levels measured before and after sodium 
octanoate treatment (n = 6-8 mice per group). (E-G) Hepatic gene expression of (E) Acadm, (F) Ehhadh, 
and (G) Fgf21 normalized to Gapdh in Iqgap1+/+ and Iqgap1-/- mice (n = 6-10 mice per group). (H) Serum 
FGF21 levels were measured by ELISA (n = 6-7 mice per group). Values are displayed as mean ± SD. 
Two-tailed unpaired t-test was used to determine significance between two groups under two conditions. 
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Figure 3.5. Iqgap1-/- mice accumulate excess hepatic fat when challenged with KD. 
Iqgap1+/+ and Iqgap1-/- mice were fed KD for 4 weeks and fasted overnight (n = 6 mice per group). Control 
mice were fed normal chow ad libitum (n = 9-10 mice per group). (A) Body weight measured over time 
during KD feeding. (B) Liver weight normalized to total body weight. (C) Gross appearance of livers from 
KD-fed Iqgap1+/+ and Iqgap1-/- mice. Scale bar: 1 cm. (D) Hepatic triglyceride was measured in Iqgap1+/+ 
and Iqgap1-/- mice (n = 6 mice per group). (E) Representative images of H&E-stained and Oil red O-
stained liver sections from KD-fed mice (n = 6 mice per group). (F and G) Serum NEFA and triglyceride 
(TG) levels (n = 3-8 mice per group). Values are displayed as mean ± SD. Two-way ANOVA with 
Bonferroni multiple comparisons test was used to determine significance between two groups under two 






Figure 3.6. Characterization of WAT size and gene expression in mice on KD. 
Iqgap1+/+ and Iqgap1-/- mice were fed KD for 4 weeks. (A) WAT weight normalized to body weight. (B-D) 
WAT gene expression of (B) Atgl, (C) Hsl, and (D) Lpl normalized to 36b4 expression. Values are 
displayed as mean ± SD. Two-way ANOVA with Bonferroni multiple comparisons test was used to 
determine significance between two groups under two conditions. Significance is indicated with * P < 






Figure 3.7. Ketogenesis is significantly reduced when IQGAP1 is deleted. 
Iqgap1+/+ and Iqgap1-/- mice were fed KD for 4 weeks. (A-H) Hepatic gene expression of β-oxidation 
genes (A) Cpt1a, (B) Acadm, (C) Ehhadh, and (D) Hadha and ketogenesis genes (E) Hmgcs2, (F) Bdh1, 
and (G) Fgf21, and (H) ω-oxidation gene Cyp4a10. All gene expression was normalized to Gapdh 
expression. (I) Serum β-hydroxybutyrate levels (n = 6-7 mice per group). (J) Schematic depicting genes 
with altered expression in Iqgap1-/- mice in blue and their position within the fatty oxidation and 
ketogenesis pathways. Values are displayed as mean ± SD. Two-way ANOVA with Bonferroni multiple 
comparisons test was used to determine significance between two groups under two conditions. 







Figure 3.8. PPARα activation is dysregulated in Iqgap1-/- livers. 
Iqgap1+/+ and Iqgap1-/- mice were administered vehicle (CO) or Wy-14,643 (WY) daily for 4 days. (A-E) 
Hepatic gene expression of (A) Ppara, β-oxidation genes (B) Acadm and (C) Hadha, and ketogenesis 
genes (D) Hmgcs2 and (E) Bdh1 shows decreased induction in Iqgap1-/- animals. (F and G) Hepatic gene 
expression of β-oxidation genes (F) Cpt1a and (G) Ehhadh shows similar induction. (H and I) Hepatic 
gene expression of (H) Fgf21 and (I) ω-oxidation gene Cyp4a10. Expression was normalized to Gapdh 
expression (n = 5-6 mice per group). Values are displayed as mean ± SD. Two-way ANOVA with 
Bonferroni multiple comparisons test was used to determine significance between two groups under two 

















































































































































































Figure 3.9. mTORC1 activity is enhanced in the absence of IQGAP1. 
Iqgap1+/+ and Iqgap1-/- mice were fasted for 24 hours or fasted 24 hours then fed chow for 2 hours (RF). 
(A) Immunoblot of liver extracts from fasted and RF mice. Each lane is a mixture of liver extracts from 2 
mice. Western quantification by densitometry at right. (B) Immunoblot of cell extracts from Iqgap1+/+ and 
Iqgap1-/- primary hepatocytes cultured for 24 hours on collagen-coated plates. Each lane represents 
hepatocytes from an individual mouse (n = 3 mice per group). (C) HepG2 cells were transfected with dox-
inducible FLAG-IQGAP1 construct and treated with 2 ng/µL doxycycline (+Dox) or vehicle (-Dox) for 24 
hours. Immunoblot of protein extracts. Each lane represents an individual well. IQGAP1 levels were 
normalized to GAPDH expression and P-S6 (S240/244). Levels were normalized to total-S6 expression. 
Average relative level in presence of dox relative to vehicle is indicated. (D) FLAG-tagged IQGAP1 was 
immunoprecipitated using anti-FLAG antibodies from equal amounts of cell lysate from HEK293T cells 
expressing FLAG-IQGAP1 (+Dox) or controls (-Dox). Overexpression of FLAG-IQGAP1 was confirmed 
and mTOR levels were examined in whole cell lysates (input). Ponceau S was used as a loading control. 
Pulled down proteins were then separated by SDS_PAGE and blotted for mTOR (IP:FLAG). (E) 
Immunoblot of Iqgap1+/+ and Iqgap1-/- liver extracts from ad libitum fed, fasted, and RF mice. Each lane is 
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Figure 3.10. Effect of mTOR inhibition in Iqgap1-/- mice. 
Iqgap1+/+ and Iqgap1-/- mice were fasted for 24 hours and administered 10 mg/kg rapamycin 1 hour prior 
to RF. (A) Immunoblot of liver extracts. Ponceau S was used as a loading control. Each lane represents 
an individual mouse. (B-D) Hepatic triglycerides (B), serum triglycerides (C), serum NEFA (D), and serum 
ketones (E) were measured (n = 4-8 mice per group). (F-K) Hepatic gene expression of Ppara (F), Cpt1a  
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Figure 3.10. (Continued) 
(G), Ehhadh (H), Acadm (I), Srebp1c (J), and Fasn (K) normalized to Gapdh expression. Values are 
displayed as mean ± SD. Two-way ANOVA with Bonferroni multiple comparisons test was used to 
determine significance between two groups under three conditions. Significance is indicated by * P < 







Figure 3.11. Re-expressing IQGAP1 in Iqgap1-/- livers restores appropriate mTORC1 and PPARα 
signaling. 
Adenoviruses expressing either Gfp (AD.GFP) or Iqgap1 (AD.IQGAP1) were injected into female Iqgap1-/- 
mice via the tail vein. Two weeks later, mice were fed ad libitum or fasted 24 hours. (A) Immunoblot of fed 
AD.GFP and AD.IQGAP1 liver extracts. Each lane represents an individual mouse (n = 3 mice per group). 
Quantification of protein levels by densitometry displayed at right. (B) Serum ketone levels (n = 3 mice per 
group). (C-F) Hepatic gene expression of (C) Cpt1a, (D) Ehhadh, (E) Cyp4a10, and (F) Acadm. 
Expression was normalized to Gapdh expression. Values are displayed as mean ± SD. Two-way ANOVA 
with Bonferroni multiple comparisons test was used to determine significance between two groups under 




Table 3.1. Primers used. 
Gene Species Forward (5’ → 3’) Reverse (5’ → 3’) 
36b4 Mouse AGATGCAGCAGATCCGCAT GTTCTTGCCCATCAGCACC 
Acadm Mouse GATGAAGGTTGAACTCGCTAGG CCTTGCAATCGAGGCATAGTA 
Atgl Mouse TCCGTGGCTGTCTACTAAAGA TGGGATATGATGACGTTCTCTCC 
Bdh1 Mouse GTTAACAACGCAGGCATCTC CACTTCAGCCACCTCCTTAT 
Cpt1a Mouse TGATGACGGCTATGGTGTTTC CAAACAAGGTGATAATGTCCATC 
Cyp4a10 Mouse GCTGAGGTGGACACATTCAT AGGCTCTGAACTTCCTCTCT 
Ehhadh Mouse GCCATCAAGGAAGAAGCAAAG CTGAGGGAGTTGACCACTTATT 
Fasn Mouse GCTGCGGAAACTTCAGGAAAT AGAGACGTGTCACTCCTGGACTT 
Fgf21 Mouse CAAATCCTGGGTGTCAAAGC CATGGGCTTCAGACTGGTAC 
Gapdh Mouse AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
Hadha Mouse CGAAGTGGGTGTGGATGTAG CCTTGGAGACCATCTGTTTCA 
Hmgsc2 Mouse CCTCTGTGAATCCTGGGTGT CTGTGGGGAAAGATCTGCAT 
Hnf4a Mouse AGGTGCCAACCTCAATTCATC TCGAGGCTCCGTAGTGTTT 
Hsl Mouse CTGGTGCAGAGAGACACTTC CTTGCGTCCACTTAGTTCCA 
Lpl Mouse AACAAGGTCAGAGCCAAGAG CCATCCTCAGTCCCAGAAAAG 
Pepck Mouse GTTCCCAGGGTGCATGAAAG AGGGCGAGTCTGTCAGTTCAA 
Pgc1a Mouse CCCACAGAAAACAGGAACAG CTGGGGTCAGAGGAAGAGAT 
Ppara Mouse ACAAGGCCTCAGGGTACCA GCCGAAAGAAGCCCTTACAG 





Table 3.2. Antibodies used. 
Target Antibody Source Catalog # Dilution 
FLAG Mb anti-FLAG M2-Peroxidase (HRP) Sigma-Aldrich A8592 1:1000 
GAPDH Rb anti-GAPDH Sigma-Aldrich G9545 1:5000 
IQGAP1 Rb anti-IQGAP1 [EPR5220] Abcam Ab133490 1:1000 






mTOR Rb anti-mTOR (7C10) Cell Signaling #2983 1:1000 
P-4EBP1 Rb anti-Phospho-4E-BP1 (T37/46) Cell Signaling #2855 1:1000 
P-S6 
(S235/236) 
Rb anti-Phospho-S6 Ribosomal 
Protein (Ser235/236) (2F9) 
Cell Signaling #4856 1:1000 
P-S6 
(S240/244) 
Rb anti-Phospho-S6 Ribosomal 
Protein (Ser240/244) 
Cell Signaling #2215 1:1000 
Rabbit IgG 
Gt anti-Rabbit IgG (H+L) Secondary 
Antibody, HRP 
Thermo Fisher #31460 1:5000 





Table 3.3. Metabolic characterization of Iqgap1+/+ and Iqgap1-/- mice. 
 Fed Fast 
 Iqgap1+/+ Iqgap1-/- Iqgap1+/+ Iqgap1-/- 
Energy balance 
     Body weight (g) 27.1 ± 2.8 25.1 ± 3.8 24.7 ± 4.9 21.0 ± 2.1 
     Liver weight (g) 1.03 ± 0.26 0.95 ± 0.14 0.80 ± 0.35 0.66 ± 0.08a 
     Liver-body weight ratio (%) 3.75 ± 0.77 3.83 ± 0.48 2.72 ± 0.56 3.14 ± 0.22a 
     WAT weight (g) 0.75 ± 0.28 0.50 ± 0.18b 0.67 ± 0.19 0.38 ± 0.08b 
     WAT-body weight ratio (%) 2.76 ± 0.90 1.95 ± 0.53b 2.72 ± 0.56 1.78 ± 0.33b 
Serum parameters 
     Glucose (mg/dL) 144.4 ± 14.2 167.6 ± 14.5b 96.2 ± 21.9a 78.6 ± 18.3a,b 
     Triglycerides (mg/dL) 142.2 ± 32.3 103.1 ± 26.4b 103.1 ± 25.7a 6.71 ± 4.4a,b 
     NEFAs (mEq) 1.61 ± 0.46 1.19 ± 0.06 2.28 ± 0.60a 1.63 ± 01.8b 
     Cholesterol (mg/dL) 152.2 ± 33.1 126.4 ± 26.1 153.1 ± 41.2 94.4 ± 15.3b 
Hepatic parameters 
     Triglycerides (mg/g liver) 19.0 ± 6.0 16.3 ± 0.9 77.1 ± 16.8a 68.1 ± 15.6a 
aP < 0.05 compared with fed genotype control 





Table 3.4. Comparison summary between Iqgap1-/-, Ppara-/-, and Fgf21-/- mice. 
Parameter Iqgap1-/- Ppara-/- Fgf21-/- 
Fed 
      Body weight NS NS (1) NS (2, 3, 4) 
      Serum ketones NS ↓ (5, 6); NS (7); ↑ (1) ↓ (4); NS (2, 3, 7, 8) 
      Serum NEFAs NS NS (5, 7); ↑ (1, 6) NS (2, 3, 4, 7, 8) 
      Serum triglycerides ↓ NS (5, 7) NS (2, 3, 4, 7, 8) 
      Hepatic triglycerides NS NS (1, 6, 7) NS (7, 8) 
Fast 
      Serum ketones ↓ ↓ (1, 5, 7); NS (9) NS (2, 4); ↑ (3) 
      Serum NEFAs ↓ ↑ (1, 5, 7); NS (9) ↓ (2); ↑ (3, 4, 8) 
      Serum triglycerides ↓ NS (7, 9) NS (2, 3, 4, 8) 
      Hepatic triglycerides NS ↑ (1, 7, 9) NS (3); ↑ (8) 
KD    
      Serum ketones ↓ NS (7); ↓ (6) ↓ (2, 7) 
      Serum NEFAs NS ↑ (6, 7) NS (2), ↑ (7) 
      Serum triglycerides NS NS (7); ↑ (6) ↑ (2, 7) 
      Hepatic triglycerides ↑ ↑ (6, 7) ↑ (2, 7) 
References: 
(1) Montagner, 2016 (4) Pothoff, 2009 (7) Badman, 2007 
(2) Badman, 2009 (5) Kersten, 1999 (8) Antonellis, 2016 
(3) Hotta, 2009 (6) Oishi, 2010 (9) Nakagawa, 2016 
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CHAPTER 4: HEPATIC IQGAP1 IS REGULATED BY BILE ACIDS AND PROTECTS THE 




Liver disease affects approximately 1 in 10 Americans. A common cause of liver disease is chronic liver 
injury, resulting in a subsequent elevation in the levels of serum bile acids, bilirubin, and liver enzymes 
ALT and AST. The increased bile acid level can, in turn, also exacerbate liver injury due to the 
hydrophobic chemical nature of bile acids. In the past two decades, bile acids have also been shown to 
function as signaling molecules via activating nuclear receptors and modulating kinase signaling, and this 
signaling has been implicated in liver proliferation. The scaffold protein IQGAP1 has been shown to be 
important for bile acid-stimulated proliferation. Here we show that hepatic IQGAP1 is regulated by bile 
acids at a transcript level and is specifically induced in response to cholestatic liver injury. Our results 
suggest that this regulation is, in part, regulated by Farnesoid X Receptor since bile acids that most 
potently activate this receptor are able to induce Iqgap1 expression in cell culture. We also show that 
IQGAP1 deletion makes mice more susceptible to both cholic acid- or DDC-induced liver injury. We 
observed an increase in E-cadherin levels upon with DDC feeding, but this induction was blunted in 
Iqgap1-/- livers. We suggest that the loss of E-cadherin induction could result in a leaky blood-bile barrier, 
which is consistent with the exacerbated liver injury observed in the absence of IQGAP1. In conclusion, 




 Bile acids (BA) are cholesterol derivatives that are synthesized in the liver and form the major 
organic component of bile. They are essential for emulsifying lipids to promote absorption in the intestine. 
They also act as signaling molecules by primarily binding and activating the nuclear receptor farnesoid X 
receptor (FXR) (Makishima, 1999) and the G protein-coupled receptor TGR5 (Kawamata, 2003). As 
amphipathic molecules, their levels are tightly regulated to avoid toxicity (Goodwin, 2000). Approximately 
95% of BAs are re-absorbed in the ileum and are taken back up by the liver (Gonzalez, 2012). Through 
FXR both in hepatocytes (Goodwin, 2000) and enterocytes (Inagaki, 2005), BAs can activate a negative 
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feedback pathway to shut of their own synthesis. Furthermore, BA levels can be modulated by transport 
into and out of hepatocytes. Uptake from serum in controlled by the organic anion-transporting 
polypeptide 2 (OATP2) and the sodium/bile acid cotransporter (NTCP) while secretion into bile canaliculi 
is controlled primarily by the Bile Salt Export Pump (BSEP). Bile canaliculi are formed by adhesion of 
adjacent hepatocytes, and the strength of the cellular junctions is integral for maintaining the separation 
of blood and bile in the liver (Kawaguchi, 2000; Mottino, 2007; Chen, 2009). Together, synthesis, uptake, 
and secretion of BA regulate the flux of BA in the liver. 
 Despite their tight regulation, BA levels become elevated in a number of liver disease states 
(Jorquera, 2005; Ferslew, 2015; Pellicelli, 2015). Elevated BAs are toxic because they can induce 
hepatocyte injury (Galle, 1990; Spivey, 1993; Sokol, 1995), leading to hepatocyte swelling, and, in turn, 
intracellular accumulation of BAs (Kountouras, 1984). BAs have been shown to cause damage to the 
plasma membrane (Schubert, 1988) and the mitochondria (Sokol, 1995; Rolo, 2003). Consequently, 
hepatocytes release growth factors, pro-inflammatory molecules, and reactive oxygen species leading to 
inflammation, fibrosis, and injury of other cells (Maher, 1993). Apart from injury, BAs are also known to 
stimulate liver proliferation of the healthy hepatocyte population (Barone, 1996; Columbano, 2003; Zhang, 
2004). In fact, the transient increase in BA levels during liver regeneration has been shown to be 
important for the regenerative response (Huang, 2006). Thus, BAs function as a double-edged sword by 
alleviating some of the injury they cause by stimulating liver growth. 
 We previously found that the expression of IQGAP1 is induced by BAs, and this induction is 
crucial for hepatocyte proliferation (Anakk, 2013). IQGAP1 is a cytoskeleton-associated scaffolding 
protein with pleiotropic functions including regulating adherens and tight junctions (Tanos, 2015; Yuan, 
2013), cytoskeleton integrity (Emadali, 2006; Benseñor, 2007), and proliferation (Jadeski, 2008; Jin, 
2015).  While it is expressed in low levels in the adult liver, its levels are increased upon liver injury 
(Emadali, 2006; Kunimoto, 2009). However, its function in the liver injury response and how its 
expression is regulated in the context of injury is unknown. 
 In this study, we investigated how BAs regulate IQGAP1 expression. We show that Iqgap1 
transcript levels are induced by BAs using three models of cholestasis - cholic acid (CA) feeding, α-
naphthyl isothiocyanate (ANIT) treatment, and 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) feeding. 
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To test if an increase in BA levels is necessary for this IQGAP1 induction in liver injury, we treated mice 
with the Fas agonist Jo2, which causes liver injury without BA accumulation, and found that Jo2 treatment 
failed to up-regulate Iqgap1. We also confirmed that BAs can act directly on hepatocytes to induce Iqgap1 
in a dose-dependent manner. We next examined if this effect was a detergent effect or if it involved actual 
BA signaling by treating hepatocytes with varying concentrations of a detergent, CHAPS. Unlike BAs, 
CHAPS was unable to induce mRNA levels of Iqgap1 in cell culture. To test which of the signaling 
mechanisms downstream of BAs activate Iqgap1 levels, we treated cells with chenodeoxycholic acid 
(CDCA) and deoxycholic acid (DCA), which potently activate FXR, and found an increase in Iqgap1 
expression, but this was absent when cells were treated with ursodeoxycholic acid (UDCA), an FXR 
antagonist. In vivo, IQGAP1-deletion did not alter BA synthesis and transport genes but displayed 
increased hepatic BA when challenged with a CA diet. Iqgap1-/- mice also showed a severe phenotype 
when fed a DDC-containing diet, with increased liver injury and BA excess. We found that loss of IQGAP1 
resulted in lower E-cadherin expression, suggesting that weakened canaliculi barriers could contribute to 
BA accumulation in the liver and subsequent increase in liver injury. We conclude that pathological levels 




For CA and DDC experiments, Iqgap1+/+ and Iqgap1-/- mice maintained on a 129/SVJ background were 
generated in Dr. A. Bernards laboratory (Li, 2000) and acquired from Dr. Valentina Schmidt, Stony Brook 
University, Stony Brook, NY, USA. Mice were housed in flow cages at 24 ℃ on a 12/12 hours light/dark 
cycle. Genotype was confirmed by performing PCR on genomic DNA from tail clips. Male 8-12 week old 
mice were used for all experiments. Mice were allowed ad libitum access to food and water. Their normal 
diet (chow) was Teklad F6 Rodent Diet (8664, Envigo). Custom diets containing 1% CA and 0.1% DDC 
were made using the normal chow as a base (Envigo). Liver samples from ANIT-treated mice were 
provided by Dr. Jongsook Kemper (University of Illinois at Urbana-Champaign) and were treated as 
previously described (Byun, 2018). For Jo2 treatment, adult male 129/SVJ mice were injected with Jo2 or 
saline and were sacrificed 6 hours later. 
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Primary hepatocyte isolation 
Mouse hepatocytes were isolated as previously described (Erickson, 2018). Briefly, male adult 129/SVJ 
Iqgap1+/+ mice fed chow or DDC for 2 weeks were anesthetized using flow-controlled isoflurane with 
oxygen and livers were perfused first with 50 mL HBSS containing EDTA (solution 1) then 50 mL HBSS 
containing collagenase and trypsin inhibitor (solution 2). The liver was then transferred to a Petri dish 
containing 1X PBS and gently massaged to loosen cells. The cell suspension was filtered and spun at 50 
g for 10 minutes. The pellet was then incubated in red blood cell lysis buffer, spun down, and washed with 
1X PBS. After a final centrifugation at 320 g, TRIzol was added to the pellet and RNA was isolated as 
described below for quantitative RT-PCR analysis. 
 
Cell culture 
HepG2 cells (ATCC HB-8065) were cultured according to ATCC specifications. At the start of each 
experiment, passage 5-15 HepG2 cells were plated in 6-well plates at 106 cells/mL in DMEM containing 
10% FBS. The next day, cells were washed with 1X PBS before switching the media to DMEM without 
FBS. Cells were serum starved for 24 hours then treated with the indicated concentration of BAs for an 
additional 24 hours in serum-free media. DMSO (vehicle) was limited to < 0.2% of total volume. After 24 
hours of treatment, cells were washed with 1X PBS then RNA was extracted using TRIzol. 
 
Quantitative RT-PCR 
TRIzol solution (Invitrogen) was used to isolate total RNA from frozen whole liver tissue or cell lines 
according to manufacturer’s protocol. The ratio of A260/280 and bleach gel was used to determine RNA 
quality (Aranda, 2012). RNA (5 µg) was treated with DNase (Promega) and reverse transcribed using 
random hexamer primers (New England Biosciences) and Maxima Reverse Transcriptase kit (Thermo 
Scientific). Gene expression was measured using an Eco Real-Time PCR System (Illumina), and samples 
were run in triplicate using 50 ng of cDNA per reaction and PerfeCTa SYBR Green FastMix (Quanta). All 
assays were run with an initial activation step for 10 min. at 95 ℃, followed by 40 cycles of 95 ℃ for 10 




Serum was thawed on ice prior to performing each serum assay. Assays were run in duplicate or triplicate 
for serum bile acids (Total Bile Acid (TBA) Colorimetric Assay Kit, BQ Kits BQ 092A-EALD), total bilirubin 
(Total Bilirubin Reagent, Thermo 1245-250), alanine aminotransferase (ALT) (Infinity ALT Reagent, 
Thermo Fisher Scientific TR71121), and aspartate aminotransferase (AST) (Infinity AST Reagent, 
Thermo Fisher Scientific TR70121). All assays were run according to the kit instructions. 
 
Hepatic BA measurement 
Approximately 50 mg of liver was weighed and homogenized in 1 mL of 75% ethanol. The homogenate 
was incubated in a 50 ℃ water bath for 2 hours then centrifuged at 6,000 g for 10 minutes. BAs were 
measured in the supernatant using the colorimetric kit described above. The concentration of BAs in the 
supernatant was multiplied by the supernatant volume to determine the total amount of BAs, which was 
divided by the weight of liver used to normalize the values. 
 
Histology 
Formalin fixed liver samples were embedded in paraffin wax. Five-micron sections were cut for 
hematoxylin and eosin (H&E) (Cardiff, 2014) and Sirius Red (Lattouf, 2014) stains according to standard 
methods. 
 
Western blot analysis 
Approximately 50 mg of frozen liver was homogenized in RIPA buffer using a bullet blender as previously 
described (Erickson, 2018). Protein concentration was measured by BCA assay (Pierce BCA Protein 
Assay Kit, Thermo Fisher Scientific). For Western blot, 50 µg of total protein was loaded onto a 10% 
SDS-PAGE gel. After transfer, the membrane was incubated with antibodies described in Table 4.2.  
 
Statistics 
All data are presented as mean ± SD. We chose sample sizes typical for this type of work (n = 5-6 mice 
per group). All statistical analyses were performed using GraphPad Prism software version 7. Student’s 
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unpaired 2-tailed t test was used to compare two groups. One-way ANOVA with Bonferroni’s multiple 
comparisons test was used to determine significance between more than two groups. Two-way ANOVA 
with Bonferroni’s multiple comparisons test was performed to compare two groups with two treatments. 
Asterisks indicate a statistically significant difference (P < 0.05) between the indicated groups. 
 
Study approval 
All animal studies were approved by the University of Illinois at Urbana-Champaign Institutional Animal 
Care and Use Committee and were carried out as outlined in the Guide for the Care and Use of 
Laboratory Animals (National Academies Press, 2011). 
 
Results 
Hepatic Iqgap1 is regulated by BAs 
 We previously showed that hepatic IQGAP1 protein is induced by feeding mice a diet containing 
the primary BA cholic acid (CA) for 2 weeks (Anakk, 2013). To determine how IQGAP1 is regulated by 
BAs, we examined whether IQGAP1 is also regulated at an mRNA level and found that CA feeding for as 
little as 3 days resulted in a 2 to 3-fold induction of Iqgap1 mRNA (Figure 4.1, A). We next asked whether 
this was a common result of treatments that increase BA levels or if it is an effect specific to CA. 
Therefore, we assessed Iqgap1 expression in the liver of mice treated with α-naphthyl isothiocyanate 
(ANIT), which induces cholangitis and hepatocellular damage (Kossor, 1995). Within 48 hours of ANIT 
treatment, hepatic Iqgap1 mRNA was significantly induced (Figure 4.1, B). We also fed mice a diet 
containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), which inhibits heme biosynthesis and is 
used as a model of cholestatic liver injury (Fickert, 2007). Within 3 days of starting the diet, mice exhibited 
increased hepatic Iqgap1 expression, which continued to increase through 2 weeks on the diet (Figure 
4.1, C). While the liver is primarily composed of hepatocytes and whole liver gene expression largely 
reflects the gene expression of hepatocytes (Figure 3.1, C), DDC treatment does stimulate bile duct 
epithelial cell proliferation and infiltration of immune cells (Fickert, 2007). Therefore, we checked whether 
the increased Iqgap1 expression could be due to increased expression of Iqgap1 in hepatocytes or 
increased numbers of non-parenchymal cells, which basally have higher Iqgap1 expression (Figure 3.1, 
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C). In hepatocytes isolated from DDC-treated mice, Iqgap1 mRNA was induced 8 to 10-fold, confirming 
that the increased hepatic Iqgap1 expression can contribute significantly to increased expression in liver 
(Figure 4.1, D). Additionally, since changes to the cellular milieu occurs, we cannot rule out their 
contribution to Iqgap1 expression. Since these treatments can also cause liver injury, we checked 
whether treatment with the Fas agonist Jo2, which causes liver failure, could induce Iqgap1 expression. 
We found no difference in Iqgap1 expression between Jo2 and vehicle treated livers indicating that liver 
injury alone is not sufficient to up-regulate Iqgap1 expression (Figure 4.1, E). Taken together, these data 
show that BAs in excess is necessary to induce Iqgap1 mRNA expression in the liver. 
To confirm that BAs regulate Iqgap1 expression by directly acting on hepatocytes, we next turned 
to a homogenous cell culture system to study the regulation of Iqgap1 expression. Treating confluent 
HepG2 (hepatoblastoma) cells with multiple concentrations of the BA chenodeoxycholic acid (CDCA) for 
24 hours resulted in a dose-dependent induction of Iqgap1 (Figure 4.2, A). Importantly, only pathological 
levels of CDCA (150 µM and 200 µM) significantly induced Iqgap1 expression. To rule out the detergent 
effect of BAs, we also treated cells with different concentrations of the detergent CHAPS and found that it 
failed to induce Iqgap1 at all concentrations tested (Figure 4.2, B). Thus, BAs likely regulate Iqgap1 
expression by signaling through receptors. 
Several varieties of BAs are formed in vivo that differ based on their chemical characteristics and 
affinity for BA receptors. CDCA and deoxycholic acid (DCA) are more hydrophobic and are known to 
potently activate FXR (Makishima, 1999). On the other hand, lithocholic acid (LCA) is more hydrophilic 
and preferentially activates TGR5 (Kawamata, 2003). Ursodeoxycholic acid (UDCA) is an epimer of 
CDCA and is thought to function as an FXR antagonist (Mueller, 2015). To identify potential receptors 
that could regulate Iqgap1 expression, we treated HepG2 cells with these different BAs. We found that 
150 µM DCA and CDCA could significantly induce Iqgap1, while 150 µM UDCA failed to increase Iqgap1 
expression (Figure 4.2, C). LCA is a more potent and toxic BA, so we treated at a lower dose (20 µM) and 
found variable Iqgap1 expression. This could be due to cell damage and death as a result of LCA 
treatment, as the next highest dose tested (30 µM) resulted in robust cell death (data not shown). Thus, 
BAs likely regulate Iqgap1 expression by activating FXR, but we cannot rule out other BA-responsive 
receptors such as TGR5. 
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Iqgap1-/- mice accumulate hepatic BAs when fed a CA diet 
Since we showed that IQGAP1 expression is regulated by BAs, we next asked whether IQGAP1 
could mediate BA signaling in vivo. Therefore, we fed Iqgap1+/+ and Iqgap1-/- mice a 1% CA diet for 2 
weeks. We found a similar increase in liver to body weight ratio in both groups of mice on CA diet (Figure 
4.3, A) even though we have previously shown a 50% reduction in proliferating cells in the liver of 
Iqgap1-/- mice fed CA diet compared to Iqgap1 +/+ mice (Anakk, 2013).  
Next, we investigated whether BA homeostasis is altered when IQGAP1 is deleted. We carefully 
examined BA levels and expression of BA synthesis and transport genes in chow and CA-fed Iqgap1+/+ 
and Iqgap1-/- mice. CA diet increased serum BAs similarly in both groups of mice (Figure 4.3, B), but 
hepatic BAs were higher in Iqgap1-/- animals (Figure 4.3, C). BA-feedback signaling was intact as we saw 
dramatic downregulation of BA synthesis gene Cyp7a1 (Figure 4.3, D), a modest reduction in Fxra 
expression (Figure 4.3, E), increased expression of FXR target Shp (Figure 4.3, F), and increased 
expression of BA export pump Bsep (Figure 4.3, G) with CA feeding in both Iqgap1+/+ and Iqgap1-/- mice. 
Interestingly, Cyp2b10 expression was much higher in Iqgap1-/- animals fed CA (Figure 4.3, H). CYP2B10 
metabolizes BAs and targets them for excretion. It is possible that this gene is induced to respond to the 
increased hepatic BA levels in Iqgap1-/- mice. Overall, this shows that the BA synthesis and export 
machinery are not affected by IQGAP1 deletion, despite excess BA accumulation in the liver of these 
mice. 
 
Loss of IQGAP1 exacerbates DDC-induced liver injury 
 We next asked whether the hepatic BA accumulation observed in Iqgap1-/- mice fed a CA diet 
could be aggravated by a more severe cholestatic insult. To address this, we fed Iqgap1+/+ and Iqgap1-/- 
mice a 0.1% DDC diet for 2 weeks. We chose this diet because it resulted in the most highest increase in 
Iqgap1 transcript levels. DDC inhibits heme biosynthesis, causing accumulation of porphyrin 
intermediates, ductular reaction, and, subsequently, build-up of BAs, liver injury, and hepatocyte 
proliferation (Fickert, 2007). DDC-mediated increase in liver size was comparable between the Iqgap1+/+ 
and Iqgap1-/- mice (Figure 4.4, A). As expected, DDC also increased levels of serum liver injury markers 
ALT, AST, and total bilirubin, but these were significantly higher in Iqgap1-/- mice (Figure 4.4, B-D). Serum 
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and hepatic BA levels were also dramatically induced in Iqgap1-/- mice compared to Iqgap1+/+ mice fed 
DDC (Figure 4.4, E-F). Histologically, DDC treatment resulted in increased hepatocyte size, increased 
bile duct number, and increased inflammatory cell accumulation surrounding portal triads (Figure 4.4, G). 
Also visible in H&E stained sections are bile lakes, which are pigmented accumulations of bile acid 
porphyrin intermediates. These are primarily localized to the periportal region of Iqgap1+/+ livers but are 
found more widely throughout the parenchyma in Iqgap1-/- livers. These data show that IQGAP1 protects 
the liver from injury and reduced BA accumulation in the liver. 
 A primary response to liver injury is induction of early response genes such as Egr1 and Fos, 
which code for transcription factors that regulate expression of late response genes (Mohn, 1990). While 
the expression of these genes is not affected by DDC treatment in Iqgap1+/+ mice, their expression is 
robustly induced in Iqgap1-/- livers (Figure 4.5, A and B). A consequence of this early response gene 
induction is increased proliferation, and consistently we found expression of Ccnd1 was induced in 
Iqgap1-/- livers with DDC feeding (Figure 4.5, C). Since this excess proliferation could be subsequent to 
increased cell death, we checked gene expression of pro-apoptotic gene Bax and found that it was 
induced similarly in Iqgap1+/+ and Iqgap1-/- mice (Figure 4.5, D). These results were surprising since 
IQGAP1 deletion is typically associated with reduced proliferation (Emadali, 2006; Jadeski, 2008; Jin, 
2015) and increased apoptosis (Sbroggiò, 2011; Zoheir, 2016). We next asked if the increased liver injury 
observed in Iqgap1-/- mice was associated with increased inflammation. Expression of IL-6, a cytokine 
that is induced in hepatocytes in response to liver injury and promotes proliferation (Jin, 2006; Norris, 
2014), was induced specifically in Iqgap1-/- mice in response to DDC (Figure 4.5, E). However, gene 
expression of cytokines Tnfa and IL-1b were similarly induced in Iqgap1+/+ and Iqgap1-/- livers upon DDC 
treatment (Figure 4.5, F and G). Macrophage marker F4/80 transcript level was also induced in both sets 
of mice suggesting that the macrophage population size may not be affected by IQGAP1-deletion (Figure 
4.5, H). DDC treatment also results in periportal fibrosis (Figure 4.5, I), and we found increased 
expression of Col1a1 and Ctgf in Iqgap1-/- mice, which could correspond to increased fibrosis seen in the 
absence of IQGAP1 (Figure 4.5, J and K). Thus, Iqgap1-/- mice exhibit an increased early response gene, 
proliferation, IL-6, and fibrogenic gene expression on DDC diet. 
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 We were surprised to find that Iqgap1-/- mice exhibit increased serum and hepatic BA levels when 
fed DDC-containing diet since we previously showed that BAs functioned upstream of IQGAP1 
expression. This indicates that IQGAP1 is involved in a feedback loop, wherein BAs induce IQGAP1, 
which, in turn, controls BA accumulation in the liver. To determine how IQGAP1 could regulate BA levels, 
we examined expression of BA transport, synthesis, and metabolism genes in the liver (Figure 4.6, A). 
Oatp2 and Ntcp are both involved in BA uptake from the serum. Oatp2 expression was not affected by 
DDC treatment but was higher in Iqgap1-/- livers (Figure 4.6, B). Ntcp, on the other hand, was robustly 
downregulated upon DDC treatment, which could contribute to the accumulation of BA in the serum 
(Figure 4.6, C). BAs shut off their own synthesis by activating FXR, which was downregulated at a 
transcript level by DDC treatment along with its target Shp (Figure 4.6, D and E). This was surprising 
because the high BA levels were expected to induce Shp via FXR as seen with CA diet (Figure 4.3, F), 
highlighting the difference between these two cholestatic models. SHP functions to inhibit transcription of 
Cyp7a1, the rate-limiting enzyme of BA synthesis. Despite high levels of BAs after DDC diet, Iqgap1-/- 
animals did not repress Cyp7a1 expression and, on the contrary, showed an increase in Cyp7a1 
expression (Figure 4.6, F). Expression of Bsep, which transports BAs into bile canaliculi, was not affected 
by diet (Figure 4.6, G). Furthermore, expression of Mrp2 and Mrp3, which export BAs into bile canaliculi 
and serum, respectively, were both induced by DDC treatment irrespective of genotype (Figure 4.6, H 
and I). BAs can also be metabolized in the liver and targeted for excretion. Two enzymes involved in this 
process are Cyp2b10 and Cyp3a11, which were both increased in Iqgap1-/- livers on DDC (Figure 4.6, J 
and K). The gene expression data suggests that Iqgap1-/- livers exhibit increased BA synthesis but also 
BA metabolism. 
 Lastly, since IQGAP1 has been shown to interact with β-catenin and promote proliferation 
(Briggs, 2002; Sharma, 2007; Lu, 2014), we examined expression of β-catenin target genes in DDC 
treated livers. Expression of Survivin was increased upon DDC treatment in both groups (Figure 4.7, A) 
while Axin2 showed no change in expression (Figure 4.7, B) and Glul was downregulated (Figure 4.7, C), 
indicating that β-catenin signaling functions independent of IQGAP1 in response to DDC treatment. 
Another function of β-catenin is to connect E-cadherin to the cytoskeleton (Hülsken, 1994; Orsulic, 1999). 
Furthermore, IQGAP1 requires an intact cytoskeleton to stabilize E-cadherin on the cell membrane 
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(Izumi, 2004). E-cadherin is an important part of adherens junctions, which contribute to the integrity of 
bile canaliculi and BA homeostasis (Terry, 1994). We therefore assessed E-cadherin expression and 
found its levels were increased in Iqgap1+/+ mice treated with DDC (Figure 4.7, D). However, this was 
blunted in the absence of IQGAP1. Overall, our data demonstrates that deletion of IQGAP1 exacerbates 
liver injury and BA accumulation, which we propose could be due to dysregulation of adherens junctions. 
 
Discussion 
BAs can be toxic at high levels, so their levels are tightly controlled. However, their levels are 
frequently elevated in liver disease (Jorquera, 2005; Ferslew, 2015; Pellicelli, 2015). Furthermore, having 
increased BA levels alone is sufficient to promote liver injury and disease progression (Cameron, 1982; 
Anakk, 2011; Anakk, 2013; Sun, 2016). BAs can function both as a detergent and as a signaling molecule 
with many different effects, both deleterious and beneficial, on liver physiology (Stanimirov, 2012; de 
Aguiar Vallim, 2013). Here we show that BAs regulate expression of the scaffolding protein IQGAP1 at a 
mRNA level and that IQGAP1 induction protects against BA accumulation and liver injury. 
Since BAs primarily signal through nuclear receptors, we investigated whether the increased 
protein expression was reflected in an increase in Iqgap1 mRNA. Elevating BAs with different methods 
(CA, DDC, and ANIT treatment) resulted in increased hepatic Iqgap1 mRNA expression. Iqgap1 mRNA 
expression has been reported to have low expression in adult hepatocytes compared to the non-
parenchymal cell populations in the liver (Kunimoto, 2009; Erickson, 2018), but this induction in Iqgap1 
transcript was recapitulated in primary hepatocytes isolated from the DDC-treated livers indicating that 
hepatocyte expression of IQGAP1 is important. Since DDC diet also results in an expansion of the 
cholangiocyte and immune cell populations of the liver (Fickert, 2007), it could give rise to an additive 
effect and hence the DDC-fed livers have much higher degree of Iqgap1 induction compared to CA or 
ANIT treatment. The lack of Iqgap1 induction in mice treated with Jo2, which causes liver injury 
subsequent to Fas-mediated apoptosis (Ogasawara, 1993), indicates that BAs, rather than injury, Iqgap1 
expression. 
To identify whether BAs can directly regulate Iqgap1 expression or if Iqgap1 is induced by a 
secondary mechanism such as cross-talk between cell types, we assessed whether BAs could also 
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regulate Iqgap1 expression in vitro. We found a dose-dependent effect of BAs on Iqgap1 expression that 
was not observed with the structurally similar detergent CHAPS. This suggests that the regulation of 
Iqgap1 by BAs does not rely on the detergent function of BAs. To test the mechanism by which BAs 
regulate IQGAP1 transcript expression, we tested activating either FXR (Makishima, 1999) or TGR5 
(Kawamata, 2003) and found that potent FXR agonists CDCA and DCA can regulate Iqgap1 expression. 
To delineate the role of FXR in regulating Iqgap1, we can utilize a number of tools available in our lab, 
including tissue-specific Fxr-/- mice and the FXR synthetic agonist GW4064. We also can examine the 
respective roles of RNA and protein synthesis and degradation in the regulation of Iqgap1 expression. 
Currently, there is no known mechanism for regulation of Iqgap1 expression, so these experiments will 
enable us to understand how expression of this scaffolding protein is controlled. 
We also examined the role for IQGAP1 downstream of BAs. Iqgap1-/- mice fed a DDC diet 
exhibited increased levels of liver injury markers indicating that IQGAP1 induction is protective against 
cholestatic liver injury. We were surprised to find higher accumulation of hepatic BAs in the absence of 
IQGAP1 but at this time we do not understand the mechanism underlying this increase. Furthermore, it is 
surprising to find increased Ccnd1 expression in Iqgap1-/- livers fed DDC since IQGAP1 knockdown has 
been associated with decreased cell proliferation (Emadali, 2006; Jadeski, 2008; Jin, 2015). However, the 
functional activity of Cyclin D1 has not been evaluated and we also do not have phospho-histone H3 or 
Ki-67 immunohistochemistry data to prove cellular proliferation does occur in Iqgap1-/- mice fed a DDC 
diet. Another caveat is that 2-week feeding studies can result in a complex phenotype that includes 
secondary effects. Therefore, our lab will be performing shorter time-course studies using DDC and CA to 
further tease out the role for IQGAP1 in the injury response. 
We postulate that poor maintenance of the blood-bile barrier may be a potential mechanism for 
the increased injury and BA accumulation in the absence of IQGAP1. Bile is transported in the liver by 
canaliculi that are sealed off from blood-containing sinusoids by junctions between hepatocytes. 
Adherens junctions are important for maintaining the integrity of bile canaliculi and are composed of E-
cadherin, p120, γ-catenin, and α-catenin, which anchors the cytoskeleton to the cadherin via β-catenin. 
Disruption of these junctions via inhibition of E-cadherin (Terry, 1994) or deletion of α-catenin (Herr, 2014) 
and β-catenin (Yeh, 2010) results in cholestasis (Woods, 2011; Bai, 2016). While E-cadherin expression 
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is not altered in Iqgap1-/- animals, its induction in response to DDC is blunted in the absence of IQGAP1. 
This reduction in E-cadherin could compromise the integrity of the blood-bile barrier and explain why 
more bile lakes are observed within the parenchyma of DDC-treated Iqgap1-/- livers. To further explore 
this mechanism, we will first characterize the structure of bile canaliculi and the hepatocellular 
cytoskeleton in Iqgap1+/+ and Iqgap1-/- mice fed DDC by staining liver sections for zona occludens (ZO-1), 
E-cadherin, α-catenin, and actin. It will also be important to characterize the structure of sinusoids by 
staining for collagen IV. We can also look at the bile canaliculi transporter distribution in the liver lobules 
by staining and assess canaliculi permeability functionally using a fluorescence-tagged bile acid. These 
data would indicate whether the canaliculi are disrupted in the absence of IQGAP1 and definitively show if 
the blood-bile barrier is compromised. 
Overall, we have shown that BAs directly regulate Iqgap1 mRNA expression and have identified a 
role for IQGAP1 in protecting the liver from BA-induced injury. This has opened further areas to explore 
related to the function of IQGAP1 in hepatocyte adherens junctions, how increased inflammation could 
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Figure 4.1. Iqgap1 is induced in hepatocytes by BAs in vivo. 
Liver Iqgap1 mRNA expression in mouse models of cholestasis and liver injury. (A) Iqgap1 is significantly 
induced in the liver of C57BL/6 mice fed a 1% CA diet for 3 days. Gene expression normalized to Gapdh 
(n = 3-5 mice per group). (B) Iqgap1 is significantly induced in the liver of C57BL/6 mice 48 hours after 
ANIT treatment. Gene expression normalized to Tbp (n = 3 mice per group). (C) Iqgap1 expression 
progressively increases in 129/SVJ mice fed a 0.1% DDC diet. Gene expression normalized to Tbp (n = 
5-7 mice per group). (D) Iqgap1 is induced in hepatocytes isolated from DDC-fed mice. Gene expression 
normalized to Tbp (n = 3-7 mice per group). (E) Iqgap1 is not induced in mice treated with Jo2, which 
causes liver injury without increasing BAs. Gene expression normalized to Actb (n = 3-5 mice per group). 
Values are displayed as mean ± SD. Student’s t test was used to determine significance between two 
groups. One-way ANOVA with Bonferroni’s multiple comparisons test was used to determine significance 
between four groups. Significance is indicated by * P < 0.05, ** P < 0.01, **** P < 0.0001. Anushna Sen 





Figure 4.2. IQGAP1 mRNA is induced by BAs in vitro. 
(A) Gene expression of IQGAP1 in HepG2 cells treated with a range of CDCA concentrations for 24 
hours (n = 3 wells per group). (B) IQGAP1 expression in HepG2 cells treated with different concentrations 
of the detergent CHAPS for 24 hours (n = 3 wells per group). (C) IQGAP1 expression in HepG2 cells 
treated with 20 µM LCA or 150 µM UDCA, DCA, or CDCA for 24 hours (n = 3-4 wells per group). All gene 
expression normalized to GAPDH expression. Values are displayed as mean ± SD. One-way ANOVA 
with Bonferroni’s multiple comparisons test was used to assess differences between 4-5 groups. 



































Figure 4.3. IQGAP1 deletion results in hepatic BA accumulation in CA-fed mice. 
Iqgap1+/+ and Iqgap1-/- mice were fed a 1% CA diet for 2 weeks. (A) Liver weight normalized to body 
weight. (B) Serum BA concentration. (C) Hepatic BA levels. (D-H) Gene expression of Cyp7a1 (D), Fxra 
(E), Shp (F), Bsep (G), and (H) Cyp2b10. Gene expression normalized to Actb (n = 4-7 mice per group). 
Values displayed as mean ± SD. Two-way ANOVA with Bonferroni’s multiple comparisons test was used 
to determine significance between two groups under two conditions. Significance is indicated by * P < 
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Figure 4.4. Deletion of Iqgap1 exacerbates DDC-induced liver injury. 
Iqgap1+/+ and Iqgap1-/- mice were fed a 0.1% DDC diet for 2 weeks or chow as a control. (A) Liver weight 
normalized to body weight. (B-E) Serum levels of ALT (B), AST (C), total bilirubin (D), and BAs (E). (F) 
Hepatic BA levels. (G) Representative H&E images of chow and 2-week DDC livers. Scale bar is 100 µm. 
PV = portal vein; CV = central vein; white arrows point to bile lakes. Values are displayed as mean ± SD. 
Two-way ANOVA with Bonferroni’s multiple comparisons test was used to assess differences between 
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Figure 4.5. DDC feeding results in increased proliferation, fibrosis, and IL-6 expression in Iqgap1-/- livers 
Iqgap1+/+ and Iqgap1-/- mice were fed a 0.1% DDC diet for 2 weeks. (A-H) Gene expression of early 
response genes Egr1 (A) and Fos (B), proliferation marker Ccnd1 (C) and cell death marker Bax (D), and 
inflammation markers IL-6 (E), Tnfa (F), IL-1b (G), and F4/80 (H). Picrosirius red stain for collagen fibers 
(red). Representative images of n = 3 Iqgap1+/+ and 6 Iqgap1-/- livers. Scale bar is 100 µm. Values are 
displayed as mean ± SD (n = 3-6 mice per group). Significance is indicated by * P < 0.05, ** P < 0.01, *** 





Figure 4.6. Iqgap1 deletion increases expression of BA synthesis and metabolism genes. 
Iqgap1+/+ and Iqgap1-/- mice were fed DDC-containing diet for 2 weeks. (A) Summary of major BA 
homeostasis proteins in hepatocytes. (B-K) Gene expression of BA importers Oatp2 (B) and Ntcp (C), BA 
regulatory/synthesis genes Fxr (D), Shp (E), and Cyp7a1 (F), BA exporters Bsep (G), Mrp2 (H), and Mrp3 
(I), and BA metabolism genes Cyp2b10 (J) and Cyp3a11 (K). Gene expression normalized to Tbp 
expression. Two-way ANOVA with Bonferroni’s multiple comparisons test was used to determine 
significance between groups. Significance is indicated by * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 






Figure 4.7. IQGAP1 is required for DDC-induced E-cadherin upregulation. 
(A-C) Gene expression of β-catenin target genes Survivin (A), Axin2 (B), and Glul (C) in the liver of mice 
fed chow or DDC for 2 weeks. Gene expression normalized to Actb (n = 3-4 mice per group). (D) 
Immunoblot of liver homogenates from mice fed chow or DDC for 2 weeks. Each lane contains protein 







Table 4.1. Primers used. 
 
Gene Species Forward (5’ → 3’) Reverse (5’ → 3’) 
GAPDH Human ATGACATCAAGAAGGTGGTGAA GCTGTTGAAGTCAGAGGAGAC 
IQGAP1 Human AGAACGTGGCTTATGAGTACCT CAGTCGCCTTGTATCTGGT 
Actb Mouse TCTCCAGGGAGGAAGAGGAT GCTACAGCTTCACCACCACA 
Axin2 Mouse CCTATGCCCGTTTCCTCTAATG TCACCCAACAAGGAGTGTAAAG 
Bax Mouse CAAGAAGCTGAGCGAGTGT TGTCCACGTCAGCAATCATC 
Bsep Mouse GAATTGGAGTGGAGGGAAGATT GAATTGGAGTGGAGGGAAGATT 
Ccnd1 Mouse TTCGTGGCCTCTAAGATGAAG CCGGATAGAGTTGTCAGTGTAG 
Col1a1 Mouse GAAACCCGAGGTATGCTTGA GTTGGGACAGTCCAGTTCTT 
Ctgf Mouse CCACCCGAGTTACCAATGAC GACAGGCTTGGCGATTTTAG 
Cyp2b10 Mouse TTAGTGGAGGAACTGCGGAAA CGCAAGAACTGACGGTCTG 
Cyp3a11 Mouse CAGCTTGGTGCTCCTCTACC CTCTGGGTCTGTGAACAGCAA 
Cyp7a1 Mouse CCTAAGAGCAAAGCAAAGGAAAC CTTTGTGGTATGACAGGGAGTT 
Egr1 Mouse TTCCACAACAACAGGGAGAC TGGATAGTGGAGTGAGCGA 
F4/80 Mouse TACCACTTGCCCAGCTTATG GGGCCTTGAAAGTTGGTTTG 
Fos Mouse CCGTCTCTAGTGCCAACTTTAT CACGGAGGAGACCAGAGT 
Fxra Mouse ACAGCTAATGAGGACGACAG GATTTCCTGAGGCATTCTCTG 
Gapdh Mouse AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
Glul Mouse TCCATCCTGTTGCCATGTT CTGCAGGTTTCCGGTTATACT 
IL-1b Mouse GGCAGGCAGTATCACTCATT GAAGGTGCTCATGTCCTCATC 
IL-6 Mouse CCGGAGAGGAGACTTCACAG TCCACGATTTCCCAGAGAAC 
Iqgap1 Mouse CATCAACACCCACACTCTCC GTCGTTTGAATTGCCACAGC 
Mrp2 Mouse GCACTGTAGGCTCTGGGAAG CATTTTCAAGTCTGGGAGGA 
Mrp3 Mouse ATCAATTGTGCTTGCTGGTG CTCCTGGTCTTCATCTGGTG 
Ntcp Mouse CTCAGCGTCATTCTGGTAGTT CCAGAAGTGAGCCTTGATCTT 
Oatp2 Mouse ACCAGCATCCCCTTTTTCTT AAGGCATTGACCTGGATCAC 
Shp Mouse CGATCCTCTTCAACCCAGATG AGGGCTCCAAGACTTCACACA 
Survivin Mouse GAGGAGCATAGAAAGCACTCC GCTCTCTGTCTGTCCAGTTTC 
Tbp Mouse GGACTTACTCCACAGCCTATTC TTGCTACTGCTTGCTGTT 





Table 4.2. Antibodies used. 
 
Target Antibody Source Catalog # Dilution 
E-Cadherin E-Cadherin (24E10) Rabbit mAb Cell Signaling #3195 1:1000 
GAPDH Rb anti-GAPDH Sigma-Aldrich G9545 1:5000 
Rabbit IgG 
Gt anti-Rabbit IgG (H+L) 
Secondary Antibody, HRP 












IQGAP1 is a large, ubiquitously expressed scaffolding protein that is overexpressed in a number of 
cancers, including liver cancer, and is associated with many pro-tumorigenic processes including cell 
proliferation, motility, and adhesion. It’s ability to scaffold, and thus integrate, multiple signaling pathways 
via its five protein binding domains suggests that IQGAP1 could be an effective anti-tumor target. 
However, additional data have shown that reduced IQGAP1 expression in stromal cells can increase 
cancer cell proliferation in the liver. Therefore, the objective of this study was to examine the role of 
IQGAP1 in liver tumorigenesis and determine whether there is a dose-dependent effect of IQGAP1 on 
hepatic tumor initiation and promotion. We found that overexpressing IQGAP1 in a mouse model of 
hepatocellular carcinoma (HCC) driven by β-catenin and MET increased tumor burden and activation of 
β-catenin but not MET. Furthermore, overexpressing IQGAP1 in HCC cell lines was sufficient to increase 
β-catenin activity and cell proliferation. On the other hand, we were surprised to find that Iqgap1-/- mice 
also had a higher tumor burden than Iqgap1+/+ and Iqgap1+/- mice following a single injection of the 
chemical carcinogen diethylnitrosamine at 12-15 days of age. Iqgap1-/- tumors had higher MET 
expression and cell proliferation, and knocking down IQGAP1 in HCC cell lines increased MET 
expression and activation without affecting β-catenin activation. Overall, these findings show that both too 
much and too little IQGAP1 can promote hepatic tumorigenesis through different pathways. 
 
Introduction 
 Liver cancer has a high mortality rate, which can, in part, be attributed to lack of effective 
systemic therapies (Villanueva, 2019). For hepatocellular carcinoma, the major form of primary liver 
cancer, a large portion of cases are diagnosed at advanced stages (Martini, 2017) for which only two 
systemic therapies have shown efficacy to extend overall survival by a matter of months (Llovet, 2008; 
Kudo, 2018). Interestingly, both of these therapies function as multi-kinase inhibitors, with Sorafenib 
targeting the serine-threonine kinases Raf-1 and B-Raf, vascular endothelial growth factor receptors 
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(VEGFR) 1-3, and platelet-derived growth factor receptor (PDGFR) β (Llovet, 2008) and Lenvatinib 
targeting VEGFR 1-3, fibroblast growth factor receptors 1-4, PDGFRα, stem cell factor receptor (KIT), and 
rearranged during transfection (RET) (Kudo, 2018). Yet, many other kinase inhibitors have failed to 
improve on this survival benefit in phase III trials (Johnson, 2013; Llovet, 2013; Cheng, 2013; Zhu, 2014; 
Cainap, 2015; Zhu, 2015). It is clear that this necessitates a better understanding of liver biology for more 
effective therapeutic strategies. 
 IQGAP1 is a pleiotropic, multi-domain scaffolding protein that is overexpressed in many types of 
human cancer (Dong, 2006; Walch, 2008; Hayashi, 2010; Liu, 2010; Fowler, 2011; White, 2011; Dong, 
2016) including 60-80% of HCCs (White, 2010; Chen, 2010; Xia, 2014; Jin 2015), and this 
overexpression is associated with worse clinical outcomes (Xia, 2014). This scaffold protein interacts with 
many pro-tumorigenic processes including kinase signaling (Yamaoka-Tojo, 2004; Roy, 2005; McNulty, 
2011; White, 2011), cell proliferation (Jadeski, 2008; Chen, 2010), motility (Mataraza, 2003), and 
adhesion (Kuroda, 1998; Li, 1999). Furthermore, many in vivo studies demonstrate that increased 
IQGAP1 expression can promote tumor growth indicating that IQGAP1 could be an effective molecular 
target for HCC (Schmidt, 2008; Jameson, 2013; Liang, 2017). Yet, other studies revealed that deletion of 
IQGAP1 in cancer cells and/or stromal cells can also enhance tumorigenesis by modulating TGFβ 
signaling (Liu, 2013; Hensel, 2015) and adherens junction stability (Bessède, 2016). These contradictory 
findings suggest that IQGAP1 can have many roles in regulating tumorigenesis. 
 In this study, we investigated the dose-dependent role of IQGAP1 in promoting hepatic 
tumorigenesis by directly comparing IQGAP1-overexpression and IQGAP1-knockout (Iqgap1-/-) in mouse 
models of HCC in collaboration with the Duncan laboratory at the University of Pittsburgh. We show that 
overexpression of IQGAP1 can enhance the growth of tumors initiated by a hyper-active β-catenin mutant 
and MET overexpression. Overexpression of IQGAP1 in this model also enhanced β-catenin activation 
and increased expression of alpha-fetoprotein. We also show that overexpression of IQGAP1 is sufficient 
to promote proliferation. Next, using the diethylnitrosamine (DEN) model of liver cancer, we show that 
deletion of both copies of Iqgap1 increases the incidence and multiplicity of liver tumors and increases the 
percent of HCCs with enhanced glutamine synthetase expression. Iqgap1-/- tumors exhibited increased 
proliferation, protein levels of the growth factor receptor MET, and alpha-fetoprotein gene expression. 
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Knockdown of IQGAP1 in cell culture increased MET expression and enhanced HGF-induced MET 
activation. Overall, we show that both overexpression and deletion of IQGAP1 can promote the 
development of liver tumors in mice. While there are some similar molecular changes with IQGAP1 
overexpression and deletion, the differences may reveal compensatory pathways that should be 




Male WT FVB/NJ mice (Jackson Labs, Bar Harbor, ME) were used for all transposon overexpression 
experiments. These nimals were housed at the University of Pittsburgh in Optimice Cages (AnimalCare 
Systems, Centennial, CO) with Sani-Chip Coarse bedding (P.J. Murphy, Montville, M) at 24 ℃ on a 12/12 
light/dark cycle with lights on starting at 5AM CST, corresponding to zeitgeber time (ZT0). Iqgap1+/+, 
Iqgap1+/-, and Iqgap1-/- mice maintained on a 129/SVJ background (129-Iqgap1tm1aber/VSJ) were used for 
all diethylnitrosamine (DEN) experiments. These mice were generated in Dr. Andrew Bernards’s 
laboratory (Massuchusetts General Hospital, Boston, Massachusetts, USA) and were obtained from Dr. 
Valentina Schmidt (Stony Brook University, New York, USA). Animals were housed at the University of 
Illinois at Urbana-Champaign on conventional racks at 24 ℃ on a 12/12 hour light/dark cycle with lights on 
starting at ZT 0. Genotype was confirmed by PCR analysis of genomic DNA from tail clips (Li, 2000). Mice 
were allowed ad libitum access to Teklad F6 Rodent Diet (Envigo 8664) and water. 
 
Mice Experiments 
Hydrodynamic tail vein injections were performed in 6 to 8-week-old male FVB/NJ mice as previously 
described (Tao, 2014). Briefly, mice were injected with 20 mg of pT3-EF5α-hMet-V5, pT3-EF5α-S45Y-β-
catenin-Myc, or pT3-EF5α-IQGAP1-HA, or combination of EF5α-hMet-V5 and pT3-EF5α-S45Y-β-catenin-
Myc, or combination of EF5α-hMet-V5, pT3-EF5α-S45Y-β-catenin-Myc, and pT3-EF5α-IQGAP1-HA along 
with the sleeping beauty transposase (SB) (0.8 mg) in a ratio of 25:1. Injections were diluted into a total of 
2 mL of normal saline (0.9% NaCl) and injected into the lateral tail vein in 5 to 7 seconds. At the time of 
sacrifice, livers from experimental animals were excised, washed in PBS, and weighed. The percentage 
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of the weight occupied by the liver was determined by dividing the liver weight by the total body weight of 
the mouse. 
 
Male (n = 77) and female (n =15) littermate Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- mice were injected with 5 
mg/kg DEN (N0258, Sigma-Aldrich) in sterile 1x PBS at 12-15 days of age via intraperitoneal injection (10 
µL/g body weight). All mice were monitored for signs of morbidity and discomfort. Mice were sacrificed at 
ZT 4-6 both 20 weeks and 50 weeks after administration to assess tumor burden. At the time of sacrifice, 
blood was collected by retro-orbital bleeding, and serum was separated by centrifugation and immediately 
stored at -80 ℃ in opaque tubes. Liver, gonadal white adipose tissue, spleen, and quadriceps tissues 
were collected, weighed, and flash frozen for analysis. A piece of each liver/tumor were fixed in 10% 
formalin for histological analysis. 
 
Constructs used 
pEGF-IQGAP1 was a gift from David Sacks (Addgene plasmid #30112; http://n2t.net/addgene:30112; 
RRID:Addgene 30112). Using this construct, an HA tag was added to IQGAP1 and cloned via Gateway 
PCR (Invitrogen, Carlsbad, CA) into a pT3-EF5α vector kindly provided by Satdarshan Monga. 
 
Serum chemistry 
Sera were thawed on ice, with minimized freeze-thaw cycles. Assays were run in triplicate for alanine 
aminotransferase (ALT) (Infinity ALT Reagent, Thermo Fisher Scientific TR71121), aspartate 
aminotransferase (AST) (Infinity AST Reagent, Thermo Fisher Scientific TR70121), and total bilirubin  




Liver and tumor samples were fixed in formalin for > 24 hours. They were then processed and embedded 
in paraffin wax. Four or five µm sections were cut. Hematoxylin and eosin staining were performed 
according to published methods (Cardiff, 2014). For immunohistochemistry, sections were deparaffinized 
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using xylene and graded ethanol (100-95%) washes and incubated in citric acid-based antigen retrieval 
(Vector, Burlingame, CA). Following antigen retrieval, liver sections were blocked with either 5% normal 
goat serum in 5% bovine serum albumin in TBST or Avidin/Biotin blocking solution (Vector SP-2001). 
Slides were incubated with primary antibody (concentrations indicated in Table 5.1) in 5% BSA overnight 
in a humidified chamber at 4 ℃. The next day, the slides were washed in 1X TBST (2 x 5 min) and 
incubated in 0.03% H2O2 for 15 minutes to inactivate any endogenous peroxide activity. After an 
additional TBST wash, the sections were incubated with secondary antibody (concentrations indicated in 
Table 5.1). in 5% BSA for 1 hour. Slides were then washed and developed using DAB Peroxidase (HRP) 
Substrate Kit (Vector Labs Sk-4100) or avidin-conugated peroxidase (Vector ABC kit PK-6100) with 
ImmPACT DAB Peroxidase Substrate (Vector Labs SK-41105). Sections were counterstained with 
Modified Harris Hematoxylin (Richard Allen 72711), dehydrated with ethanol and xylene washes, and 
mounted with Permount (Fisher). 
 
Ki-67 quantification 
Based on morphology, each liver section was divided into 2-7 sections that were classified as liver or 
tumor. For each region, 4-7 images were collected for quantification. To blind the quantification, images 
were collected in 3 sets of 200-250 images and were randomly assigned numbers 1-250 at the time of 
collection. The number of Ki-67 positive cells was then hand counted for each de-identified image. Once 
counting was complete, the identity of each image was assigned and the number of Ki-67 positive cells 
per image was averaged across all liver and tumor regions for each mouse to determine the proliferative 
index of each tissue. 
 
Cell culture 
The following cell lines were obtained from ATCC: HepG2 (HB-8065), Huh7, and Snu-449 (CRL-2234). 
HepG2 and Huh7 were maintained in 10% fetal bovine serum (FBS) (Atlanta Biologicals) in DMEM. Snu-
449 cells were maintained in 10% FBS in RPMI-1640. Cells were incubated at 37 ℃ in a humidified 5% 
carbon dioxide atmosphere. For overexpression experiments in cultured cells, HepG2, Huh7, and Snu-
449 cell lines were transfected with 500 ng control, IQGAP1, or β-catenin expression constructs for 72 
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hours. Cell lysates were assessed for mRNA expression or for TOPFlash luciferase reporter activity 
(Addgene plasmid #12456) to assess β-catenin activation. To measure proliferation, Snu-449 cells were 
transfected with 500 ng of either control or IQGAP1 expression constructs. After 70 hours, cells were 
pulsed with 10 mM EdU. Cells were then fixed and stained for EdU and counterstained with PI to detect 
cell nuclei. Single cell suspensions were analyzed by FACS. For knockdown experiments, Snu-449 cells 
were transfected with 40 nM control, IQGAP1, or CTNNB1 siRNA for either 48 or 72 hours. Cell lysates 
were assessed for gene expression and TOPFlash luciferase reporter activity. An additional set of Snu-
449 cells were transfected with siRNA and, after 48 hours, were treated with 50 ng HGF for 15 minutes. 
Additionally, HepG2 cells were infected with lentivirus expressing either shScrambled and shIQGAP1 
constructs (Thermo Scientific) and infected cells were selected by culturing cells in 1 µg/mL puromycin for 
72 hours. Cell lysates were assessed for gene and protein expression.  
 
Luciferase assay 
Cell lines were transfected simultaneously with 500 ng TOPFlash firefly luciferase reporter and 100 ng 
Renilla luciferase constructs alongside either siRNA or expression constructs using Lipofectamine 2000 
(Life Technologies). Transfected cells were harvested after 72 hours and processed with Dual-Luciferase 
Reporter Assay kit (Promega). Luciferase assay was detected with an infinite M200 PRO microplate 
reader (Tecan, Männedorf, Switzerland). Relative luciferase activities of transfected plasmids are 
represented as the activity of firefly luciferase activity normalized to Renilla activity. 
 
RNA isolation, quantitative RT-PCR, and PCR 
Total RNA from fresh liver and tumor samples collected at sacrifice was extracted using TRIzol solution 
(Invitrogen) according to the manufacturer’s protocol and subjected to qRT-PCR to quantify expression of 
protein coding genes. A260/280 and bleach RNA gel (Aranda, 2012) were used to assess RNA quality. 
RNA with an A260/280 > 2.0 and a 28S/18S RNA ratio of approximately 2 was used for further analysis. 
Complementary DNA (cDNA) synthesis and qRT-PCR were performed as previously described (Erickson, 
2018) or using M-MLV (Life Technologies) followed by q-PCR performed with SYBR Green Master Mix 
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(Life Technologies). Primer sequences are described in Table 5.2. Relative expression was calculated 
using the ΔΔCt method Gapdh and B2m were used as loading controls. 
 
Western blotting 
Protein was extracted from approximately 50 mg frozen tumor tissue using RIPA buffer as previously 
described (Erickson, 2018). For Western blot, 50-200 µg total protein was loaded onto 8%-12% SDS-
PAGE gels. Protein were transferred to Immobilon-P PVDF membrane (IPVH00010, Millipore) overnight 
at 35V and 4 ℃. After transfer, the membrane was incubated with antibodies described in Table 5.1. Band 
intensity was quantified by densitometry using Image Lab software. 
 
Statistical analysis 
Data are expressed as mean ± SD. All statistical analyses were performed using GraphPad Prism 
software version 7. For contingency data, χ2 test was used to compare 3 croups and Fisher’s exact test 
was performed to assess differences between 2 groups. One-way ANOVA with Bonferroni post-test was 
performed to compare 3 groups while two-way ANOVA with Tukey’s post-test or Bonferroni’s multiple 
comparisons test was used to compare 2 groups, paired tissue (liver and tumor) or unpaired respectively, 
in 3 groups. Asterisks indicate a statistically significant difference between groups. Significance is defined 




All animal studies were approved by the University of Illinois at Urbana-Champaign and University of 
Pittsburgh Institutional Animal Care and Use Committees and were carried out as outlined in the Guide 





Overexpression of IQGAP1 promotes β-catenin/MET-driven hepatic tumorigenesis 
 Since IQGAP1 expression is induced in a majority of HCC cases, we first asked whether 
overexpression of IQGAP1 was sufficient to promote tumor growth. To do this, we turned to a well-
established HCC model that uses hydrodynamic tail vein injection (HDTVI) with the Sleeping Beauty 
transposase (referred to hereafter as the “transposon system”) to deliver human activated Myc-tagged β-
catenin (S45Y) and V5-tagged hepatocyte growth factor receptor (MET) (B+M) to the liver of WT mice 
(Tao, 2016). Simultaneous expression of B+M via the transposon system generates microscopic lesions 
that are visible by 2 weeks after injection and macroscopic HCC nodules within 6-9 weeks, which are 
69% genetically similar to human HCC (Tao, 2016). 
 Using the transposon system, we overexpressed epitope-tagged B+M with or without concurrent 
expression of HA-tagged human IQGAP1 (B+M+I) and harvested livers after 4 or 8.5 weeks (Figure 5.1, 
A). As early as 4 weeks after delivery, β-catenin and MET were upregulated in liver lysates from the B+M 
and B+M+I groups compared to non-treated (NT) controls, and IQGAP1 was upregulated only in the 
B+M+I group (Figure 5.1, B). To validate co-expression of the three constructs we performed 
immunofluorescent staining on liver sections from NT, B+M, and B+M+I mice at 4 weeks, which showed 
foci that expressed all the delivered epitope-tagged proteins (Figure 5.1, C). 
 We next characterized the livers by macroscopic and microscopic appearance as well as 
expression of Alpha-fetoprotein (Afp), a marker of highly aggressive HCC (Imamura, 2003; Peng, 2004; 
Lee, 2015). Macroscopic disease was not evident after 4 weeks (Figure 5.2, A), but there were dysplastic 
foci that were GS positive (indicating β-catenin activation) in both B+M and B+M+I groups (Figure 5.2, B). 
At this time point, the liver to body weight ratio was increased only in the B+M+I group compared to NT 
(Figure 5.2, C). Afp was induced similarly in both B+M and B+M+I groups (Figure 5.2, D). At 8.5 weeks, 
macroscopic tumor nodules were visible in both the B+M and B+M+I groups (Figure 5.2, E). These 
tumors showed typical HCC morphology, as analyzed by H&E staining, and were GS positive (Figure 5.2, 
F). The tumors at this time point were advanced and highly necrotic. Strikingly, the liver weight to body 
weight ratio in the B+M+I group was double to that of the B+M group indicating increased tumor burden 
(Figure 5.2, G). Afp was significantly higher in B+M+I mice compared to the B+M group indicating more 
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aggressive tumors (Figure 5.2, H). Together this shows that overexpression of IQGAP1 can promote the 
growth of aggressive HCC. 
 
IQGAP1 overexpression enhances β-catenin activation 
 We next examined the mechanism underlying IQGAP1-mediated tumor growth. Since these liver 
tumors were driven by MET and β-catenin activation, we first examined the activation of these pathways. 
The tyrosine kinase receptor MET is known to activate many pro-tumorigenic pathways including 
MEK/ERK, PI3K/AKT/mTOR, and others, resulting in increased protein phosphorylation (Giordano, 2014). 
Therefore, we assessed phosphorylation of MET Y1234/1235 in B+M and B+M+I livers. Total MET 
expression was not different between groups, but phosphorylated Met at Y1234/1235 was 2-fold higher in 
B+M+I livers (Figure 5.3, A). However, downstream MET targets AKT, mTOR, and STAT3 showed similar 
activation in both groups. Thus, while phosphorylation of MET is increased with IQGAP1 overexpression, 
MET is not able to further activate its downstream targets, suggesting that MET downstream signaling 
does not contribute to the increased tumor burden in B+M+I mice. 
 Therefore, we next investigated if IQGAP1-dependent tumor promotion relied on activation of the 
β-catenin/Wnt signaling pathway. At 4 weeks, there was no difference in expression of canonical β-
catenin targets Survivin, Lect2, Glul, or Axin2 between B+M and B+M+I groups (Figure 5.3, B-E). But at 
8.5 weeks, gene expression of Survivin was induced 2-fold higher in B+M+I tumors compared to B+M 
tumors (Figure 5.3, B). Lect2 and Glul were also significantly induced in the B+M+I groups compared to 
NT at this time (Figure 5.3, C-D). Axin2 exhibited variable expression and was not significantly induced in 
any condition (Figure 5.3, E). Thus, IQGAP1 overexpression resulted in enhanced expression of a subset 
of β-catenin target genes in vivo. 
 To test whether IQGAP1 could directly enhance β-catenin activity, we overexpressed IQGAP1 in 
HCC cell lines and found a 2-3 fold increase in the expression of β-catenin (CTNNB1) and cyclin D1 
(CCND1), a marker of cell proliferation (Figure 5.4, A). Importantly, Wnt/β-catenin activity increased up to 
6-fold, as measured by the TOPFlash reporter assay (Figure 5.4, B). The degree of reporter activation 
was similar to transfection with an activated form of β-catenin alone. Finally, consistent with increased 
Wnt/β-catenin signaling, which is associated with increased cell proliferation, IQGAP1 overexpression 
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doubled the percentage of proliferating cells, as measured by incorporation of the thymidine analogue 
Edu (Figure 5.4, C). Together, the data indicate that IQGAP1 overexpression enhances Wnt/β-catenin 
signaling to promote proliferation with subsequent increases in HCC burden. 
 
Deletion of IQGAP1 promotes DEN-induced tumorigenesis 
Since we found that overexpression of IQGAP1 promotes growth of an aggressive form of HCC, 
we next asked if IQGAP1 knockout mice are protected against developing hepatic tumorigenesis. We 
used the DEN model of liver cancer, which is a gold standard model used for chemical carcinogenesis in 
the liver and mimics the delayed development of HCC in humans that can occur over decades (Lee, 
2004; Heindryckx, 2009). Following a previously published protocol (Vesselinovitch, 1983), we treated 
male and female Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- mice with 5 mg/kg DEN via intraperitoneal injection at 
12-15 days of age and assessed tumor burden 20- and 50-weeks post-treatment. Visible tumors were 
observed in 0/9 Iqgap1+/+, 1/3 Iqgap1+/-, and 0/3 Iqgap1-/- female mice at the 50-week time point, which is 
consistent with previous reports that females are protected from developing HCC (Naugler, 2007; Bray, 
2018). Therefore, we performed all further analysis on male mice only. No macroscopic nodules were 
observed at 20 weeks after DEN treatment (Figure 5.5, A), but microscopic lesions were observed in 3/9 
Iqgap1+/+ (33.3%), 3/10 Iqgap1+/- (30.0%), and 3/5 Iqgap1-/- (60.0%) livers at that time point (Figure 5.5, 
B).  
Visible tumors were observed at 50 weeks (Figure 5.6, A), and we were surprised to find 
significantly higher incidence (Figure 5.6, B) and multiplicity (Figure 5.6, C) of liver tumors in Iqgap1-/- 
mice compared to Iqgap1+/- mice indicating that loss of both copies of Iqgap1 promotes tumorigenesis. 
However, Iqgap1-deletion did not affect maximum tumor size (Figure 5.6, D). Liver weight to body weight 
ratios distributed into 2 groups, and when we separated these, we found that Iqgap1-/- livers were 
significantly larger than Iqgap1+/+ and Iqgap1+/- livers in the subset of mice with a liver to body weight ratio 
> 7% (Figure 5.6, E). These data indicate that the tumor burden is higher in Iqgap1-/- animals. 
Since we previously showed that Iqgap1-/- mice have lower adipose weight (Erickson, 2018) and 
body composition is an independent predictor of outcome for liver cancer patients (Labeur, 2018), we 
asked whether the increased tumor burden in Iqgap1-/- animals could be subsequent to differences in 
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body composition. Body weight was lower in Iqgap1-/- animals than both Iqgap1+/+ and Iqgap1+/- mice at 
50 weeks post-treatment (Figure 5.7, A). A similar trend was observed as early as 10 weeks of age 
indicating that the effect of Iqgap1-deletion on body weight occurred prior to tumor formation (Figure 5.7, 
B). However, there was no difference in WAT nor quadriceps muscle (Quads) weight as an absolute 
value or when normalized to total body weight (Figure 5.7, C-F). Levels of serum injury markers ALT, 
AST, and total bilirubin were elevated but not different between grounds (Figure 5.7, G-I). This suggests 
that the increased tumor burden in Iqgap1-/- animals is likely not due to differences in body composition or 
increased liver injury. 
Unlike the B+M model of HCC, the DEN model generates both hepatocellular adenoma (HCA), a 
benign tumor, and HCC (Vesselinovitch, 1983). These can be differentiated histologically as HCC 
typically has a thick trabecular structure, while in HCA the cells are arranged in thin trabeculae or in cords 
similar to normal hepatocytes but with no vasculature. Both tumor types were observed in all the cohorts 
of mice (Figure 5.8, A). HCA nodules were found in 6/9 Iqgap1+/+ (66.7%), 4/8 Iqgap1+/- (50.0%), and 9/12 
Iqgap1-/- (75.0%) tumor-bearing livers while HCC nodules were found in 6/9 Iqgap1+/+ (66.7%), 5/8 
Iqgap1+/- (62.5%), and 9/12 Iqgap1-/- (75.0%) livers (Figure 5.8, B). The steatotic subtype of HCA was 
observed in 1/6 Iqgap1+/+ (16.7%), 3/5 Iqgap1+/- (60.0%), and 1/9 Iqgap1-/- (11.1%) livers with HCA. 
Pockets of inflammation were infrequent, consistent with DEN-induced tumors having low immunogenicity 
(Yim, 2018). 
We next asked if there were any fundamental differences in the molecular characteristics of these 
tumors. Liver cancer can be divided into at least six molecular subtypes (Boyault, 2007; Calderaro, 2017). 
These include G3 tumors, which are more likely to have TP53 mutations and increased proliferation, and 
G5/G6 tumors, which are characterized by β-catenin activating mutations. Proliferation marker Rrm2 and 
TGFβ receptor Tgfbr1 are both upregulated in G3 tumors and were both increased in expression in 
Iqgap1+/- and Iqgap1-/- tumor tissue relative to the surrounding liver tissue (Figure 5.9, A-B). 
Gluconeogenic enzyme phosphoenolpyruvate carboxykinase (Pepck) is downregulated in both G1/G2 
and G3 tumors and was significantly decreased in expression in all DEN tumor cohorts (Figure 5.9, C). 
Similarly, lipogenic gene fatty acid synthase (Fasn) is upregulated in both G1/G2 and G3 tumors and was 
significantly increased in expression in both Iqgap1+/+ and Iqgap1-/- tumors (Figure 5.9, D). These together 
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show close alignment with the G3 subset of HCC. However, angiogenesis genes are typically 
downregulated in G3 tumors, but we found increased expression of Angiopoietin 2 (Angpt2) in all tumors 
(Figure 5.9, E). C-reactive protein, a marker of inflammation, is not altered in G3 tumors but was 
significantly downregulated in all tumor cohorts (Figure 5.9, F). Overall, we show that Iqgap1-deletion 
does not favor any particular molecular subtypes of liver tumors. 
We also confirmed that deletion of Iqgap1 did not result in compensatory expression changes of 
its homologs Iqgap2 and Iqgap3. Of the three homologs, IQGAP1 has the widest tissue distribution and is 
more frequently altered in cancer (Zoheir, 2015). As expected, Iqgap1 was induced in Iqgap1+/+ tumors 
relative to the surrounding healthy liver, and the Iqgap1+/- mice exhibited an approximately 50% reduction 
in Iqgap1 expression compared to controls (Figure 5.9, G). Iqgap2 is more highly expressed in the liver 
(Cq = 18-19) than Iqgap1 (Cq = 23-24) but its expression is decreased in tumor tissue (Figure 5.9, H). 
Iqgap3 expression is typically seen only in proliferating cells (Kunimoto, 2009) and thus has much lower 
expression in the adult liver (Cq = 30-31). Its levels are dramatically induced in tumor tissue (Figure 5.9, 
I), but neither Iqgap2 nor Iqgap3 expression was altered by Iqgap1-deletion. 
 
A subset of Iqgap1-/- tumors are characterized by enhanced glutamine synthetase expression 
 We next asked whether altered activation of tumor drivers could explain the increased tumor 
burden in Iqgap1-/- mice. DEN-induced tumors are frequently driven by mutations in Hras and subsequent 
MAPK signaling and, to a lesser extent, mutations in β-catenin (Tolba, 2015). We examined whether 
deletion of Iqgap1 altered the activation of these pathways by performing immunohistochemistry for 
phosphorylated ERK1/2 (P-ERK), which is downstream of HRas, and GS, a marker of β-catenin activity. 
We divided liver tumors into four categories based on staining pattern: GS and P-ERK negative, P-ERK 
positive, GS positive, and both P-ERK and GS positive (Figure 5.10, A). Iqgap1-deletion did not affect the 
zonal expression pattern of GS nor P-ERK staining in tumor-adjacent liver tissue. Hras and Ctnnb1 
mutations are typically mutually exclusive as evidenced by the low number of tumors that were both P-
ERK and GS positive (Tolba, 2015). HCAs were primarily P-ERK positive, with 9/11 Iqgap1+/+ (81.2%), 
9/9 Iqgap1+/- (100.0%), and 12/13 Iqgap1-/- (92.3%) tumors expressing P-ERK positive staining (Figure 
5.10, B). On the other hand, a substantial portion of HCCs had increased GS expression, with 4/12 
91 
 
Iqgap1+/+ (33.3%), 2/9 Iqgap1+/- (22.2%), and 7/15 Iqgap1-/- (46.7%) HCC tumors exhibiting GS-positive 
staining (Figure 5.10, C). 
 The increased proportion of Iqgap1-/- HCCs with GS-positive staining was intriguing since we 
previously showed that overexpression of IQGAP1 enhances β-catenin activity in HCCs. To see if this 
corresponded to increased expression of other β-catenin targets in Iqgap1-/- tumors, we examined 
expression of canonical β-catenin targets. In all groups, there was increased expression of Ctnnb1 and its 
target Survivin (Figure 5.10, D-E). Gene expression of other bona fide β-catenin targets, including Glul, 
Lect2, and Axin2, were also increased but only in a small subset of tumors, while they were decreased in 
a majority of tumors (Figure 5.10, F-H). Afp showed a trend for increased expression in all tumor tissue 
but was only significantly induced in Iqgap1-/- mice (Figure 5.10, I). 
 To address if loss of IQGAP1 directly affects Wnt/β-catenin signaling, we knockdown down 
IQGAP1 in HepG2 (human hepatoma), Huh7 (human HCC), and Snu-449 (human HCC) cell lines and 
evaluated β-catenin activity using the TOPFlash luciferase reporter assay (Figure 5.10, J-K). In contrast 
to CTNNB1 depletion, loss of IQGAP1 had no impact on β-catenin transcriptional activity in Huh7 and 
HepG2 cells (Figure 5.10, K). Loss of IQGAP1 or CTNNB1 did not reduce β-catenin activity in Snu-449 
cells, most likely because baseline β-catenin activity in these cells is minimal. Together, the in vivo and in 
vitro data suggest that Wnt/β-catenin signaling is unaffected by Iqgap1 deletion but we cannot fully rule 
out the indirect association of increased β-catenin activation in a subset of Iqgap1-/- HCCs. 
 
Loss of IQGAP1 promotes tumor cell proliferation and primes for enhanced MET activation 
 Because β-catenin activation was found in a small portion of DEN-induced tumors, we asked if 
MET could contribute to the increased tumor burden in Iqgap1-/- mice. While MET activation was not 
affected by IQGAP1 overexpression in the B+M model, Iqgap1 deletion increased MET expression in the 
DEN-induced tumor model, though this was not accompanied by an increase in MET (Y1234/1235) 
phosphorylation (Figure 5.11, A). However, phosphorylation of MET target AKT was increased in 50% of 
Iqgap1-/- tumors (Figure 5.11, A). Since MET signaling is a potent mitogenic cue, we assessed cellular 
proliferation by performing immunohistochemistry for Ki-67, which marks non-quiescent cells (Figure 5.11, 
B). Tumor-adjacent liver tissue of tumor-bearing mice exhibited low levels of Ki-67 positive cells 
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regardless of genotype. However, there was a stark increase in Ki-67 positive cells in tumor tissue in 
Iqgap1-/- mice compared to Iqgap1+/+ mice (Figure 5.11, C). Iqgap1+/- tumors showed an intermediate level 
of Ki-67 staining.  
 In addition, we knocked down IQGAP1 using lentivirus-delivered shRNA in HepG2 cells and 
found a 1.63-fold induction of MET protein, indicating that knockdown of IQGAP1 is sufficient to increase 
MET expression (Figure 5.11, D). To determine whether the increased MET expression correlated with 
increased proliferation, we checked the expression of CCND1 in these cells, which was 2-fold higher with 
reduced IQGAP1 expression (Figure 5.11, E). The increased CCND1 expression appeared to be 
independent of β-catenin signaling as expression of CTNNB1 and its target AXIN2 were not affected by 
IQGAP1 knockdown (Figure 5.11, E). Thus, IQGAP1-deletion could promote proliferation through HGF 
signaling. 
 Our assessment of MET activation so far has been in unstimulated cells and ad libitum fed mice, 
which have low MET activity. To determine whether IQGAP1-deletion could potentiate MET signaling by 
increasing MET levels, we knocked down IQGAP1 using siRNA in Snu-449 cells and treated the cells 
with HGF for 15 minutes. Consistent with our previous results, knockdown of IQGAP1 in this cell line 
increased MET expression in unstimulated cells, but phosphorylation of MET or its target AKT was barely 
detectable in this condition (Figure 5.11, F). Remarkably, stimulation with HGF resulted in a 50% increase 
in MET phosphorylation in the absence of IQGAP1 compared to control. Phosphorylation of downstream 
targets of MET, AKT (S473) and P38α/β, were not upregulated even in siControl samples treated with 
HGF, which could be due to the short treatment time. Together, the data indicate that loss of IQGAP1 
results in increased MET signaling, which could facilitate HCC oncogenesis. 
 
Discussion 
Our results show that both overexpression and deletion of the scaffolding protein IQGAP1 can 
promote tumorigenesis in the murine liver. IQGAP1 is frequently overexpressed in human HCC (White, 
2010; Chen, 2010; Xia, 2014; Jin, 2015) and corresponds with a worse prognosis, which is consistent 
with our finding that overexpression of IQGAP1 can exacerbate growth of aggressive HCC. We predicted 
that IQGAP1-deletion would have the opposite effect on tumor burden and were surprised to also find 
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increased tumorigenesis in Iqgap1-/- mice treated with DEN. Based on these data, we conclude that 
IQGAP1 expression has a bimodal effect on promoting hepatic tumorigenesis. 
 We demonstrate that increasing IQGAP1 levels in the B+M model of HCC results in aggressive 
tumorigenesis and increased β-catenin transcriptional activity. β-catenin functions as a transcription factor 
downstream of the Wnt signaling pathway and recruits transcriptional activators for pro-tumorigenic genes 
(Kumar, 2017). In line with our results, previous studies have shown that overexpression of IQGAP1 
increases the nuclear localization of β-catenin and, subsequently, its transcriptional activity (Briggs, 2002; 
Wang, 2008; Jin, 2015). However, β-catenin is also found in the cytoplasm and at the cell membrane and 
is a fundamental part of the adherens junction complex (Monga, 2014). Since total β-catenin levels are 
similar between B+M and B+M+I livers (Figure 5.1, B), it is possible that overexpression of IQGAP1 shifts 
β-catenin away from adherens junctions and toward the nucleus, allowing for tumors to rapidly invade and 
divide (Hirohashi, 1998; Kim, 2011b). But this line of thought would require additional experiments. 
Moreover. IQGAP1 overexpression has been shown to decrease the strength of cell adhesion (Kuroda, 
1998) and increase the invasiveness (Sakurai-Yageta, 2008; Dong, 2016) and proliferative capacity 
(Dong, 2016) of cancer cells in vitro. As of now, we propose that increased β-catenin activation 
contributes to the increased tumor burden in B+M+I mice, but we cannot confirm whether this is due to 
the increased nuclear activity of β-catenin alone or in combination with its depletion from adherens 
junctions. 
While we expected overexpression of IQGAP1 to promote tumorigenesis, we were intrigued to 
find that deletion of IQGAP1 also increased tumor burden. In cell culture, a large body of literature has 
shown that knockdown of IQGAP1 results in reduced cell proliferation (Emadali, 2006; Jadeski, 2008; 
Meyer, 2008; White, 2011; Huang, 2014; Lu, 2014; Meng, 2015; Sun, 2015; Jin, 2015; Su, 2016; Dong, 
2016) and migration/invasion (Mataraza, 2003; Yamaoka-Tojo, 2004; Ikeda, 2005; Mataraza, 2007; 
Benseñor, 2007; Bogatkevich, 2008; Dong, 2008; Sakurai-Yageta, 2008; Chen, 2010; Hayashi, 2010; Liu, 
2010; Lee, 2010; Wu, 2011; Huang, 2014; Lu, 2014; Meng, 2015; Jin, 2015; Sun, 2015; Dong, 2016; Li, 
2019), which are pro-tumorigenic processes. Conversely, we found increased proliferating cells in 
Iqgap1-/- tumors and increased Ccnd1 expression in HepG2 cells after 4 days of shIQGAP1 treatment 
(Figure 5.11, C and E). At the same time, knockdown of IQGAP1 was sufficient to induce the expression 
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of the receptor tyrosine kinase MET potentiate HGF-induced MET activation (Figure 5.11, A and D-F). 
IQGAP1 has not been shown to bind directly to MET but can bind to and regulate the signaling of other 
receptor tyrosine kinases (Yamaoka-Tojo, 2004; Tamaoka-Tojo, 2006; Benseñor, 2007; McNulty, 2011; 
White, 2011; Kohno, 2013; Chawla, 2017). IQGAP1 has also been shown to function downstream of 
HGF-MET signaling to promote cell adhesion (Tian, 2014; Tian, 2015). It is unclear whether IQGAP1 
regulates MET expression directly or if the increased in MET expression could be compensatory to 
IQGAP1 deletion. We also haven’t ruled out that IQGAP1-deletion could promote tumorigenesis indirectly 
by affecting stromal cell activation (Liu, 2013). 
 Together, our data show that overexpression and deletion of IQGAP1 promote hepatic 
tumorigenesis through different mechanisms; with overexpression increasing β-catenin activation and 
deletion increasing MET expression. These paradoxical findings contribute to a larger body of work that 
has revealed that many proteins have dual roles in hepatic tumorigenesis (Feng, 2012). These include 
NF-κB (Pikarsky, 2004; Haybaeck, 2009), Jnk kinases (Hui, 2008), STAT3 (Yu, 2009), and even MET 
(Wang, 2001) and β-catenin (Nejak-Bowen, 2010), which have expected oncogenic function, yet blocking 
their signaling in vivo can also promote tumorigenesis (Maeda, 2005; Takami, 2007; Lin, 2009; Das, 
2011; Nejak-Bowen, 2011). These unexpected findings are typically associated with excessive oxidative 
stress, hepatic injury, inflammation, and compensatory proliferation (Maeda, 2005; Sakurai, 2006; Zhang, 
2010). While we did see increased proliferation in Iqgap1-/- mice 50 weeks after DEN treatment, we did 
not find any difference in serum liver injury markers ALT, AST, and total bilirubin (Figure 5.7, G-I) nor the 
expression of inflammatory marker C-reactive protein (Figure 5.9, F). It is possible that the differences 
contributing to this phenotype are present at an earlier point in tumor development and are no longer 
detectable at this later time point. As a scaffolding protein, the optimal concentration of IQGAP1 is 
required to promote signaling, and too much or too little IQGAP1 can reduce the efficacy of signal 
transduction. For example, both overexpression and knockdown of IQGAP1 diminishes EGF-induced 
activation of the EGF receptor and downstream signaling (Roy, 2005). Thus, we conclude that 



























































Figure 5.1. Validation of B+M+I model. 
Male WT mice livers were forced to express β-catenin (S45Y), MET, and IQGAP1 by hydrodynamic tail 
vein injection (HDTVI). (A) Experiment schematic. (B) Immunoblot of protein lysates from 4-week livers. 
Each lane contains lysates from a single mouse. (C) Immunofluorescent stain for Myc-β-catenin, V5-MET, 
HA-IQGAP1, and Hoechst in non-treated (NT), B+M, and B+M+I livers 4 weeks after injection. Scale bar 

































































































Figure 5.2. Overexpression of IQGAP1 promotes liver tumor growth. 
Male WT mice with forced expression of β-catenin (S45Y) and MET ± IQGAP1 were aged to 4 (n = 3-5 
mice per group) and 8.5 (2-6 mice per group) weeks-post injection. (A) Representative photos of gross 
liver at 4 weeks. Scale bar is 1 cm. (B) Representative images of H&E stained and anti-GS stained liver 
sections at 4 weeks. Scale bar is 100 µm. (C) Liver weight normalized to body weight at 4 weeks. (D) 
Hepatic Afp expression normalized to B2m expression. (E) Representative photos of gross liver at 8.5 
weeks. Scale bar is 1 cm. (F) Representative images of H&E stained and anti-GS stained liver sections at 
8.5 weeks. Scale bar is 100 µm. (G) Liver weight normalized to body weight at 8.5 weeks. (H) Hepatic Afp 
expression normalized to B2m expression at 8.5 weeks. Values are displayed as mean ± SD. One-way 
ANOVA with Bonferroni multiple comparisons test was used to determine significance. Significance is 
indicated by * P < 0.05, ** P < 0.01, *** P < 0.001. Evan Delgado, PhD (Duncan Lab, University of 





Figure 5.3. IQGAP1 overexpression increases β-catenin target gene expression. 
(A) Immunoblot of protein extracts from B+M and B+M+I tumors. Each lane represents a single mouse. 
Quantification of the immunoblot (by densitometry) is provided at the right. (B-E) Liver tumor mRNA 
expression of β-catenin target genes Survivin (B), Lect2 (C), Glul (D), and Axin2 (E) normalized to B2m 
expression at 4 and 8.5 weeks after HDTVI. Values are displayed as mean ± SD. One-way ANOVA with 
Bonferroni multiple comparisons test was used to determine significance between groups. Significance is 
indicated by * P < 0.05, *** P < 0.001. Evan Delgado, PhD (Duncan Lab, University of Pittsburgh) 





Figure 5.4. IQGAP1 overexpression enhances β-catenin activity and proliferation in HCC cell lines. 
IQGAP1 was overexpressed in HCC cell lines HepG2 and Huh7. (A) Gene expression of IQGAP1, 
CTNNB1, and CTNND1 in Huh7 cells normalized to B2M expression. (B) β-catenin activation measured 
by TOPFlash reporter assay in HepG2 and Huh7 cells. (C) EdU incorporation in Huh7 cells 
overexpressing IQGAP1. Values are displayed as mean ± SD. Student’s t test was used to determine 
significance between two groups. Significance is indicated by * P < 0.05, ** P < 0.01, **** P < 0.0001. 

























Figure 5.5. Dysplastic foci are observed 20 weeks post-DEN treatment. 
(A) Representative liver photos from mice 20 weeks after DEN treatment (n = 9, 10, and 5 Iqgap1+/+, 
Iqgap1+/-, and Iqgap1-/- mice, respectively). Scale bar is 1 cm. (B) Representative H&E images of livers 
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Figure 5.6. IQGAP1 deletion increases incidence and multiplicity of DEN-induced tumors. 
Male Iqgap1+/+ (n = 13), Iqgap1+/- (n = 24), and Iqgap1-/- (n = 16) mice were treated intraperitoneally with 5 
mg/kg diethylnitrosamine (DEN) in sterile PBS at 12-15 days of age. At 1 year, tumor burden was 
assessed. (A) Representative photos of gross liver. Tumor nodules are indicated by a white dashed 
border. Scare bar is 1 cm. (B) Tumor incidence based on presence of visible liver nodules. (C) Tumor 
multiplicity was measured by counting the number of visible tumors per liver. (D) Tumor size was 
assessed by measuring the diameter of the largest visible tumor. (E) Liver to body weight ratio divided 
into low (< 7%) and higher (> 7%) subgroups. Values are displayed as mean ± SD. For tumor incidence, 
χ2 test was used to determine significance between all three groups. One-way ANOVA with Bonferroni’s 
multiple comparisons test was used to determine significance between three groups. Significance is 





Figure 5.7. Characterization of DEN-treated mice at 50 weeks. 
Male Iqgap1+/+ (n = 13), Iqgap1+/- (n = 24), and Iqgap1-/- (n = 16) mice were treated with 5 mg/kg DEN at 
12-15 days of age. After 50 weeks, tissues were harvested for analysis. (A) Body weight at time of 
sacrifice. (B) Body weight of DEN-treated Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- mice 10 weeks after DEN 
treatment. (C-D) Gonadal white adipose tissue (WAT) weight (C) normalized to total body weight (D). 
(E-F) Quadriceps muscle (Quads) weight (E) normalized to body weight (F). (G-I) Serum levels of ALT (I), 
AST (J), and total bilirubin (K) were measured. Hemolyzed samples were excluded from analysis. Values 
are displayed as mean ± SD. One-way ANOVA with Bonferroni’s multiple comparisons test was used to 




















































Figure 5.8. DEN induces both HCA and HCC tumors. 
(A) Representative H&E images of normal liver tissue (N) and both hepatocellular adenoma (HCA) and 
hepatocellular carcinoma (HCC) tumor tissue (T) in Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- mice (n = 9, 8, and 
12 mice per group, respectively). Scale bar is 200 µm; 100 µm (inset). (B) The relative incidence of mice 





Figure 5.9. Hepatic gene expression in DEN tumors. 
Gene expression of Rrm2 (A), Tgfbr1 (B), Pepck (C), Fasn (D), Angpt2 (E), Crp (F), Iqgap1 (G), Iqgap2 
(H), and Iqgap3 (I) in tumor-adjacent liver tissue and tumor tissue. Values are displayed as mean ± SD. 
Two-way ANOVA with paired Tukey’s multiple comparisons test was used to determine significance. 
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Figure 5.10. DEN-induced tumors are either P-ERK or Glutamine Synthetase positive. 
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Figure 5.10. (Continued) 
(A) Representative immunohistochemistry images of phospho-ERK1/2 (P-ERK) and Glutamine 
Synthetase (GS) staining in normal liver tissue and tumor tissue classified as either GS and P-ERK 
negative, P-ERK positive, GS positive, or GS and P-ERK positive. Scale bar is 100 µm. (B) The percent 
of HCA tumors with each molecular classification (n = 12, 9, and 15 Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- 
tumors, respectively). (C) The percent of HCC tumors with each molecular classification (n = 11, 9, and 
13 Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- tumors, respectively). (D-I) Gene expression of Ctnnb1 (D), Survivin 
(E), Glul (F), Lect2 (G), Axin2 (H), and Afp (I) in paired tumor-adjacent liver tissue and tumor tissue 
normalized to Gapdh expression. (J) Confirmation of IQGAP1 knockdown in Huh7 and Snu-449 cell lines 
transfected with siControl and siIQGAP1. (K) Relative luciferase unit (RLU) measured from TOPFlash 
luciferase reporter assay in Hepg2, Huh7, and Snu-449 cells transfected with siControl, siIQGAP1, and 
siCTNNB1. Values are displayed as mean ± SD. For gene expression, two-way paired ANOVA with 
Tukey’s multiple comparisons test was used to assess differences between groups. For cell culture 
expression, student’s t test was used to compare groups. Significance is indicated by * P < 0.05, ** P < 
0.01, *** P < 0.001, **** P < 0.0001. Evan Delgado, PhD (Duncan Lab, University of Pittsburgh) collected 
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Figure 5.11. IQGAP1 knockdown enhances MET expression and activation. 
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Figure 5.11. (Continued) 
(A) Immunoblot of DEN-treated Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- tumor extracts. Each lane contains 
extracts from a single mouse. Quantification of immunoblots by densitometry provided at right. (B) 
Representative images of Ki-67 immunohistochemistry staining in liver and tumor tissue of Iqgap1+/+, 
Iqgap1+/-, and Iqgap1-/- animals (n = 9, 8, and 12 mice per group, respectively). Scale bar is 100 µm. (C) 
Quantification of proliferating (Ki-67 positive) nuclei in liver and tumor tissue. (D) Immunoblot of HepG2 
cells infected with lentivirus expressing shScrambled (shScr) and shIQGAP1. (E) Gene expression in 
HepG2 cells infected with shScr and shIQGAP1 normalized to Gapdh expression. (F) Immunoblot of Snu-
449 cells transfected with siControl and siIQGAP1 and treated with HGF for 15 minutes. Quantification of 
immunoblots by densitometry at right. Values are displayed as mean ± SD. To compare 2 groups, 
Student’s t test was performed. Two-way paired ANOVA with Tukey’s multiple comparisons test was used 
to assess differences between groups. Significance is indicated by * P < 0.05, ** P < 0.01, *** P < 0.001, 






Table 5.1. Antibodies used. 
 
Target Antibody Source Catalog # Dilution 
Western Blots 
β-Catenin Beta-catenin Rabbit mAb Cell Signaling #9562 1:1000 
GAPDH Rb anti-GAPDH Sigma-Aldrich G9545 1:5000 
HA-IQGAP1 Anti-HA tag antibody [HA.C5] Abcam Ab18181 1:1000 
IQGAP1 
Rb anti-IQGAP1 antibody 
[EPR5220] 
Abcam Ab133490 1:1000 
MET Met (25H2) Mouse mAb Cell Signaling #3127 1:500 
Mouse IgG 







mTOR Rb anti-mTOR (7C10) Cell Signaling #2983 1:1000 
Myc-β-Catenin Myc-Tag (9B11) Mouse mAb Cell Signaling #2276 1:500 
P38α/β 
P38 MAPK (D13E1) XP(R) Rabbit 
mAb 
Cell Signaling #8690 1:1000 
Pan AKT Akt (pan) (C67E7) Rabbit mAb Cell Signaling #4691 1:1000 
Phospho-AKT1 
(S473) 
P-Akt (S473) (D9E) XP(R) Rabbit 
mAb 




XP(R) Rabbit mAb 
Cell Signaling #3077 1:500 
Phospho-mTOR 
(S2448) 
Phospho-mTOR (Ser2448) (D9C2) 
XP(R) Rabbit mAb 





Cell Signaling #4511 1:200 
Phospho-STAT3 
P-Stat3 (Y705) (D3A7) XP(R) 
Rabbit mAb 
Cell Signaling #9145 1:1000 
Rabbit IgG 
Goat anti-Rabbit IgG (H+L) 
Secondary Antibody, HRP 
Thermo Fisher #31460 1:5000 
STAT3 STAT3 Antibody (F-2) Santa Cruz Sc-8019 1:500 
V5-MET 
V5 tag monoclonal antibody 
(TCM5) 
eBioscience 14-6796-82 1:500 
Immunofluorescence 
HA-IQGAP1 Anti-HA tag antibody [HA.c5] Abcam Ab18181 1:100 





V5 tag monoclonal antibody 
(TCM5) 




Mouse anti-Glutamine Synthetase Fisher Scientific BDB610518 1:400 
Ki-67 Purified Mouse Anti-Ki-67 BD Biosciences 550609 1:100 
Mouse IgG 








P-p44/42 MAPK (T202/Y204) 
(D13.14.4E) XP(R), Rabbit mAb 
Cell Signaling 4370 1:400 
Rabbit IgG 
Goat anti-Rabbit IgG (H+L) 
Secondary Antibody, HRP 
Thermo Fisher #31460 1:250 
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Table 5.2. Primers used. 
Gene Species Forward (5’ → 3’) Reverse (5’ → 3’) 
AXIN2 Human GCTCCAGAAGATCACAAAGAGC AGCTTTGAGCCTTCAGCATC 
CCND1 Human GCTGGCCATGAACTACCT GGGATGGTCTCCTTCATCTTAG 
CTNNB1 Human GAAACGGCTTTCAGTTGAGC CTGGCCATATCCACCAGAGT 
GAPDH Human ATGACATCAAGAAGGTGGTGAA GCTGTTGAAGTCAGAGGAGAC 
IQGAP1 Human AGAACGTGGCTTATGAGTACCT CAGTCGCCTTGTATCTGGT 
MET Human TTACGGACCCAATCATGAGC GCTGCAAAGCTGTGGTAAAC 
Afp Mouse CCGGAAGCCACCGAGGAGGA TGGGACAGAGGCCGGAGCAG 
Angpt2 Mouse ACAGCTGTGATGATAGAGATTGG CGAGTCTTGTCGTCTGGTTTAG 
Axin2 Mouse GCTCCAGAAGATCACAAAGAGC AGCTTTGAGCCTTCAGCATC 
B2m Mouse CAGCAAGGACTGGTCTTTCTAT AACTCTGCAGGCGTATGTATC 
Ctnnb1 Mouse ACTTGCCACACGTGCAATTC AAGGTTGTGCAGAGTCCCAG 
Crp Mouse CGTATGGCGGTGACTTTGA GTGCTGATCTGTTCTGGAGATAG 
Fasn Mouse GCTGCGGAAACTTCAGGAAAT AGAGACGTGTCACTCCTGGACTT 
Gapdh Mouse AACTTTGGCATTGTGGAAGG ACACATTGGGGGTAGGAACA 
Glul Mouse TCCATCCTGTTGCCATGTT CTGCAGGTTTCCGGTTATACT 
Iqgap1 Mouse GATTCCCTGCACGAGAAGTT CGATGGCTGGGTTCATGTAT 
Iqgap2 Mouse TCAAGATTGGACTGCTGGTG AGGTTTGGTCTGGAGGAGGT 
Iqgap3 Mouse CTCTGGTCACCTTGCAGAAT CAGCAGCTCTTGGTAGACAG 
Lect2 Mouse CCCACAACAATCCTCATTTCAGC ACACCTGGGTGATGCCTTTG 
Pepck Mouse GTTCCCAGGGTGCATGAAAG AGGGCGAGTCTGTCAGTTCAA 
Rrm2 Mouse GTTGTCTTTCCCATCGAGTACC GAGCTTCCCAGTGCTGAATATC 
Survivin Mouse CCAAATACCACGTCTCCTTCTCT GCCACGCATCCCAGCTT 




CHAPTER 6: GENERAL DISCUSSION 
 
 IQGAP1 is a ubiquitously expressed and evolutionarily conserved scaffolding protein that is 
implicated in a number of disease states (Kalantari, 2009; Chen, 2010; Hayashi, 2010; Fowler, 2011; 
Zhou, 2014; Huang, 2015). Notably, IQGAP1 is frequently overexpressed in human cancer (Miyamoto, 
2000; Takemoto, 2001; Sugimoto, 2001; Nabeshima, 2002; Nakamura, 2005; Dong, 2006; Walch, 2008; 
Chen, 2010; Hayashi, 2010; Liu, 2010; Fowler, 2011; White, 2011; Wu, 2011; Lu, 2014; Jin, 2015; Meng, 
2015; Sun, 2015; Dong, 2016; Su, 2016). Its central role in regulating many diverse signaling pathways 
has led many to conclude that IQGAP1 could be an effective therapeutic target in the context of 
malignancy. However, the physiological role of IQGAP1 is not well understood. The overall goal of this 
dissertation was to investigate the regulation and role of IQGAP1 in different liver contexts in which 
IQGAP1 expression is induced. Within this dissertation, I performed three investigations (Chapters 3-5), 
the results of which are summarized below. Together, these studies elucidate novel functions for IQGAP1 
in regulating the adaptive response to nutritional and cholestatic stress and liver tumor progression, which 
contributes to the understanding of the dynamic function of scaffolding proteins along a spectrum of 
healthy physiological responses to disease and suggests that IQGAP1 could be an effective therapeutic 
target in these contexts. 
 In chapter 3, I found that IQGAP1 protein levels were induced in the liver upon a 24-hour fast in 
Iqgap1+/+ animals. Additionally, I reported that mice with germline deletion of both copies of the Iqgap1 
gene via a deletion of Exon 29 (Iqgap1-/- mice), resulting in a functional deletion of IQGAP1 protein, 
exhibit a blunted response to 24-hour fasting and long-term ketosis. These results indicated that IQGAP1 
was required for complete induction of PPARα genes and subsequent increase in serum ketone body 
levels in response to fasting, ketogenic diet-feeding, and PPARα agonism. Activation of mTORC1, which 
has been shown to inhibit PPARα activity (Sengupta, 2010), was increased in the absence of IQGAP1. I 
found that re-expressing IQGAP1 in the liver of Iqgap1-/- mice was sufficient to decrease mTORC1 
activation and increase expression of PPARα target genes. Further experiments will be needed to 
determine how IQGAP1 regulates the activation of these proteins.  
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 In chapter 4, I show that IQGAP1 transcript levels are induced in hepatocytes as a direct 
response to increases in BA signaling. I also found that deletion of IQGAP1 exacerbates BA-induced liver 
injury and accumulation of BA in the liver. Since IQGAP1 is a cytoskeleton-associated scaffolding protein 
that can regulate adherens junction stability, I asked whether decreased cell adhesion could contribute to 
leaky bile canaliculi in Iqgap1-/- mice and found lower E-cadherin expression. Further experiments will 
need to confirm whether the disruption of the bile-blood barrier contributes to the severe cholestasis that 
occurs in the absence of IQGAP1 in response to DDC feeding. 
 In chapter 5, I show that while IQGAP1 is typically overexpressed in HCC, both overexpression 
and deletion of IQGAP1 can result in increased liver tumor burden. Overexpression of IQGAP1 led to an 
increase in β-catenin activity without affecting activation of MET signaling, while IQGAP1 deletion did not 
affect β-catenin activity but did potentiate MET activation. Cell proliferation was also increased in tumors 
in the absence of IQGAP1, despite many reports in cell culture linking lower levels of IQGAP1 expression 
to decreased proliferation. This is the first direct comparison of the effects of IQGAP1 overexpression and 
deletion in the context of HCC, and the results suggest that IQGAP1 levels determine the balance 
between β-catenin and MET signaling in HCC. Further studies should focus on identifying whether other 
pathways are also differentially regulated by IQGAP1 overexpression and deletion to contribute to this 
dual effect of IQGAP1 on liver tumor growth. 
 The results of these studies highlight the complex relationship between IQGAP1 expression and 
the adaptive response to nutritional stress, liver injury, and carcinogen exposure. Hepatic IQGAP1 can 
have a protect the liver from fat accumulation by promoting adaptation to ketotic states and from 
increased injury induced by toxin exposure, but it can have both a protective and detrimental role in 
promoting hepatic tumorigenesis. These data suggest that IQGAP1 could be considered as a potential 
therapeutic target in these conditions, but there are still many areas requiring further consideration in 
order to pursue the development of therapeutic strategies targeting IQGAP1. These include: 
• Dosage: How much does IQGAP1 expression need to be altered to have a desired effect? 
Since IQGAP1 is typically overexpressed in HCC and this dissertation showed that IQGAP1 
overexpression can increase tumor burden, a likely therapeutic strategy for HCC will be to reduce 
the effective amount of IQGAP1. However, when I used Iqgap1+/+, Iqgap1+/-, and Iqgap1-/- mice to 
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examine how reducing global IQGAP1 expression by 50% or 100% would affect tumor burden, I 
found that a 50% reduction of IQGAP1 expression did not alter tumor burden, but a 100% 
reduction unexpectedly increased it. This suggests that a potential therapeutic strategy for 
reducing HCC burden should aim for a reduction in IQGAP1 expression to 50-100% of wild-type 
liver levels but not as low as 0%, since this could lead to an unintended increase in tumor burden. 
Conversely, in the context of liver disease, a therapeutic strategy could be to increase IQGAP1 
expression since IQGAP1 deletion exacerbated DDC-induced liver injury and promoted fat 
accumulation in the liver in mice fed a ketogenic diet. While I showed that overexpressing 
IQGAP1 in the liver restored the fasting response in Iqgap1-/- animals, it is unknown if increasing 
IQGAP1 expression above wild-type levels will have a further protective effect in these conditions. 
Since each of these studies included a condition in which modifying IQGAP1 expression resulted 
in a worse phenotype than in wild-type conditions, future studies should focus on identifying 
whether altering IQGAP1 levels could lessen impact of these conditions compared to wild-type. 
These will be important studies for confirming whether targeting IQGAP1 can have a beneficial 
effect in these contexts while also minimizing unintended consequences. For example, it is 
possible that increasing IQGAP1 expression could have a protective role in the context of liver 
injury, but it is possible that this could promote tumor growth at the same time. 
• Timing: When would IQGAP1 need to be targeted to impact each pathological process? 
Therapeutic interventions typically have transient effects and can be intermittently administered to 
reach an optimal efficacy. However, a majority of the studies in this dissertation used a mouse 
model in which IQGAP1 is deleted for the entire lifespan of the animal, so it is possible that the 
effects observed in these studies would not be observed if IQGAP1 levels were manipulated 
transiently or at a later stage in development. While I didn’t find any overt differences between 
adult Iqgap1+/+ controls and Iqgap1-/- animals at baseline, it is possible that the long-term deletion 
of IQGAP1 could predispose an animal to have a different response to a stressor such as fasting 
or toxin-induced liver injury. This may not be the case since re-expressing IQGAP1 via 
adenovirus for 2 weeks in the liver of adult Iqgap1-/- mice was able to restore the fasting 
response. However, IQGAP1 has high expression in early development and decreases with age 
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(Kunimoto, 2009), so it is possible that changing IQGAP1 levels could affect liver development 
and thus the response to stressors at an earlier age. This is most relevant for the DEN-induced 
tumor model in which mice were treated at 2 weeks old. If this were the case, the paradoxical 
finding that both overexpression and deletion of IQGAP1 promotes hepatic tumorigenesis could 
be due to IQGAP1 loss having an effect on liver function at an early stage when DEN is 
administered (tumor initiation) leading to long-term effects on tumor burden while overexpression 
of IQGAP1 could have an effect at a later stage of tumor growth (tumor progression). Such an 
effect is seen in the case of conditional β-catenin knockouts in which early deletion of β-catenin 
results in altered DEN activation and increased tumor burden (Zhang, 2010). Future studies 
should assess the effect of transient versus long-term manipulation of IQGAP1 expression and its 
timing with respect to the progression of a physiological/pathological process (i.e. tumor initiation 
versus tumor progression). This will be important for identifying when targeting IQGAP1 would 
have a desired effect (i.e. reduced tumor growth) while avoiding potentially detrimental 
unintended effects (i.e. increased liver injury). 
• Tissue specificity: What are the consequences of systemic IQGAP1 manipulation and is it 
possible to target specific tissues? IQGAP1 is ubiquitously expressed in humans and mice. 
While this dissertation focused on the role for IQGAP1 in regulating liver function, IQGAP1 has 
reported functions in many tissues including the brain (Balenci, 2006; McDonald, 2007; Gao, 
2011; Lu, 2014), stomach (Li, 2000), and immune cells (Sharma, 2011). In developing a strategy 
to target IQGAP1 using a systemic therapy, it is necessary to consider the role of IQGAP1 in 
other tissues as well to reduce unintended outcomes and side effects. For example, seeking to 
reduce IQGAP1 expression in cancer cells to inhibit tumor growth could also reduce IQGAP1 
expression in myofibroblasts leading to their activation and further tumor promotion (Liu, 2013). 
Future studies should examine how IQGAP1 regulates cross-talk between cell types and identify 
how systemic manipulation of IQGAP1 expression could affect the function of other tissues. This 
will be important for identifying whether targeting IQGAP1 will need to be directed toward a 
specific tissue or if a second intervention such as altering immune system activation (Panigraphy, 
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2019) or the metabolic context (Hopkins, 2018) could reduce compensatory cross-talk that would 
reduce the efficacy of such a treatment. 
• Selectivity: Which functions of IQGAP1 should be targeted by therapeutics and how can 
this be done to retain the other functions of IQGAP1? In these studies, I used mouse models 
in which the full IQGAP1 protein was either deleted or overexpressed, which can affect the 
function of multiple pathways depending on the physiological state including PPARα, mTORC1, 
E-cadherin, β-catenin, and MET function. But it is possible that other pathways could also be 
responsible for the observed phenotypes. Since IQGAP1 has been shown to bind to over 140 
different proteins, it will be important to identify which of these alone or in combination are 
dysregulated and could be targeted to reduce unintended effects from altering the full-length 
IQGAP1 protein expression/function. To promote the beneficial effects of IQGAP1 manipulation 
while limiting the detrimental effects, it will be necessary to identify a strategy to selectively 
influence certain IQGAP1 functions while retaining others. For example, it might be optimal to 
retain the E-cadherin stabilizing function of IQGAP1 and its regulation of mTORC1 activity to 
respond appropriately to nutritional and cholestatic stress, while inhibiting its ability to promote 
β-catenin activation to limit the growth of HCC. An attempt at achieving this specificity is the use 
of a peptide mimicking the WW domain to block ERK1/2 binding to IQGAP1 and thus disrupt 
IQGAP1’s MAPK scaffolding function, which was effective at reducing the growth of MAPK-
positive skin tumors in mice (Jameson, 2013). However, as highlighted in chapter 2, the multiple 
binding domains of IQGAP1 can function interdependently. Thus, such a peptide could also affect 
IQGAP1’s scaffolding function at other domains. Furthermore, it is unknown where many proteins 
interact with IQGAP1, so it is possible that this strategy could still have unintended 
consequences. Future studies should focus on characterizing the binding sites of all IQGAP1 
binding partners and how these interactions are dynamically regulated. These mechanistic 
studies will be important for identifying strategies that can selectively manipulate certain functions 




Overall, the studies presented in this dissertation show that dysregulation of IQGAP1 expression 
can result in altered liver function across a spectrum of liver states – from ketosis and cholestatic injury to 
hepatocellular carcinoma. These data contribute to our understanding of IQGAP1 in a physiological 
context and demonstrate the need for more animal studies to elucidate IQGAP1 function. Future studies 
should take into consideration the dosing and timing of IQGAP1 manipulation in vivo and should 
investigate how IQGAP1 regulates cross-talk between different pathways and cell types. Since IQGAP1 is 
ubiquitously expressed and regulates a large number of proteins, it will be important to develop strategies 
to specifically alter certain IQGAP1 functions while retaining others. These strategies will be useful for 
elucidating the mechanism by which IQGAP1 regulates physiological processes and could potentially be 
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